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Abstract
Dissolution dynamic nuclear polarisation is an emerging clinical technique which en-
ables the metabolism of hyperpolarised 13C-labelled molecules to be dynamically and
non-invasively imaged in tissue. The first molecule to gain clinical approval is [1-
13C]pyruvate, the conversion of which to [1-13C]lactate has been shown to detect early
treatment response in cancers and correlate with tumour grade. As the technique has
recently been translated into humans, accurate and reliable quantitative methods are
required in order to detect, analyse and compare regions of altered metabolism in
patients. Furthermore, there is a requirement to understand the biological processes
which govern lactate production in tumours in order to draw reliable conclusions from
this data.
This work begins with a comprehensive analysis of the quantitative methods which
have previously been applied to hyperpolarised 13C data and compares these to some
novel approaches. The most appropriate kinetic model to apply to hyperpolarised
data is determined and some simple, robust quantitative metrics are identified which
are suitable for clinical use. A means of automatically segmenting 5D hyperpolarised
imaging data using a fuzzy Markov random field approach is presented in order to
reliably identify regions of abnormal metabolic activity. The utility of the algorithm
is demonstrated on both in silico and animal data. To gain insight into the processes
driving lactate metabolism, a mathematical model is developed which is capable of
simulating tumour growth and treatment response under a range of metabolic and
tissue conditions, focusing on the interaction between tumour and stroma. Finally,
hyperpolarised 13C-pyruvate imaging data from the first human subjects to be imaged
in Cambridge is analysed. The ability to detect and quantify lactate production
in patients is demonstrated through application of the methods derived in earlier
chapters. The mathematical approaches presented in this work have the potential
to inform both the analysis and interpretation of clinical hyperpolarised 13C imaging
data and to aid in the clinical translation of this technique.
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Chapter 1
Background
1.1 Metabolism in cancer
Abnormal metabolism is a prominent feature of almost all cancers and as such, has
been an active driver of basic research since its importance was first observed by
Otto Warburg in the late 1920s. The rapid proliferation of cancer cells creates addi-
tional demand on both the energy and molecular synthesis requirements of the cells
compared to normal tissue. The alternative metabolic pathways which must there-
fore be accessed in order to fulfil these additional needs separate malignant from
healthy cells, providing a clear target for therapeutic agents and molecular imaging
probes. Reprogramming of energy metabolism is so widely observed in malignant
cells that this feature has been identified as one of the key hallmarks of cancer [1].
Although metabolic phenotypes may be heterogeneous between and even within can-
cers, there are typical features which allow for broad clinical exploitation, the most
common of which is aerobic glycolysis. Commonly referred to as the ‘Warburg effect’,
this particular feature of cancer cells not only inspired a wealth of chemotherapeu-
tic agents, but is also behind the success of molecular imaging techniques such as
18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) and hyperpo-
larised imaging with 13C-pyruvate for the detection and monitoring of disease.
1.1.1 Anaerobic glycolysis
The Warburg effect is a phenomenon observed almost ubiquitously in which cancer
cells generate a high proportion of their energy through anaerobic glycolysis, even
in the presence of adequate oxygen for oxidative phosphorylation. In 1929, Otto
Warburg observed that cancer cells taken from mouse ascites produced around half
of their adenosine triphosphate (ATP) from glycolytic metabolism, compared to less
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than 1% in healthy liver and kidney cells [2]. This seemingly inefficient form of energy
production produces just 2 ATP per glucose compared to a possible 38 from mitochon-
drial respiration. In order to maintain energy requirements, cellular glucose uptake
is heavily upregulated to maintain sufficient levels of ATP production; this leads to
the production of large amounts of lactate which is pumped out of the cell thereby
acidifying the extracellular environment. This microenvironmental acidification has
been shown to promote tumour invasion and aggressiveness [3], making tumour pH
and anaerobic glycolysis popular targets when considering potential therapies.
Despite its low ATP yield, aerobic glycolysis may not be as inefficient as it ap-
pears and there is mounting evidence that this alternative metabolic pathway pays
an important role in healthy tissues. Lactate production is a well known feature of
exercising muscle cells [4] and there is growing evidence that other healthy cells, for
example in the brain [5, 6] and gut [7], regularly utilise anaerobic metabolism when
rapid energy production is required. Upregulated glucose uptake is also known to
occur at sites of inflammation, with recent evidence pointing to high levels of gly-
colytic activity from activated T-cells rapidly expanding during an immune response
[8]. A simple systems biology approach by Vazquez et al considers the limited spa-
tial capacity which a cell may dedicate to different metabolic pathways; for rapidly
proliferating cells capable of rapid glucose uptake, the Warburg effect is shown to be
the most efficient method of energy production in terms of solvent capacity [9].
1.1.2 Other metabolic changes in cancer
The abnormal use and production of lactate is one of the most clinically important
and ubiquitous hallmarks of cancer, however there are a number of other commonly
observed metabolic changes which separate healthy from malignant tissue. Cancer
cells must not only produce high levels of ATP, but synthesise the macromolecules
needed in order to rapidly divide. Increased glutamine uptake has been widely ob-
served in many cancers [10, 11, 12]. DeBerardinis et al used 13C spectroscopy to
demonstrate that the increased uptake of glutamine by in vitro glioblastoma cells
far exceeded the cells’ requirements for protein and nucleotide synthesis [13]. Not
only did the rate of glutamine to lactate metabolism produce sufficient NADPH to
support fatty acid synthesis, but the increased glutamine was found to heavily sup-
plement reduced glucose entering the TCA cycle as a carbon source, facilitating the
production of many important precursors for biosynthesis. This over-reliance on glu-
tamine metabolism has been termed ‘glutamine addiction’ and has been shown to be
caused by mutation of the Myc oncogene [14].
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One of the products of excessive glutamine metabolism, citrate, is used for another
process shown to be upregulated in tumours; that of fatty acid synthesis [15]. Since
high levels of fatty acids are required for rapid proliferation, identifying means of
limiting their production may slow cancer growth significantly. A study by Thupari
et al showed increased levels of fatty acid synthase enzymes in human breast cancer
cells [16]. They demonstrated that inhibition of this enzyme led to apoptosis in the
tumour cells but not in normal proliferating tissue, highlighting the enzyme acetyl-
CoA carboxylase as a potential therapeutic target in this process. High levels of fatty
acid synthase have been shown to be present in tissue exhibiting advanced disease
[17] and increased levels of the enzyme correlate with poor prognosis [18].
The rapid biosynthesis of nucleotides, fatty acids, proteins and their necessary
precursor molecules demanded by cancer cells, causes differential metabolite uptake
to be displayed across cancers. Metabolic flux shows high heterogeneity between and
within tumours and is heavily influenced by microenvironmental conditions, with
many molecules providing useful clinical targets for probing disease. Non-FDG PET
imaging is a good example of how these metabolic changes may be clinically exploited.
Uptake of 11C-choline has been shown to occur across multiple different grades of
prostate cancer; for identifying low grade tumours it therefore provides an advantage
over FDG which shows little or no uptake at low grades [19]. Limited success with
this tracer has been also been demonstrated for imaging lymph node metastases [20].
[18F]fluoro-L-dihydroxyphenylalanine ([18F]FDOPA), a labelled dopamine precursor,
has proven a useful tracer in the detection of neuroendocrine tumours [21] and of
low-grade brain tumours, both of which demonstrate upregulated dopamine uptake
[22]. Although the exact mechanisms driving metabolic changes are often poorly un-
derstood, identifying the differential uptake of a molecule between cancer and normal
tissue provides a means for identification and stratification of tumours, as well as
opportunities for therapeutic targeting of these pathways [23]. Figure 1.1 highlights
some of the main differences between the metabolic processes utilised by normal and
malignant cells.
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Figure 1.1: Glucose metabolism and energy production pathways in normal (left) and
malignant (right) cells. Large arrows denote upregulated processes in cancer cells,
either to synthesise the necessary molecules and ATP required for rapid proliferation,
or for other advantageous means. Reproduced from Jozwiak et al, 2014 [24].
1.1.3 Environmental drivers of metabolic changes in cancer
Although there are certainly commonalities in the metabolic features of cancers, het-
erogeneity between and within tumours remains an active area of both basic research
and clinical concern. Within a single tumour, multiple clonal populations displaying
divergent metabolic phenotypes are likely to co-exist as a consequence of acceler-
ated genetic evolution [25, 26]. Although a full discussion of genetic heterogeneity
is beyond the scope of this work, there exists a second strong driver of differential
phenotypes within and between tumours; that of the tumour microenvironment. The
metabolic phenotype expressed by a given cell will, in general, depend on its access
to nutrients, its interactions with neighbouring cells and the chemical concentrations
and gradients of various growth factors, cytokines, hormones and other important
signalling molecules. It is crucial therefore, to consider not the tumour alone, but the
tumour-host ecosystem with its multiple complex feedback mechanisms when inter-
preting metabolic data. The interaction between the tumour and the most commonly
involved host cells is described below in the context of ovarian cancer, however it is
worth mentioning here one of the most important modulators of the tumour environ-
ment which is the vascular system.
High vascularity has been consistently linked to poor prognosis and increased
proliferation rates in many different cancers [27, 28, 29]. Tumour angiogenesis and
its most important driver, vascular endothelial growth factor (VEGF) are therefore
common therapeutic targets, with both anti- and pro-angiogenesis agents trialed in
recent years [30, 31, 32]. Although a strong tumour vascular system provides access to
vital nutrients such as glucose for fast proliferation, it also increases the delivery rate of
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chemotherapy agents and facilitates the removal of acid from the system. The build up
of lactate generated by high aerobic glycolysis damages the surrounding stroma and is
known to be a key potentiator of invasion and agressiveness [33]. Tumour vascularity
is often disorganised, heterogeneous and inefficient, leading to regions of hypoxia
within the tumour. This not only promotes an acidic, glycolytic phenotype, but
stabilises the production of hypoxia-inducible transcription factors (HIF); this in turn
increases VEGF and therefore angiogenesis [34]. The positive feedback mechanisms
at play here highlight the complexity and compromises which take place to generate
a heterogeneous metabolic tumour environment.
1.1.4 Lactate shuttling and intratumoural cooperation
The propensity of tumours towards lactate production via anaerobic metabolism has
been well documented and known for many years. However, it is only recently that
the potential function of this excess lactate as an alternative fuel source has been
suggested. This is well known to occur in healthy tissue; the ‘cell-cell lactate shuttle’
theory [35], describes how cells with insufficient oxygen supply, such as in exercising
muscle fibre, may produce lactate which is then transported out of the cell via the
cell membrane channel protein monocarboxylate transporter 4 (MCT4) and can be
taken up by neighbouring cells to be utilised as a fuel source. There are numerous
examples of lactate shuttling throughout the body; the transfer of lactate produced
by astrocytes, shown to be taken up by neurones for energy production, is one notable
example [36]. The same process has now been suggested to occur in cancer, creating
a coupled metabolism between heterogeneous regions of the tumour.
Hypoxic areas rely heavily on aerobic glycolysis for energy production, however
the lactate produced by these cells diffuses down the lactate gradient towards well
oxygenated cells which then can take up the lactate by MCT1 transporters. From here
it enters the oxidative phosphorylation pathway to produce ATP, thereby preserving
glucose for the anaerobic cells which require it in large quantities [37]. To support
this theory, Sonveaux et al showed that when MCT1 is inhibited, the tumour is
forced to use glucose which, when in short supply, causes the cells to necrose [38].
These results point to cooperation between environmentally distinct tumour regions,
in order to optimise available resources for the whole tumour. Lactate has also been
identified as a signalling molecule involved in the activation of HIF-1α regardless of
oxygen levels; HIF-1α is then responsible for a whole cascade of growth, angiogenic
and metabolic changes in the cell [39, 40].
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1.1.5 Tumour-stroma coupling and the reverse Warburg ef-
fect
Rather than being a purely intra-tumoural effect, lactate shuttling may take place
between the tumour and cells known as cancer associated fibroblasts (CAFs). Fi-
broblasts are a common stromal cell type which become activated in normal tissue
as part of the wound healing process. These cells can be recruited by tumours and
utilisted for a multitude of purposes, primarily the secretion of useful growth factors
and matrix degredation proteins. In a similar mechanism to the intratumoural lac-
tate shuttling described above, peripheral CAFs have been shown to take up lactate
produced by hypoxic tumour cells, deacidifying the tumour microenvironment. Kouk-
ourakis et al found that while colorectal cancer cells had high levels of LDH5 and
MCT1 for lactate production and extrusion respectively, the CAFs showed increased
LDH1 for lactate oxidation, reduced glucose consumption and increased MCT1/2 for
lactate transportation [41]. In a computational model by Capuani et al, this type of
tumour-stroma metabolic coupling via a lactate shuttle was demonstrated to be en-
ergetically favourable under a broad range of conditions given simple physiochemical
constraints [42]. An evolutionary game theory model by Basanta et al had similar
findings, demonstrating the advantages of tumour-stroma coupling in prostate cancer
through lactate exchange [43].
In a recently identified phenomenon termed the ‘reverse Warburg effect’, cancer
cells may induce metabolic changes in adjacent stromal fibroblasts to increase their
rate of anaerobic glycolysis; this provides lactate for aerobically respiring cancer cells
to metabolise and fuel rapid growth [44]. Wiechen et el analysed complementary
DNA strands from normal and cancerous ovarian tissue, showing that this process is
most likely to be to be mediated by a loss of caveolin-1 (Cav-1), a probable tumour-
suppressor gene underexpressed in many cancers including breast and ovarian [45, 46].
There is very strong evidence that loss of stromal Cav-1 in breast cancer correlates
with increased risk of recurrence and poor survival [47], and Cav-1 expression has
been shown to correlate with histological grade and aggressiveness in serous ovar-
ian carcinoma, with parallel changes between stromal and perivascular Cav-1 also
observed [48].
Martinez-Outschoorn et al propose that the reverse Warburg effect is caused by
tumour cells secreting hydrogen peroxide, which has the effect of inducing oxidative
stress in the neighbouring stroma [49]. They demonstrated that this oxidative stress
causes autophagy and mitophagy in the stromal cells, leading to their producing en-
ergy rich nutrients including lactate, fatty acids and glutamine, which mitochondrially
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respiring tumour cells feed on. In a further study by Pavlides et al, the subsequent loss
of stromal Cav-1 by autophagy was shown to feed back, inducing further oxidative
stress which leads to aerobic glycolysis and inflammation [50]. More controversially,
Martinez-Outschoorn went on to suggest that the ‘traditional’ Warburg effect is an
in vitro phenomenon, not representative of in vivo metabolism. Co-cultured fibrob-
lasts and tumour cells were shown by fluorescence-activated cell sorting analysis to
respectively decrease and increase their mitochondrial activity compared to in single
cell-type cultures, with the reverse effect observed for glucose uptake [49]. This has
obvious implications for the analysis of 18F-FDG PET data, as these results would
imply that the increased glucose uptake by CAFs, rather than tumour, creates the
image contrast. Although a large amount of further evidence demonstrating this ef-
fect will be necessary before the well-established paradigm of the Warburg effect is
reconsidered, it would appear that fibroblasts do have a role to play in the apparent
metabolic phenotype of cancers.
1.2 Biology of ovarian cancer
Ovarian cancer is the fifth highest cause of cancer-related mortality in women, mak-
ing it the most lethal gynaecological malignancy in the western world [51]. Despite
relatively low incidence compared to other cancer types, ovarian cancer has a dispro-
portionately high mortality rate which is due in part to the majority of cases, around
65%, going undiagnosed before the cancer has reached an advanced stage and has
spread throughout the peritoneal cavity; at this point 5-year survival is less than 30%
[52]. Although serum markers such as CA125 have been trialled as early predictors
for ovarian cancer [53], there are currently no effective screening programs in place.
Furthermore, although most patients are symptomatic from stage I, symptoms are
common to many gastrointestinal and genitourinary conditions and go unnoticed in
the majority of cases [53]. Around 10% of ovarian cancer cases are related to mu-
tations in the DNA repair genes BRCA1 and BRCA2, with woman bearing these
mutations having a much higher probability (10% to 60%) of developing breast or
ovarian cancer during their lifetime [54]. Prophylactic mastectomy and oophorectomy
are often offered to these women as a preventative measure. Following presentation,
standard of care treatment generally involves platinum-based chemotherapy, followed
by de-bulking surgery to remove the majority of masses from the peritoneal cavity
with possible follow-up chemotherapy. Despite this, the majority of patients relapse
within a year [55].
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1.2.1 Carcinogenesis and histological types
Although it was believed for a long time that ovarian cancer emanated from the
ovarian surface epithelium, this has been challenged by recent evidence. It is now
thought that ovarian carcinomas have their origin in Mu¨llerian-duct derived tissues,
such as those comprising the fallopian tubes and fimbriae, based on the observation
that the tumour cells share histological and protein expression profiles with these
tissues and with cells of the endocervix and uterus, but have little in common with
the ovarian epithelium [56, 57]. This was first formalised by Dubeau in 2008, who
argues that the fimbriae cause inflammation by physically rubbing against the surface
of the ovary during ovulation making them a likely site for metaplasia [58]. This is
consistent with pre-neoplastic changes [59], and with p53 mutations [57], both seen
in the fimbriae of oophorectomy patients with BRCA mutations.
Ovarian cancer is a complex and heterogenous disease displaying many sub-types.
By far the most common type seen in ∼90% of cases, is epithelial cell ovarian cancer
which can be divided into four main histological subtypes: serous, endometrioid,
mucinous and clear cell, with serous representing around 60% of cases [60]. Gonadal-
stromal and germ cell cancers make up the remaining 6% and 4% of cases respectively.
The diversity between subtypes of epithelial ovarian cancer in terms of their molecular
and gene expression profiles is huge; clear cell ovarian carcinoma, for example, has
more in common with renal cancer than with serous ovarian cancer. Despite subtypes
sharing little more than an anatomical location in terms of their biology, similar
treatment strategies are often applied. Although 80-90% of serous and endometrioid
cases respond to the most commonly given drug cisplatin, response is only seen in
5% of patients with the remaining two subtypes; a similar result is seen for other
platinum-based chemotherapies [61].
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1.2.2 Metastasis
Figure 1.2: Mechanisms of transcoelomic metastasis in ovarian cancer. Step 1:
Epithelial ovarian cancer cell (green) detaches after altered gene expression. Step
2: peritoneal or ascitic current (blue arrows) facilitates peritoneal, lymphatic, and
haematogenous metastasis. Step 3: immune evasion by complement inhibition and
secretion of FAS ligand. Step 4: spheroid formation. Step 5: ascitic components stim-
ulate further metastatic progression. Step 6: peritoneal activation and implantation.
B7-H4=Immune costimulatory protein B7-H4; CXCL12=ligand of chemokine (CXC
motif) receptor 4 (CXCR4); FHL1=factor H-like protein 1; LPA=lysophosphatidic
acid; MMP=matrix metallopeptidase; VEGF=vascular endothelial growth factor.
Reproduced from Tan et al [62]
Despite the histological diversity present in ovarian cancer, metastatic patterns are
highly predictable and common amongst all types. The most frequently involved site
(83-100% of cases) is the peritoneum and in particular the omentum, a large fat pad
extending from the stomach across the bowel, which has metastases present in 80%
of all serous ovarian cancer cases [63]. Other common sites are the lymph nodes (50-
60% of cases), with the paraaortic lymph nodes more commonly involved than the
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pelvic nodes, the genitourinary and gastrointestinal systems and the liver [64]. The
peritoneum has a natural circulation of fluid, facilitating transcoleomic metastasis by
transporting detached malignant cells throughout the cavity (see figure 1.2). There
is mounting evidence that this is not purely a passive process, but involves adaptive
behaviour on behalf of the tumour cells. Upregulation of pathways responsible for
preventing apoptosis upon detachment from the extracellular matrix (ECM) may be
the first step towards dissemination from the primary site [62]. An alternate theory
has been also put forward; according to the metaplasia theory, peritoneal metastases
may in fact be independent instances of carcinogenesis based on evidence of genetic
heterogeneity between primary and peritoneal implants [65]. Although this theory
provides an explanation for the high proportion of cases displaying bilateral ovarian
involvement (57.5% of serous carcinomas) [60], it is unlikely to be the full story due
to the pattern of metastasis duly following the peritoneal flow.
Peritoneal metastases are frequently associated with the accumulation of malig-
nant ascites, raising the question as to whether the tumour cells are responsible for the
production of this ascites, producing a favourable growth medium in which they can
proliferate. The ascites is thought to accumulate through a combination of reduced
lymphatic drainage due to tumour cell blockage, tumour angiogenesis and microvessel
hyperpermeability in the peritoneal lining [66]. VEGF, a glycoprotein over expressed
in ovarian cancer, has been found in high concentrations in cell-free malignant ascites,
and has been shown to cause leakage of protein from the omentum into the fluid and
driving osmosis. VEGF is upregulated by hypoxia, inducing angiogenesis and vessel
permeability, with high levels linked to aggressive cancer and poor prognosis [67].
Many additional supernatants found in ascites fluid are thought to have similar pro-
tumoral properties. Amongst other factors, high concentration lysophosphatidic acid
has been found in malignant ascites, which promotes growth and metastasis by up-
regulating protease expression and angiogenic factors, and inhibiting apoptosis [68].
1.2.3 Stromal interaction
The observed proportion of stroma from histological analysis of ovarian cancer ranges
from around 7% to 83% (median 50%) of total tissue composition, with this estimate
proving fairly consistent across histotype and grade [69]. The relative abundance
of stromal cells, along with the tumour microenvironmental composition, has been
shown to have significant prognostic value and correlate negatively with overall sur-
vival alluding to a beneficial symbiotic relationship between tumour and associated
stroma. However, the nature of this relationship depends highly on stromal cell
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type; where omental fibroblasts have been shown to increase cancer cell adhesion and
invasive behaviour, mesothelial cells derived from the omentum actually inhibited
aggressiveness [70].
CAFs evidently play a crucial role, although their exact origin is unknown. They
may stem from the recruitment of normal tissue fibroblasts, senescent fibroblast pro-
motion or recruitment of mesenchymal stem cells, a differentiation event stimulated
by the lysophosphatidic acid abundant in malignant ascites [71]. CAFs have been
found in the omentum of patients without metastasis, which may suggest that these
cells arrive prior to tumour cells in order to prime the environment for metastasis;
there is abundant evidence that the CAFs produce factors promoting adhesion, an-
giogenesis, lymphangiogenesis and other growth factors important for metastasis to
occur [72, 73, 74]. Interestingly, normal stromal cells have actually been shown to
inhibit tumour growth, but were not able to survive long-term at the tumour site
[74]. In a mouse model by Granot et al, injected CAFs labelled with MRI-visible
tracer were observed to migrate towards the ovarian tumours and to align around the
outer rim, colocalising with the angiogenic neovasculature on the tumour nodules and
stabilising the vasculature [75]. It appears that tumour cells can recruit and pheno-
typically alter the adjacent stroma to support their growth via transforming growth
factor-β1 (TGF-β1) and that subsequent over expression of hepatocyte growth factor
(HGF) and matrix metalloproteinase-2 (MMP-2) drives invasiveness [73].
The omentum, a highly vascular organ within the peritoneal cavity and comprised
mainly of adipocytes, is the most common site for ovarian cancer metastases. In
addition to fibroblasts, there is mounting evidence to support the theory that in
a range of cancers including ovarian, tumours may recruit adipocytes to become
cancer associated adipocytes (CAAs), inducing phenotypical changes within them in
order to promote tumour growth [63]. A recent study by Nieman et al showed that
co-injecting human omental adipocytes with human ovarian cancer cells into mice
offered a proliferative advantage compared to the cancer cells alone, with tumours
growing on average three times larger [76]. Metabolic changes in both tumour and
adipocytes were observed in the in vitro co-culture, with the CAAs showing increased
lipolysis, providing vital fatty acids to the tumour cells, which in turn showed reduced
lipogenesis. The authors suggest FABP4 as the key mediator of this interaction.
1.2.4 Immune involvement
The presence or absence of tumour-infiltrating T-cells in immunohistochemical anal-
ysis of ovarian cancer tissue has been shown to be predictive of overall survival, with
11
38% of patients with T-cells present surviving five years compared to just 4.5% of
patients who had no T-cell infiltration [77]. For patients with complete clinical re-
sponse following surgery and platinum chemotherapy, these numbers were 73.9% and
11.9% respectively. The presence of T-cells was also found to independently correlate
with delayed recurrence, and negatively correlated with increased levels of VEGF. An
important step in the metastatic pathway is the avoidance of an immune response
during transit to the metastatic site; the presence of immunomodulatory factors in
the ascites suggests that host immune response plays a role in its production [62].
One way in which ovarian cancer cells have been shown to gain this immune privilege
is through the recruitment of regulatory T-cells (T-regs), which migrate preferentially
to the ascites and tumour site due to the tumours production of chemokine CCL22
[78]. From there, the T-regs suppress the immune response allowing further tumour
growth; imunohistochemical analysis of ovarian cancer tissue by Curial et al demon-
strated that increased T-reg populations in and around the tumour site correlate with
poor survival [78].
1.2.5 Therapy and resistance
Current standard-of-care treatment for ovarian cancer involves the administration
of platinum-based chemotherapy followed by de-bulking surgery. Initially, patients
can be divided into three cohorts; non-responders, or platinum-refractory; those who
relapse within 6 months, termed platinum-resistant; and those who are platinum-
responsive. The majority of platinum-responsive patients will also generally relapse,
but unusually, those with a long interval may be rechallenged with the same drug in
a phenomena known as platinum-sensitive recurrence [79]. The mechanism behind
this, and indeed behind the gradual build up of platinum resistance which follows are
not well understood.
Platinum-based agents such as cisplatin have multiple mechanisms of action, how-
ever the best understood is through the generation of distorting lesions on the DNA,
which induces activation of DNA repair mechanisms and ultimately apoptosis [80].
BRCA-positive patients, who already have defective DNA repair mechanisms, will in
general display a greater response to platinum-based treatments than similar cancers
in BRCA-negative patients, however in both cohorts acquired chemoresistance is a
very common problem [81].
A multitude of molecular mechanisms for aquired platinum-resistance have been
identified and studied [82], however the mechanisms associated with platinum-sensitive
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recurrence are less well documented. Steg et al provide the following plausible ex-
planation; the chemo-naive tumour contains a heterogeneous population of chemo-
sensitive, quiescent stem cells, and chemo-resistant cells. Platinum administration will
target the first of these populations, leaving a much smaller tumour bulk comprising
merely the latter two. The quiescent cells then over time may rapidly repopulate the
tumour with further treatment-sensitive cells, a model supported by their evidence
that post-chemotherapy tumours have higher proportions of cancer stem cells than tu-
mours at recurrence long after treatment, which have a similar stem cell density to the
primary [83]. Tumour cells may also resist initial treatment by entering a quiescent
state triggered by unfavourable microenvironmental factors, for example hypoxia and
nutrient depletion. Long after treatment when conditions become favourable again,
they are able to repopulate the tumour with treatment-sensitive cells [84]. Autophagy
may be a key initiator of this dormant state; in a study by Lu et el, they demonstrate
how ARHI, a tumour suppressor gene responsible for autophagy-induced cell death,
can switch to promoting dormancy of the tumour cells under certain microenviron-
mental conditions [85]. Finally, the ECM may also play a role in protecting cells from
chemotherapy. Contact with particular components of the ECM, in particular colla-
gen VI, has been shown in several studies to confer resistance to cells, with collagen VI
production additionally shown to be upregulated in platinum-resistant cells [86]. The
ECM demonstrates further involvement by acting as a regulator for cell dormancy
and for the establishment of stem cell populations [87]. Response to treatment may
therefore be highly dependant on the spatial location of the cell within the ECM.
1.3 Mathematical oncology
A small but rapidly growing area of cancer research, mathematical oncology describes
the process of using formal mathematical techniques to study the behaviour and dy-
namics of cancer within a theoretical framework. This is certainly not a new idea;
mathematical models have been applied to problems in cancer since the 1950s. How-
ever, the vast quantity of experimental biological and clinical data generated in re-
cent years, particularly in genetics metabolomics and proteomics, has provided an
increased need for complex analysis techniques to be developed [88]. Systems biology
saw widespread adoption across many fields as a means of studying a large number
of complex interactions within a biological system. Where linear thinking and reduc-
tionist approaches failed, systems biology instead provided insight into the emergent
and non-intuitive functions and behaviours of a system, through a rigorous analysis
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of the system as a whole [89]. Given the recent shift in thinking towards cancer as a
complex ecosystem, combined with a need to explain large and growing data sets, it
is perhaps unsurprising that mathematical oncology has enjoyed a resurgence within
the last fifteen years or so.
Mathematical modelling of cancer allows the complexities of the biology to be
translated into a set of rules defined through mathematical formalism. Although
the discipline has received criticism in the past for the simplifications of biological
components that this process necessarily demands, in reality many experimental set-
ups, in vitro cell culture for example, require similar simplifying assumptions in order
for conclusions to be drawn. By performing mathematical analysis on biological
models, a set of predicted outcomes and dynamics with clear limitations is obtained.
There are two main classes of model; the first are data driven models, which seek to fit
and explain phenomenological experimental data so that future data may be utilised
for predictive purposes. The second are theoretical, aiming to provide a mathematical
framework which describes the underlying biological processes. This can then be used
to explore system dynamics and to make predictions for experimental verification.
Both approaches have been successfully applied to common problems in oncology,
advancing knowledge and providing testable predictions for, for example, radiotherapy
[90], breast cancer [91, 92], tissue invasion [93, 94, 95], metastasis [96] and prostate
cancer [97, 98]. Given the huge range of different mathematical approaches which may
be applied to clinically relevant questions, the breadth of the field is quite significant.
The following sections will therefore focus on mathematical oncology as applied to
just three aspects of cancer; growth, metabolism and the interaction with the host
immune system.
1.3.1 Simple models of cancer growth
Some of the earliest examples of mathematical modelling being applied to cancer
describe the growth of tumours under various constraints [99]. Simple early models
such as that by Speer et al fit clinical data to models to predict growth patterns [100].
Growth was assumed to obey the commonly invoked Gompertzian law:
N(t) = N(0)exp{ln( Nth
N(0)
)[1− exp(−bt)]} (1.1)
where N is the cell count, Nth is maximum tumour cell count, and b is a parameter
controlling the curve shape. The step-wise behaviour seen in the breast tumour
growth data fit the model if spontaneous changes in growth rate were included. A
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later model by Norton proposed a correction, in which kinetic heterogeneity is treated
as an intrinsic property of neoplasia [101]. This second model provided better fits to
individual cancers and gave different predictions for optimal chemotherapy scheduling.
Other simple descriptions of tumour growth apply logistic, power law and exponential
functions to fit clinical data of tumour proliferation. Each has its success; exponential
growth is particularly good at modelling small population growth, tending to a power
law relation at large sizes, logistic functions are simple to apply within mathematical
frameworks and provide a very good approximation of most clinical data. In general,
there is no one accepted growth law amongst the mathematical oncology community,
with choice depending largely on context.
Early modelling of avascular tumour spheroids shed light on the size and growth
rate limits of such systems. Ward et al used a partial differential equation (PDE)
model, incorporating nutrient diffusion through the spheroid, where cells took two
states; alive or dead. They demonstrated that following initial exponential growth,
the system underwent two retardation periods; the first due to nutrient limitations and
the second from contraction of necrotic cells [102]. Tindall et al built on this model by
examining the relative contributions from apoptosis of nutrient-deprived proliferating
cells to necrosis from quiescent cells, setting limits on the critical oxygen partial
presssure required to maintain cell integrity [103]. Models such as that by Delsanto
et al operated at multiple scales, bridging the gap between the microscopic tumour
spheroid with complex interactions between individual cells, and the macroscopic
scale of larger tumour growth [104]. They use a PDE model of the tumour spheroid,
taking the hydrostatic pressure at the spheroid wall as an output metric. This is
used to model macroscopic implantation and subsequent growth of the spheroids into
tissues with varying ECM pressure.
Mathematical models of larger tumours must incorporate some kind of vascular
system and often include a description of angiogenesis. An early paper by Anderson
et al presents two different treatments of tumour induced angiogenesis in a model
with both discrete and continuous elements [105]. Nonlinear PDEs are used to de-
scribe the response of endothelial cells to diffusable angiogenic factors released by the
tumour. At the sprout tips, a discretised version of the model is used to develop a
biased random walk which allows anastomosis, mitosis and branching to be explic-
itly incorporated. Xu et al also utilise a PDE approach for their model of tumour
growth with angiogenesis [106]. Tumour, capillaries, nutrient and angiogenic growth
factor are explicitly modelled, with sprouting of capillaries dependant on both thresh-
old concentrations of nutrients and spatial distance from previous branches. Finally,
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Swanson et al incorporate angiogenesis into a model of macroscopic glioma growth by
treating the vessels as a continuous density which responds to local concentrations of
growth factors [107]. A similar approach to vasculature modelling is used by Gallaher
et al in a comparative study of breast versus lung tumour growth dynamics [108].
Continuous models of tumour growth must either incorporate complicated discrete
dynamics at the individual vessel level, or else treat the vasculature as a continuous
density, with local nutrient concentrations proportional to this density. Agent based
models, which treat each cell as an individual evolving on a grid according to a set of
pre-defined deterministic and/or stochastic rules, are a popular way of circumventing
the continuum problem and have been used extensively in mathematical oncology
[109, 110, 111]. Although generally unable to withstand the rigorous mathematical
analysis of dynamical stability that can be applied to differential equation models,
agent-based models are flexible and intrinsically spatial, making them a valuable tool
for investigating the processes that govern tumour heterogeneity. A simple cellular
automata (CA) model by Kansal et al demonstrates brain tumour growth on a 3D
grid with just four tunable parameters [112]. Their model is able to replicate the
growth dynamics of macroscopic tumours from medical data, demonstrating the for-
mation of a spontaneous layer structure from proliferating cells, quiescent cells, then
a necrotic core. Monteagudo et al take a different approach, using the CA framework
to investigate how several hallmarks of cancer affect tumour initiation from a cancer
stem cell population [113]. CA models have also been successfully applied to avas-
cular growth of small tumours [114], the growth of small cell lung cancer [115] and
pathogenesis in breast cancer [116].
1.3.2 Mathematical modelling of cancer metabolism
Cellular metabolism is a natural candidate for study with a systems biology approach.
The cycles and networks which make up metabolic processes operate under a clear set
of physiological and biochemical constraints and, whilst often too complex to study
intuitively, their structured and deterministic nature is well suited to analysis through
computational modelling. The abnormal metabolism that is such a well recognised
hallmark of cancer has therefore generated a wealth of mathematical modelling studies
focusing on the role of metabolism in tumours [117].
A specific form of PDEs known as ‘reaction-diffusion’ equations lend themselves
very well to modelling the interaction between the tumour and environmental nutri-
ents. The ‘reaction’ term describes the local production and uptake of a particular
metabolite; most commonly, the concentrations of glucose, oxygen and lactate are
16
modelled. The ‘diffusion’ term then accounts for the movement of these molecules
within the simulation domain, either through free diffusion or, in some cases, in
a preferred direction. The same types of equations can simultaneously be used to
model the interactions and movements of various cells types. An early model by
Venkatasubramanian et al extends the simple growth model of the tumour spheroid
to explicitly include cellular glycolytic metabolism by modelling the movement and
usage of oxygen, glucose and lactate in addition to living and dead cell populations
[118]. Cascari et el used a similar framework with many more metabolites, including
bicarbonate, CO2 and free protons into the stoichiometrics governing the spheroid
metabolism [119].
The glycolytic production of lactate and subsequent acidification of the cellu-
lar environment can have profound consequences on tumour growth dynamics [120].
Gatenby and Gawlinski use a reaction-diffusion model to demonstrate that acid pro-
duction is a key driver of invasive behaviour [121]. Their model predicts a hypocellular
gap at the tumour-host interface, caused by the acidic death of the host cells, which
they are able to experimentally demonstrate both in vitro and in vivo. This gap
reduces the interstitial pressure at the tumour boundary, aiding fast growth and in-
vasion toward the host tissue. Webb et al applied a reaction-diffusion approach to the
study of intracellular environmental acidification, predicting a reversed pH gradient
in tumour cells [122].
Hybrid models, which treat cells as discrete grid points in an agent-based model,
but use reaction-diffusion PDEs to describe the movement and use of nutrients across
the domain, have produced some of the most complex yet enlightening simulations
of metabolism in tumours. An early model by Alarcon et al uses a simple CA model
of tumour cells, whose growth dynamics are determined by the local oxygen con-
centration [123]. Oxygen is provided by a heterogeneous, static vascular network
and its concentration at each point in the domain is calculated at each time step by
finding the PDE steady-state solution. Their model predicts that normalising the
vasculature by increasing its homogeneity would be an effective means of targeting
tumour growth. A model of tumour growth and invasion through ECM degradation
by Anderson used a similar hybrid system to model individual tumour cells and con-
tinuous oxygen [124]. Patel et al incorporate a more complete treatment of glycolytic
metabolism and environmental acidification into a hybrid model. They demonstrate
the importance of lactate production for invasion and predict the existence of an
optimal tumour vascularity to achieve this [125]. Later models begin to include phe-
notype switching or clonal evolution to examine how the nutrient environment drives
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metabolic heterogeneity through evolution [126, 127]. One example by Robertson-
Tessi et al demonstrates very elegantly the non-linear evolution of the tumour cells
towards an aggressive glycolytic phenotype [128]. Figure 1.3 shows some of the results
from this model, both in real cellular space and in pheonotype space.
Figure 1.3: Hybrid model of tumour growth and metabolism with phenotypic drift;
A. Network showing the decision process for each cell, with green arrows denoting met
and red unmet conditions; B. Colourmap of phenotypic drift space with acid resistance
(y-axis) and glycolysis (x-axis); C-F. Model results with spatial tumour growth (top)
and phenotypic maps (bottom) 285 days after an anti-angiogenic treatment is applied
to the left column tumour. Adapted from Robertson-Tessi et al, 2017 [128].
Another type of mathematical modelling which has been gathering momentum in
cancer research is that of evolutionary game theory. These models may be spatial
or non-spatial in design and use a set of axioms to define pay-offs for individuals
based on a particular behavioural or evolutionary strategy. Although most commonly
applied to study of the genetic or phenotypic evolution of cancer populations, there
have been some interesting examples of game theory models with a metabolic focus.
Kianercy et al developed a non-spatial game-theoretic model of lactate shuttling
between hypoxic and normoxic tumour cells, using the overall ATP production as the
strategic reward [129]. Their model predicts stable states with both strong and weak
coupling, depending on the strategy-switching rate of the hypoxic cells. A similar
model by Basanta et al examines metabolic coupling between tumour and stroma in
prostate cancer within a 2D spatial domain [43].
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1.3.3 Mathematical modelling of the tumour-immune inter-
action
In recent years, the role of the immune system in the prevention, control and treat-
ment of cancer has become a key focus of both experimental biology and clinical
research with immunotherapies. However, study of the immune-tumour interaction
is not a new topic in mathematical oncology. The ‘predator-prey’ like dynamic of the
immune system in the presence of tumour antigens has historically lent itself well to
mathematical analysis; simple ordinary differential equation (ODE) models with few
equations are able to determine critical transitions between behaviours such as control
or outgrowth [130]. Pillis et al present a simple but rigorous three equation system
of tumour, antigen and effector cells, which they are able to validate with patient
data to predict immunotherapy response [131]. More complex ODE systems with
many equations describing the dynamical behaviour of various cells and signalling
molecules have provided insight into the complex feedback mechanisms between the
many different immune cell types [132]. A PDE model by Matzavinos et al explores
the conditions required for the immune system to recognise and remove an early ma-
lignancy by introducing a lymphocyte population into a model of tumour spheroid
growth [133].
Optimal control is a mathematical optimisation method for deriving the laws by
which a system may be optimally manipulated within a set of constraints. It has
been utilised frequently in recent models of the tumour-immune interaction, gener-
ally with the objective of maximising the effectiveness of treatment through controlled
timing within the wider tumour-immune system temporal dynamics [134, 135]. Re-
cent developments and successes in immunotherapy have inspired a wealth of mathe-
matical modelling studies seeking to optimise treatment strategies for administering
immunotherapies [136, 137, 138] or concurrent chemotherapy and immunotherapy
[139, 140] through the application of optimal control theory, generally to an ODE
system. These models tend to be impressive in their complexity and in their predic-
tions, however these should be viewed with caution. The highly sensitive control of
such systems requires accurate measurement of clinical parameters, which inevitably
introduces large sources of error when these theories are clinically implemented.
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1.4 Physics and development of hyperpolarised 13C
imaging
1.4.1 Historical development
In the early 1950s, Albert Overhauser first described the process by which the nuclei
of a solid metal may be polarised in a static magnetic field [141]. The theory stated
that by heating or exciting a set of electron spins, a coupled set of nuclear spins could
simultaneously be cooled. Despite some controversy over the apparent violation of
Boltzmann statistics, Overhauser’s theory of dynamic nuclear polarisation (DNP) was
demonstrated experimentally in solid lithium later that year [142]. It was soon shown
that this behaviour was not unique to metals [143], but that the effect could also
be induced in paramagnetic materials and in both liquid and solid states [144, 145].
Research on the subject continued slowly with the first MR sensitive nuclei (1H, 2H
and 13C) being polarised in 1974 [146]. A theoretical rethink was required to explain
this behaviour and as a result, an extension of Overhauser’s theory for non-metals
termed the ‘solid effect’ was developed by Abragam in 1978 [147]. Along with the
cross effect and thermal mixing, these four models are thought to account for the
levels of DNP observed in a variety of circumstances [148] and have been developed
extensively in the literature over time, although theories remain incomplete in some
respects today [149, 150].
With hyperpolarisation proving a useful tool for signal magnification in nuclear
magnetic resonance (NMR) and due to the many and varied technical challenges of
its implementation, DNP research within NMR chemistry and the physical sciences
grew steadily following its beginnings in the 1950s. However, it was not until the
early 2000s that the full potential of DNP in the biomedical sciences began to reveal
itself. Within the NMR community, DNP of 13C-labelled organic molecules become
a developed science, with much of the optimisation work for hyperpolarising several
organic compounds well documented [151]. It was however, the development of disso-
lution DNP by Klaes Golman’s group in 2003 that allowed hyperpolarised molecules
to be brought into the liquid phase at biologically compatible temperatures, leaving
the arena of cryogenics for the first time and showing that the nuclei retained their
polarisation in solution [152, 153]. In the same year, the first endogenous metabolite,
13C-labelled urea, was hyperpolarised and dissolved for injection into a rat using dis-
solution DNP [154]. The rat was imaged with 13C magnetic resonance spectroscopy
(MRS) providing the first in vivo liquid state hyperpolarised imaging experiment.
From here, the concept of in vivo dynamic metabolic imaging proceeded to grow
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through pre-clinical research. DNP has also progressed rapidly both in the aca-
demic sciences and the commercial sector, with the first sterile clinical hyperpolariser
patented in 2011 and appearing on the market shortly after [155]. Approximately
ten years after Golman’s first animal studies, the first human study was carried out
successfully at UCSF in 2010 to 2011, using a non-sterile prototype hyperpolariser
and carrying out the pyruvate polarisation process in clean room conditions [156].
The technical difficulties involved were not inconsiderable and although no further
human imaging studies were published until 2017, many sites worked on technical
developments during this time to refine the process for clinical use.
1.4.2 Thermal mixing and the solid effect
Spin is an intrinsic quantum property of certain particles and atoms which allows them
to interact with magnetic fields. For spin-1/2 particles such as electrons, protons and
13C nuclei, the spin can exist in two eigenstates which become non-degenerate once
a magnetic field is applied; i.e. aligned, or anti-aligned with the field. Boltzmann’s
thermodynamic relation states that for spin-1/2 nuclei in a magnetic field B, the ratio
of spins pointing up n↑, to those pointing down n↓ is given by:
n↑ = n↓e
γ~B
kBT (1.2)
Where ~ and kB are constants and γ is the gyromagnetic ratio of the nuclei. This
means that in a 3 T field at room temperature, 0.001% of 1H nuclei will be polarised
and MR visible, whilst the rest will cancel each other out. However, since 62% of the
atoms in the human body are 1H, it is still possible to get good signal to noise (SNR)
by manipulating this small excess, explaining the feasibility of non-hyperpolarised 1H
MRI. Because 13C has a lower gyromagnetic ratio, it has only 0.00026% polarisation
at room temperature. Furthermore, the isotope has a natural abundance of just 1.1%,
with 13C making up 0.13% of the body’s atoms. This means that the 1H signal is
about 24000 times higher than that of natural abundance 13C, which is why imaging
13C in the body requires some additional signal-boosting techniques.
With hyperpolarisation, it is possible to align nuclei beyond these natural thermal
populations and with current hyperpolarisers, to increase the polarisation by approx-
imately 100,000 fold, from 0.00026% to ∼20-40%. This requires the application of
microwave radiation, low temperatures and high magnetic field as well as a source
of free electrons from an electron paramagnetic agent (EPA) or free radical. A basic
schematic is shown in figure 1.4.
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Figure 1.4: Visual representation of 13C spins before and after the hyperpolarisation
process. Figure adapted from [157].
In the high magnetic field and low temperature, the electron spins align to become
almost 100% polarised. A simple schematic of the possible energy levels and the tran-
sitions between them is shown in figure 1.5, where ωe is the electron paramagnetic
resonance (EPR) frequency and ωn is the nuclear Larmor frequency. Upon the appli-
cation of saturating microwave radiation detuned from the EPR frequency by ±ωn,
the corresponding forbidden transition resonant to this offset which requires both a
nuclear and electronic spin transition, can be forcefully driven causing a non-thermal
population build up in one of the lower energy levels. Over time, a net nuclear po-
larisation builds up. The consequence of having two possible transitions at ωe±ωn is
that polarisation will actually occur at two resonant frequencies; the hyperpolariser
should be carefully tuned to only one of these frequencies, allowing polarisation build
up in the lower state only. The dominant mechanism at work during DNP of 13C-
Figure 1.5: Simple energy level diagram for the transitions involved in DNP. Solid
lines represent allowed transitions and dashed lines show forbidden transitions. Elec-
tron paramagnetic resonance (EPR) frequency = ωe, nuclear paramagnetic resonance
(NPR) frequency = ωn.
labelled molecules is believed to be thermal mixing, with smaller contributions via the
solid effect [158]. Thermal mixing occurs when the EPR line width of the electrons
(the frequency range over which transitions between their up and down states can be
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induced), is greater than the Larmor frequency of the nuclei ωn. When this condition
is not fulfilled then the solid effect is dominant [159]. Both have been described in
full in the literature, with the above description providing a simplified explanation
of the solid effect. Unlike the solid effect, thermal mixing is actually a three-spin
process which is best described as three spin reservoirs in thermal contact- the nu-
clear Zeeman (NZ), electron Zeeman (EZ) and electron dipolar (ED) reservoirs [148].
The off-resonance microwave radiation causes a polarisation gradient across the ED
reservoir, equivalent to cooling it. Because this system is in thermal contact with
the NZ reservoir, this is also cooled via an energy conserving three-spin process and
nuclear polarisation is allowed to build up.
1.4.3 Chemical doping agents and glassing agents
The basic requirements for DNP by the mechanism described above are:
• An external static B field of high strength
• Saturating microwave radiation of the correct resonance frequency
• Cryogenic temperatures, allowing for full electron polarisation
• A source of free unpaired electrons
• Polarisable molecules containing one or more nuclei of non-zero spin
The first three can be termed engineering problems and will be dealt with in a
following section, but the last two have been considered in depth by NMR chemists
for many years. Unlike the metals in which Overhauser first described DNP, the
small organic molecules of interest do not have a reservoir of free electrons with
which nuclear spins may exchange. This requires them to be chemically doped with
a free radical source known as an electron paramagnetic agent (EPA). Metal ions
such as chromium(V) and organic radicals, particularly nitroxides and trityls, have
all been proven successful for this task [160, 161, 162], however the choice of EPA
for a particular system depends on two main criteria [163]. First, the EPA must be
chemically stable and completely soluble in the material to be polarised, or its solvent
if one is required, since a homogeneous distribution of free electrons within the solution
is critical to the process. For the vast majority of biological applications an organic
radical is used. Secondly, the electron paramagnetic resonance (EPR) linewidth is
required to be greater than the target molecule’s nuclear Larmor frequency. In other
words, the range of frequencies over which the free electron spins may be excited must
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be large enough to incorporate the change in energy when a nuclear spin flip occurs if
hyperpolarisation is to proceed via thermal mixing. It is worth noting that the solid
effect does not require this condition to hold and as such, polarisation of 1H nuclei is
seen in samples by this mechanism.
Figure 1.6: Structure of trityl radical OX063 used as standard EPA for hyperpolar-
isation of [1-13C]pyruvate. Figure adapted from J. H. Ardenkjaer-Larsen et al, 2008
[158].
Since the Larmor frequency of many nuclei of interest including 2H, 17O and 13C
is very low, for example the 13C frequency is just 35.8 MHz at 3.35 T, there is little
constraint on the EPR linewidth. Organic trityl radicals (figure 1.6), which display
a range of hydrophobicities are therefore favoured for most applications involving
13C-labelled molecules and have even been proven more efficient than the larger EPR
linewidth nitroxides. The trityl OX063 (tris(8-carboxyl-2,2,6,6-tetra(2-(1-methoxy-
2,2-d2-ethyl))-benzo[1,2-d:4,5-d]bis(dithiole-4-yl)methyl sodium salt) has a very short
linewidth of around 63 MHz at 3.35 T [158], yet it is now used as standard for most
preclinical research with [1-13C]pyruvic acid at an optimal doping concentration of 15
mM [164].
Doping the 13C-pyruvate and radical mixture with Gd3+ has been shown to af-
fect polarisation build up under a range of conditions, with the potential to provide a
significant increase in polarisation [158, 165]; however, the relationship between polar-
isation and Gd3+ concentration is complex. At constant field strength B, a monotonic
increase in polarisation, followed by a plateau, then a monotonic decrease in polarisa-
tion can be observed as Gd3+ concentration is increased [166]. In the thermal mixing
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regime, the theoretical maximum polarisation Pmax is given by:
Pmax = tanh(
~ωNωe
4DkBTL
1√
η(1 + f)
) (1.3)
where ~ is Planck’s constant, kB is Boltzmann’s constant, ωN and ωe are the nuclear
and electron Larmor frequencies, D is the EPR linewidth, TL is the lattice tempera-
ture, η is the ratio of the electronic Zeeman and dipolar spin-lattice relaxation times
TZ/TD and f is the nuclear polarisation ‘leakage’ or decay factor. Since ωN , ωe and
TL are all fixed by the limitations of the DNP hardware and gadolinium is likely to
have little effect on the EPR linewidth D, (TZ/TD)(1 + f) remains as the factor in-
fluenced by Gd3+ doping; it should be minimised in order for maximum polarisation
to occur. Gd3+ has been shown to lower the electronic Zeeman spin-lattice relaxation
time TZ in trityl systems [158]. At low concentrations, this effect is much larger than
the simultaneous increase in nuclear polarisation leakage and the overall polarisation
in the system increases. However, as the concentration increases, the relative sizes of
these two effects gradually switch and beyond a threshold concentration, increasing
Gd3+ doping will begin to decrease the total polarisation that can be achieved.
For medical applications, the high toxicity associated with heavy metal ions such
as Gd3+ can be greatly reduced using a gadolinium chelate as is current practice
with contrast enhanced MRI, however its use is restricted where possible. The effect
of Gd3+ doping on polarisation is dependant on numerous chemical and hardware
factors. One study has demonstrated that the enhancement visible at 3.35 T was
negligible at higher fields; at 4.6 T the additional polarisation gained by Gd3+ doping
was far outweighed by that caused by increased field strength [164]. Since most
current clinical hyperpolarisers have static B fields of 5 T, it seems uncertain as to
whether Gd3+ doping will be used in clinical practice.
It is essential for the EPA to be distributed evenly throughout the sample for
the electron spin and nuclear Zeeman reservoirs to be in good thermal contact. For
many molecules liquid at room temperature or dissolved in aqueous solution, crystal
domains will begin to form as the temperature is lowered towards those required for
DNP. The formation of these domains causes the EPA to separate out, leading to
poor thermal contact and poor polarisation. As a result, it is necessary to choose
molecules which form amorphous solids, or dissolve those that do not in glassing
agents to retain distribution of the EPA [167]. There are some examples of endogenous
small molecules which form amorphous solids such as [1-13C]pyruvic acid and 2-keto-
[1-13C]isocaproic acid [163]. This is one of the contributing factors to the success of
pyruvate as a hyperpolarisable molecule; amorphous solid forming molecules like these
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are a minority. Suitable solvents must be found for most molecules of interest, which
must not only dissolve the molecule and EPA at high enough concentrations but must
also be well tolerated in vivo. Solvents currently being used include ethanol, glycerol
and dimethyl sulphoxide which is used as a glassing agent for another promising
clinical molecule, [1,4-13C2]fumaric acid [168].
1.4.4 Technical considerations and hardware
From simple Boltzmann statistics, the fractional polarisation of spin-1/2 nuclei with
a gyromagnetic ratio γ and at temperature T in a magnetic field of strength B is
given by:
P = tanh{ γ~B
2kBT
} (1.4)
This means that for electrons with γ = 2.8 × 104 MHz/T in a field of 5 T, 99%
of the spins will be polarised at a temperature of around 5 K. For 13C nuclei with
γ = 10.705 MHz/T, the required temperature for 99% polarisation drops to 0.0018
K explaining the requirement for indirect methods of polarisation. For full electron
polarisation within a sample, temperatures must be maintained at around 1 K which
requires a vacuum. The sample must also be in a magnetic field of 3 T or higher, in
range of a microwave source and for clinical application, a sterile environment is also
required. In 2011, the first automated clinical hyperpolariser was developed to fulfil
these requirements [155]. Produced and developed by GE Healthcare, the SPINlab
clinical hyperpolariser allows multiple samples to be simultaneously hyperpolarised to
∼40% in a liquid helium-filled environment maintained at 0.8-1 K. The inner helium
sample pot in which polarisation occurs is in 5 T magnetic field and a wave guide
is used to direct microwave radiation to the sample. A schematic of the cryostat
is shown in figure 1.7. Liquid helium is an expensive resource and so to prevent
frequent refilling, there is a condenser and charcoal sorb which are used for collecting
and re-condensing any liquid helium which boils off.
In addition to the hyperpolariser, a sterile device capable of withstanding the ex-
tremely cold conditions within the cryostat is required to contain the sample. The
current solution to this problem is the sterile fluid path, which consists of a sample
vial capable of holding ∼2 ml of 13C-pyruvic acid (or other agent), which is connected
to a syringe containing up to 60 ml of dissolution media via a co-axial tube. This
dissolution media is heated and pressurised to 130 ◦C and when dissolution is required
it flows down the inner tube to the vial, dissolves the hyperpolarised pyruvate, then
flows back through the outer tube into into an exit tube connected to a syringe. Along
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Figure 1.7: Schematic of the clinical hyperpolariser cryostat. Figure taken from J. H.
Ardenkjaer-Larsen et al, 2011 [155]
this exit tube is a filter to remove the EPA and a collection vessel containing sodium
hydroxide and a buffer to neutralise the solution to physiological pH. Attached to
this vessel are appendages allowing a quality control module to monitor pH, volume,
pyruvate and EPA concentrations, temperature and polarisation to ensure these pa-
rameters are all within physiologically safe bounds. The final step of the process
is the transfer of the hyperpolarised solution to a sterile Medrad syringe, ready for
automated injection into the patient
Figure 1.8: Schematic of the sterile fluid path designed for use with the SPINlab
clinical hyperpolariser. Figure taken from J. H. Ardenkjaer-Larsen et al, 2011 [155]
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For imaging and spectroscopy following injection of the hyperpolarised media, a
3 T clinical MR scanner is required. The size of the chemical shift between different
metabolites is dependant on, and increases with B0 magnetic field; a 1.5 T imaging
magnet does not provide great enough chemical shift to resolve all metabolites of
interest. It should be noted that the majority of studies detailed below use a similar
system to that described above, the pre-clinical “Hypersense” polariser, which is a
partially automated machine. Most studies in which the Hypersense is used report
a [1-13C]pyruvate polarisation of around 20% [169, 170], although the theoretical
maximum is certainly higher. These pre-clinical studies are often undertaken using
animal imaging magnets which tend to have higher B0 fields than clinical magnets,
ranging from 3-10 T.
1.4.5 13C-labelled molecules for the clinic
Even after a satisfactory EPA and glassing agent have been found and conditions
optimised for sufficiently hyperpolarising a particular molecule, there are still many
factors remaining which determine its success as an in vivo imaging agent. When
hunting for candidate clinical molecules, it is sensible to look first at endogenous
molecules and metabolites, as this largely overcomes the issue of toxicology and eases
the way through acquiring legal and ethical approval. The fact that a molecule is
endogenous however, is not enough to claim that it will be safe when injected in the
large quantities required for imaging. Most will need to be injected in supraphysiolog-
ical concentrations to give the necessary signal-to-noise and may be poorly tolerated
or even toxic at this level. The hyperpolarised molecules must be diluted for injec-
tion and often large volumes are required to safely introduce the required amount of
the hyperpolarised molecule. Solutions to be injected will also need to be adjusted
to physiological pH and osmolality; hypotonic solutions are particularly dangerous
as the osmotic pressure can cause lysis of blood cells. The addition of neutralising
agents, EDTA to chelate impurities and simple salts for osmotic balance can usually
overcome these issues.
The next set of criteria depend on the physical properties of the molecule. The
T1 relaxation time must be sufficiently long that dissolution, QC testing, injection
and then circulation of the molecule to the tissues of interest can all occur before
the polarisation has decayed to a level undetectable by the imaging method being
deployed. The polarisation is non-renewable; it is irreversibly lost when sampled
for imaging and the T1 is strongly affected by movement through a magnetic field,
such as into the bore of a 3 T MRI scanner, and reduced greatly upon injection by
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ferromagnetic haemoglobin in the blood [171]. [1-13C]pyruvate for example, has a T1
of ∼60 s ex vivo which more than halves to 20-30 s in vivo. This means that around
two half-lives have passed before the hyperpolarised pyruvate even reaches the target
tissue. When designing a labelled molecule, there are factors to take into consideration
to maximise the T1 and the position of the
13C label within the molecule is particularly
important. Magnetisation is predominantly lost via interaction with nearby 1H nuclei,
either within the molecule itself or in surrounding water molecules. A labelled carbon
at the end of a chain of carbon atoms will be more open to interactions with external
water hydrogens than one protected in the centre of a molecule and will have a
correspondingly shorter T1. Furthermore, the greater number of hydrogen atoms
bonded to the labelled carbon, the more likely that polarisation will be lost to them.
Loss to surrounding hydrogens can be avoided by deuterating the molecule, or by
using deuterated water as the solvent, although this can be expensive and there are
some concerns regarding the toxicity of heavy water [172]. Often there is a trade off
required in the positioning between maximising T1 and ensuring the labelled carbon
undergoes sufficient change of environment during the reactions of interest that its
chemical shift is detectable with the available MR imaging hardware. Any products
are also required to have a T1 long enough to allow detection.
The final key to clinical success is choosing a metabolite which is part of a biologi-
cally interesting reaction. The ability to provide useful information about a patholog-
ical metabolic alteration which cannot be gained by any other currently technology
is crucial if hyperpolarised 13C imaging is to find its place in clinical practice. The
molecule of choice should be part of a rapid enzymatic reaction, fast enough for prod-
ucts to be detected before polarisation decay, or a reporter for a relevant cellular
function [173]. Furthermore, there must be a detectable and quantifiable change in
the metabolic process with pathology. With so many conditions to be satisfied, suit-
able metabolites for hyperpolarised metabolic imaging are rare. The current best
candidate molecules for clinical use are discussed further in section 1.6.3.
1.5 Hyperpolarised 13C MR imaging and spectroscopy
1.5.1 Basic principles of MRS/NMR physics
Any nucleus with a non-zero spin possesses a nuclear magnetic moment. This means
that in the presence of a magnetic field, these spins will precess around the z-axis,
defined as direction of the static magnetic field, with a frequency known as the Larmor
frequency; ωL = γB where γ is the gyromagnetic ratio, specific to particular nuclei
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and B is the magnetic field strength. This is shown diagrammatically in figure 1.9
Spin-1/2 nuclei such as 1H and 13C can exist in just two eigenstates; aligned or anti-
aligned with the direction of the field as discussed in section 1.4.2. This concept
is important for understanding the transition states involved in hyperpolarisation,
however in descriptions of NMR it is more normal to refer to the vector sum of
magnetic moments from many nuclear spins. This vector sum is free to point in any
direction as it is rotated by applied fields during NMR experiments. This classical
treatment is quite sufficient for a discussion of NMR; the full quantum treatment gives
the same result for the large numbers of spins which we will universally be dealing
with.
Figure 1.9: Classical depiction of a nuclear magnetic spin rotating in a static magnetic
field along the z axis. Rotation, or Larmor frequency ω is given by the product of
the field strength B with the gyromagnetic ratio γ.
Exciting the spins with a radio frequency (RF) pulse at the resonant Larmor fre-
quency drives a rotation of the spins away from the z-axis and into the transverse
plane. This angle away from the z-axis is known as the flip angle, with a 90◦ flip
angle rotating the spin fully into the transverse plane and 180◦ causing a complete
inversion, often used for refocussing. Following an RF excitation, the spins relax
back towards the z-axis with a longitudinal relaxation time T1. As they relax they
continue to precess and in doing so emit a RF signal at the Larmor frequency called
the free induction decay (FID), which is picked up by RF receive coils for analysis.
This sequence describes the basic FID pulse-and-acquire sequence sometimes used for
spectroscopy. Nuclei in different chemical environments will have a slightly different
precession frequencies, called their chemical shift, which allows them to be distin-
guished from one another. Fourier transforming the FID signal, an exponential decay
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series in the time domain, produces a series of Lorentzian peaks at each of the dif-
ferent chemical shift frequencies present in the molecular mix being sampled. From
the relative size and distribution of the peaks, it is generally possible to discern the
concentrations and species of molecules present.
1.5.2 MRI and spatial resolution
It is easy to see how dynamic MRS data can be built up by repeating the above
sequence over time, however to image the distribution of metabolites we also require
spatial localisation. This is achieved by the application of magnetic gradients along
the x, y and z axes. Since the Larmor frequency ω of each spin is dependant on the
magnetic field strength B as ωL = γB, by spatially varying the field it is possible
to spatially vary the Larmor frequency of spins within the field. An RF pulse of the
desired bandwidth may then be applied which selectively excites only those spins in
the location specified by the pulse frequency.
In order to image an axial slice, a field gradient is applied along the z axis.
In general, it is desirable to selectively excite a slice of some particular thickness,
corresponding to a particular frequency range. Figure 1.10a shows the desired slice
shape for exciting spins with a Larmor frequency between −Ω and Ω and is given by
a top hat function in the frequency domain. Fourier transforming this function will
produce the necessary input RF signal in the time domain; a sinc pulse as depicted
in figure 1.10b and commonly used for slice selection in practice.
Figure 1.10: Fourier relation ship between desired excitation range and the RF pulse
which must be applied. a) Slice to be selected in the frequency domain for spins with
a Larmor frequency between −Ω and Ω, given by a top hat function, and b) Fourier
transform into the time domain gives the RF pulse shape to be applied in order to
achieve this selection i.e. a sinc pulse.
Spatial encoding in the x-y plane is now required in order to build up a picture
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of where each spin is and this is done by further application of x and y gradients
to perform frequency and phase encoding. Here, the concept of k-space is generally
useful for understanding how the space is sampled. A position in the x-y plane in
real space corresponds to a position in k-space via a 2D Fourier transform:
G˜(kx, ky) =
1
2pi
∫ ∫
G(x, y)e−i(kxx+kyy)dxdy (1.5)
Where G(x, y) represents the spatial B field gradient as a function of real space and
G˜(kx, ky) is its Fourier transform in k-space.
These k-space points are a slightly abstract concept, with each point represent-
ing a spatial frequency. The imaging plane can be imagined as a box. We can set
up standing waves inside the box along both the x and y directions; standing waves
of different wavelengths represent the different spatial frequencies. If we know with
what amplitude each standing wave contributes to the overall image, we can build
up the picture by overlaying the waves, with areas of constructive and destructive
interference providing the contrast for the image. The low spatial frequencies, or
long wavelength waves, provide large-scale contrast and big features of the image. As
we move to higher spatial frequencies these start to build up the fine contrast and
detail. These k-space points are exactly those spatial frequency waves and as we scan
across k-space all we do at each point is measure the amplitude with which that spa-
tial frequency contributes. The lowest spatial frequency is at the centre of k-space,
with higher frequencies moving outward in each direction. The choice of low and
high spatial frequencies to be sampled in a particular scanning sequence determine
the levels of contrast and spatial resolution in the final image respectively. Scanning
across k-space collecting signal from each spatial frequency, then Fourier transform-
ing that signal, produces the corresponding image in real space. By manipulating the
x and y gradients over time, it is possible to move around k-space in a number of
ways. Standard MRI images tend to be built up by scanning one line at a time, but
‘flyback’ trajectories, which cross back and forth across each line of k-space points,
and even non-Cartesian trajectories such as spirals and rosettes are available. Figure
1.11 shows the gradient required to produce a spiral k-space trajectory and the rela-
tionship between k-space point and applied gradient. The spiral trajectory provides
the advantage of sampling the centre of k-space first before moving outwards. This
means that the bulk of the contrast information is gathered very quickly, making it an
excellent choice for fast imaging, but it misses the fine detail that other trajectories
which sample further out into k-space may be able to provide.
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Figure 1.11: Relationship between k-space and applied gradients in polar co-ordinates
for a spiral acquisition in the sagital plane. Figure adapted from Han et al, 2010 [174].
1.5.3 Non-renewable polarisation
One of the main problems associated with hyperpolarised MR is the irreversible po-
larisation and therefore signal loss as the nuclei relax exponentially over time back to
thermal equilibrium. This can only be overcome by keeping the time from dissolution
to imaging minimal, using fast spectroscopy sequences and rapid single-shot imaging
techniques. These fast imaging sequences will be discussed in the next section. The
RF pulses which are applied to the nuclei during image acquisition also reduce the
overall polarisation. For example, after a pulse with a 90◦ flip angle, there is an equal
probability of the nuclear spin relaxing to align or to anti-align with the external B
field, thus the spins will cancel each other out and the polarisation will reduce to zero.
The effect that the flip angle has on the polarisation can be calculated as follows and
is easier to visualise with a quantum treatment. The general state of a nuclear spin
in three dimensions can be fully described as:
|A(θ, φ)〉 = [cos(θ/2)| ↑〉+ e−iφ sin(θ/2)| ↓〉] (1.6)
Here θ is the rotation away from the external B field, the flip angle, and φ is the
azimuthal angle. The triangular brackets are standard quantum mechanics notation
describing the two eigenstates of the spin; aligned and anti-aligned. The probability
P ′ of a spin relaxing to the down state | ↓〉 corresponding to a loss of polarisation, is
found by taking the mod-square of its amplitude:
P ′(θ) = sin2(θ/2) =
1
2
[1− cos(θ)] (1.7)
The actual polarisation loss will be twice this as those spins lost will cancel out the
signal from an equal number which recovered, thus the new polarisation fraction P
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is given by:
P (θ) = 1− [1− cos(θ)] = cos(θ) (1.8)
It is therefore generally advantageous to use small flip-angles for dynamic hyperpo-
larised imaging in order to retain signal, however a compromise is needed as the
receive signal also depends on the flip angle; flip angles of 5◦ - 15◦ are generally used.
For a sequence with constant flip angle and n repeats, the polarisation over time will
then be:
P (t) = P (0)e−t/T1 cosn(θ) (1.9)
The number of flips n is equivalent to the total time over the repeat time tR. To
simplify calculations during analysis, it can be useful to define an effective T1 which
takes all polarisation losses into account:
1
T1,eff
=
1
T1
− ln cos(θ)
tR
(1.10)
Although the non-renewable nature of the polarisation places certain limitations
and constraints on hyperpolarised imaging, there are circumstances in which this
feature may be exploited. Johansson et al describe a method by which they may
measure the blood flow; by repeatedly measuring tissue signal, each time intention-
ally destroying all polarisation, they are able to measure the flow of hyperpolarised
tracer to the region in each time increment. If the arterial tracer concentration is
simultaneously obtained, a quantitative blood flow estimate may be derived [175]. A
further example can be seen in the spectral-spatial imaging method from Schulte et
al, discussed in more detail in section 1.5.4.2. By repeatedly destroying all lactate
polarisation in a region, its build up over each time increment may be measured [176].
1.5.4 Hyperpolarised imaging techniques
Choosing an imaging sequence for hyperpolarised carbon involves a large degree of
compromise when it comes to spatial, temporal and spectral resolution. Extra in-
formation from one aspect of the acquisition generally comes at the cost of another,
leaving the eventual choice of sequence quite subjective; different methods have been
favoured by various research groups, and each used successfully. The most commonly
used acquisition methods can be roughly divided into two groups; those with a spec-
troscopic focus and those with an emphasis on spatial imaging.
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1.5.4.1 Spectroscopy-based sequences
The main advantage of using any spectroscopy based sequence is the acquisition of
full spectra within single or multiple voxels. This allows for the direct detection and
quantification of all 13C molecules present within a particular bandwidth and as such,
is a popular choice for research focusing on quantitative analysis. This full spectral
information does however, come at the cost of spatial and often temporal resolution.
Perhaps the simplest to implement, free induction decay (FID) pulse and acquire
sequences have been used in many excellent papers to date [177, 178]. An RF pulse
is used to excite the nuclei over the desired frequency range and the resulting FID
signal is measured to produce a spectrum of peaks corresponding to the amounts
of each 13C metabolite present. This can be repeated every few seconds in order
to acquire dynamic spectra which can be used for quantitative analysis. Spatial
resolution is generally very poor, although large voxels of around 1 cm can be selected
by application of slice selective gradients.
Chemical shift imaging (CSI) allows for greater spatial resolution, yet at the ex-
pense of dynamic information. The addition of phase encoding x and y gradients,
along with a slice selective z-gradient allows for spatial bounding, producing a grid of
voxels containing localised spectra. The slow phase encode gradients mean that dy-
namic acquisition and imaging of multiple slices is slow and inefficient and often not
implemented, but CSI has still been used to good effect by some groups and although
poor, temporal resolution may even be sufficient for kinetic analysis [179, 156].
Echo-planar spectroscopic imaging (EPSI) uses a fast flyback k-space trajectory
to sample multiple voxels in a faster time frame than CSI and is used often [170, 180].
It still requires phase encoding along one direction and so limited time resolution is
available for 2D acquisitions.
1.5.4.2 Fast imaging sequences
Fast imaging sequences are generally unable to produce spectra for each voxel, with
the focus on high spatial resolution images for multiple metabolites and time points.
Spiral CSI uses a spiral trajectory to efficiently sample k-space from the centre out-
wards [181]. It has the potential to be single shot, in which the entirety of k-space is
sampled over a single readout gradient, although in practice multiple excitations are
often needed to overcome gradient limitations in the hardware. Although 13C spectra
are available with this method, they are generally not able to capture all metabolites
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of interest within the narrow bandwidth used, causing some aliasing of the peaks as
a result. Use of these spectra for quantitative analysis is therefore limited.
A more advanced method IDEAL spiral CSI has since been suggested which uses
a FID acquisition at the beginning of each scan to provide chemical shift information
with which to separate out each metabolite upon reconstruction via a simple discrete
Fourier transform [182]. A single-shot spiral then follows each RF excitation, with
echo time shifts between each excitation providing spectral encoding. This provides
not only a more robust version of spiral CSI, but full spectra are also acquired at the
beginning of each time point albeit over the whole image slice.
An interesting method entitled spatio-temporal encoding (SPEN) has been devel-
oped which may allow for fast dynamic imaging with spectral and spatial resolution
without even requiring Fourier transform during reconstruction [183, 184]. A chirped
frequency-swept pulse is played out over an encoding gradient, followed by deconvo-
lution of the encoded information during a acquisition gradient. It is theoretically
possible to extract the full spatial and spectral information from the same FID, with
2D and multiple slices. Unfortunately, this sequence is not yet thought to be clinically
viable as its implementation is overly complicated for routine use.
Finally, a further approach mentioned in the previous section uses spectral-spatial
(SPSP) excitations to selectively excite a single resonance frequency followed by single
shot spiral acquisition [176]. The SPSP pulse is simultaneously slice selective and
tuned to a particular metabolite. By shifting this frequency, separate metabolites
can be consecutively imaged. Further more, because each excitation is metabolite
specific, different flip angles can be used on different molecules allowing polarisation
to be retained in one metabolite whilst another is interrogated.
It is difficult to directly compare imaging methods in a quantitative way since
resolution, particularly spatial resolution, depends strongly on the hardware used. A
rough summary is provided in table 1.1.
1.6 Early animal studies
1.6.1 Proof of concept and angiography
Prior to the development of dissolution DNP, there was a lot of interest in the ap-
plication of hyperpolarised 13C to MR angiography, vascular and perfusion imaging
[185, 186]. 13C was an exciting new contrast agent; unlike the current standard Gd3+
chelates, it was the agent itself rather than the effect it had on its environment that
could be imaged, making for simpler interpretation. Focus was on non-endogenous,
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Table 1.1: Direct comparison of popular 13C hyperpolarised imaging and spectroscopy
methods
Imaging method Temporal Spatial Full spectra Robustness and ease
resolution resolution obtained? of implementation
FID pulse and acquire Good Poor/none Yes Very easy to implement and
very robust
CSI Poor Poor, limited
by scan time
Yes Very easy and very robust,
no 3D
EPSI Poor for 2D,
okay for 1D
Poor Yes More efficient, still robust
and easy to implement
Spiral CSI Good Good None Prone to artefacts, very sen-
sitive to gradient errors
IDEAL spiral CSI Good Good Some spectra More robust than spiral
CSI, but harder to imple-
ment
SPSP Good Good No, but FID can
be interleaved
Prone to artefact if fre-
quency drift occurs, but
highly customisable and
very efficient
soluble molecules chosen for their long T1 which were polarised often by para-hydrogen
induced polarisation as well as DNP. Even when dissolution DNP provided Golman et
al with the first images using the 13C-labelled endogenous agent [1-13C]urea in 2003
(figure 1.12) the full potential went initially unnoticed, with the researcher suggesting
13C-labelled glucose for follow up work. The concept of metabolic imaging followed
shortly with [1-13C]pyruvate taking an early lead.
Figure 1.12: First Hyperpolarised [1-13C]urea coronal projection images of a rat ac-
quired a) 0 s and b) 2 s after injection. Figure taken from Golman et al, 2003 [154].
1.6.2 [1-13C]pyruvic acid
Chosen for its hugely significant role in enzymatic reactions pertaining to a range
of pathological changes, as well as its good physical capacity for polarisation, [1-
13C]pyruvic acid has been the subject of numerous important studies and has since
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progressed to being the first hyperpolarised molecule to be imaged in humans. [1-
13C]pyruvic acid, which is injected as the salt [1-13C]pyruvate after pH neutralisation,
is part of three main pathways of interest. These comprise reduction to [1-13C]lactate
by the enzyme lactate dehydrogenase (LDH) requiring the cofactor NADH, a reaction
prevalent in tumour and ischaemic environments; transamination with glutamate by
alanine transaminase (ALT) to [1-13C]alanine and α-ketoglutarate and finally the ir-
reversible carboxylation to [13C]bicarbonate in rapid equilibrium with 13CO2. In a
paper from 2006, Golman is first to suggest pyruvate for metabolic imaging and goes
on to demonstrate the ability to image these reactions in real time in vivo using a
chemical shift imaging (CSI) technique [187]. Rats were injected with 0.79 mM/kg of
hyperpolarised [1-13C]pyruvate and pigs with 0.2 mM/kg. In both cases researchers
were able to produce dynamic images and quantitatively determine relative concen-
trations of the products [1-13C]lactate and [1-13C]alanine in the animals. Imaging of
13C-bicarbonate produced via the carboxylation pathway was achieved in a clinical 3
T MR scanner a year later [188].
1.6.2.1 Pyruvate in tumours
The Warburg effect, believed to be a fundamental process at work in the vast majority
of tumours, describes the propensity of tumours to produce energy through aerobic
glycolysis, leading to large pools of lactate within and around the tumour site [2].
The conversion of pyruvate to lactate within the glycolytic pathway is reversible,
meaning that there is constant exchange between the two even if there is no net flux.
By imaging changes in the observed 13C-lactate level after doping in vitro cells with
different quantities of non-labelled lactate, it has been shown that the exchange of
the 13C-label between the injected pyruvate and the large endogenous lactate pool
in the tumour is the dominant factor affecting the signal observed by hyperpolarised
imaging [169, 189, 190]. These studies demonstrated the potential of 13C imaging
for the detection and diagnosis of tumours, offering a level of specificity for detecting
cancers only possible due to the the almost ubiquitous Warburg effect. Elevated [1-
13C]lactate levels were observed in both primary and metastatic tumours in mice and
have been observed in a range of cancers including prostate, lymphoma, renal cancer
and glioma [191, 192, 189, 177].
Using a murine model for prostate cancer, the transgenic adenocarcinoma of mouse
(TRAMP) model, Albers et al showed that elevated lactate could be quantified suf-
ficiently accurately for tumours to be graded [193]. Normal and TRAMP mice with
high and low Gleason grade prostate tumours were imaged with a fast spectroscopic
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sequence following injection of hyperpolarised pyruvate. The mice were subsequently
dissected and histologically analysed to allow grading of the tumours. A correlation
coefficient between Gleason grade of the tumour and lactate signal from the imaging
of 0.95 was observed, indicating sensitivity enough to allow tumours to be confidently
graded without biopsy.
Clinically, the response of a tumour to treatment is currently analysed with stan-
dard anatomical imaging techniques such as CT, using the size of the tumour as the
main indicator. This requires a long timescale for changes to become visual and can
sometimes be misleading, with some tumours initially growing larger even after suc-
cessful treatment. Hyperpolarised [1-13C]pyruvate has been used to non-invasively
detect treatment response within 24 hours [169]. Dynamic MR spectroscopy was
used to measure pyruvate and lactate signal after hyperpolarised pyruvate injection
in mice with lymphoma and the apparent rate of conversion kP was calculated. This
was carried out before and then 24 hours after treatment with chemotherapy. Fig-
ure 1.13 shows an example of the dynamic spectra, and pyruvate and lactate time
courses obtained in the experiment. It was found that the rate kP decreased by ∼25%
in this time, showing a clear change in tumour metabolism following treatment. A
later study on response to radiotherapy in rats with glioma [177] had similarly rapid
results. Researchers looked at the ratio of 13C-labelled lactate in the brain to the
maximum pyruvate signal in the bloodstream, finding a reduction of 34% just 72
hours after whole brain irradiation with 15 Gy. Other papers have since focused on
using hyperpolarised imaging with pyruvate to assess the effectiveness or specificity
of a drug [194, 195]; treatment with MEK inhibitor U0126 causing a decrease in
pyruvate to lactate conversion in the breast but an apparent increase in the prostate,
highlighting the complexity of such a system.
The ability to rapidly detect if a particular drug has had an effect on a tumour is
of great clinical interest. Chemotherapy drugs are often detrimental to patient well
being and extremely expensive, so knowing quickly whether it will be effective or
not could be exceedingly valuable. This application of hyperpolarised imaging has
perhaps the most obvious clinical worth of those investigated so far.
1.6.2.2 Cardiac metabolism
Pyruvate has also been successfully applied to the analysis of cardiac metabolism
[196, 197]. The main pathway of interest in this case, is the irreversible conversion of
[1-13C]pyruvate to acetyl-CoA by the enzyme pyruvate dehydrogenase (PDH), pro-
ducing 13C-bicarbonate as a detectable by-product in rapid pH-dependant flux with
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Figure 1.13: Dynamic MR spectroscopy data showing pyruvate and lactate signal
over time in a murine lymphoma model: a) full 13C spectra acquired every 4 s over
180 seconds, with [1-13C]lactate (left peak) and [1-13C]pyruvate (right peak) clearly
visible; b) corresponding relative pyruvate and lactate signal intensity over time.
Figure adapted from Day, 2010 [169].
carbon dioxide. Schroeder et al used rats with streptozotocin-induced type 1 dia-
betes to look at the role of cardiac PDH activity in diabetes and heart failure [178].
Around 30% of energy in the heart is produced through glycolysis of pyruvate by
PDH. PDH exists in both activated and inactivated states in the heart, the ratio of
which are strongly determined by environmental factors. The increased activity of
PDH in the heart has been linked to high blood insulin levels; researchers used hyper-
polarised [1-13C]pyruvate to image and compare the amount of break-down product
13C-bicarbonate, an indicator of PDH activity, in the hearts of 1 day fasted and
normally fed rats. The depleted 13C-bicarbonate in the fasted rat heart by 74% sup-
ported the connection of PDH to insulin level and demonstrated the sensitivity of the
technique. When tested in the diabetic rat model, bicarbonate was also lowered com-
pared to the control rats by 65%, and a negative correlation between its production
and the blood glucose level of the rat was found.
Reduced 13C-bicarbonate was also observed in the myocardium of pigs following
an induced ischaemic episode [179]. A balloon catheter was introduced into the
left circumflex artery of the pig and inflated for 0, 15 or 45 min to model different
levels of ischaemia, then re-perfused before imaging with 13C-pyruvate. Before and
after images of the pig hearts clearly show damage to the myocardium with some
areas producing little or no bicarbonate after the ischaemia. Not only does this study
demonstrate the feasibility of 13C-pyruvate imaging for detecting damage to the heart
on a metabolic level following trauma, but it overcomes the signal to noise difficulties
with imaging a large animal, an encouraging step towards use in humans.
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1.6.2.3 Other applications
In a study similar to that above by Schroeder et al [178], the same diabetic rat model
was used to look at metabolic changes in the kidney associated with the disease [198].
The kidneys of the diabetic and normal control rats were imaged using hyperpolarised
MRS and blood oxygen-level dependant (BOLD) sequences. It was found that unlike
the cardiac study, the bicarbonate/pyruvate ratio was found to be unchanged, whereas
the lactate/pyruvate ratio increased by 149% in the diabetic rats. This, along with
decreased oxygen levels detected by the BOLD imaging, indicates a pseudohypoxic
condition in the diabetic kidney. Laustsen et al suggest that these ratios, along with
the bicarbonate/lactate ratio could be used as quantitative metrics for monitoring
disease by imaging metabolic changes in diabetic patents.
It has been proposed that inflammation may also cause similar metabolic changes
to those seen in ischaemia [199]. Hyperpolarised 13C-pyruvate was injected into iso-
lated perfused rat lungs in which a state of acute inflammation had been induced by
administration of bleomycin. Lungs were removed and imaged at 7 or 21 days and
the level of lactate was observed to increase by 330% in the acute inflammation con-
dition on day 7 compared to healthy controls. The researchers attribute this effect
to elevated glycolysis in the inflamed tissue and suggest further investigation with
hyperpolarised imaging for inflammatory diseases.
In addition to the tumour environment, the metabolism of pyruvate to lactate is
altered in ischaemic conditions. Low oxygen levels cause normal body metabolism
to proceed anaerobically leading to the production of lactate; a reaction which can
be probed with hyperpolarised pyruvate through exchange with the lactate pool.
Pullinger et al examined the effects of ischaemia on the isolated perfused rat lung
[200]. Each lung was imaged twice, with the order of the normoxic and hypoxic
imaging sessions reversed for half of the samples to eliminate time degradation as
a cause of lactate build up. Their theory was validated, with higher lactate signal
observed for the ischaemic condition in both groups.
1.6.3 Fumarate and other molecules
Another endogenous molecule which has shown excellent potential for clinical trans-
lation is [1,4-13C2]fumarate. It has been suggested that the production of [1,4-
13C2]malate from [1,4-
13C2]fumarate may be a sensitive marker for tumour necrosis.
In a paper by Gallagher et al, a murine lymphoma model was used to image the con-
version of fumarate to malate in vivo [168]. The tumour region was imaged before and
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then 24 hours after the administration of etoposide, which induced a significant level
of tumour necrosis. It was found that the production of 13C-labelled malate increased
2.4 fold following drug administration; possibly due to leaking of the conversion en-
zyme fumarase into the extracellular space after induced apoptosis or cell death. In
addition to the pyruvate-lactate exchange reaction, the production of malate from
fumarate may also be an indicator of tumour response to treatment. The potential
use of [1,4-13C2]fumarate in acute kidney injury has been investigated by Clatwor-
thy et al [201]. Acute kidney injury is difficult to discern from glomerulonephritis
using current imaging methods or biomarkers, however only the former is caused by
tubular necrosis. Mouse models of each disease were injected with hyperpolarised
[1,4-13C2]fumarate before undergoing MRS. A significant increase in [1,4-
13C2]malate
production was seen in the acute kidney injury mouse model, but not in the glomeru-
lonephritis or normal mice, suggesting that this may be a tool for differential diagnosis
of the disease in patients. It is likely that 13C-fumarate will be an early, if not the
second molecule to be imaged in humans and is currently undergoing review at the
University of Cambridge for its use in patient studies.
Although it is known that pH is altered in many disease states such as cancer,
ischaemia and inflammation, there is currently no good way to measure pH levels
across body tissues [202]. Bicarbonate is in fast equilibrium with CO2, with the
relative levels of each strongly pH dependant. It has been shown that by injecting
hyperpolarised 13C-bicarbonate into a murine lymphoma model and analysing the
conversion to CO2, it is possible to image the spatial distribution of reduced pH at
the tumour site [165].
Other molecules which have been successfully hyperpolarised and investigated as
in vivo metabolic probes include [5-13C]glutamine [203], [1-13C]glutamate [204], [1-
13C]acetate [205], [1-13C]α-ketoglutarate [206], 13C-glucose [207] and 13C-succinate
[208]; a brief summary of each of these is provided in table 1.2.
1.7 Early human studies with hyperpolarised 13C
1.7.1 Neurological potential
The lactate/pyruvate ratio in the brain is already used as a clinical indicator of dam-
age in traumatic brain injury and there have been numerous studies using 13C-labelled
molecules to probe neurochemistry and metabolism. Most of the research efforts to
image 13C-pyruvate metabolism in the brain have so far focused on its role in glioblas-
toma, however there are many neurological disorders which would be expected to
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Table 1.2: Possible candidate metabolites clinical translation with 13C hyperpolarised
imaging
Metabolite Product(s) In vivo T1 Clinical relevance
[1−13C]pyruvate [1−13C]lactate
[1−13C]alanine
13C-bicarbonate
29 s Indicator of tumour metabolism
(Warburg effect) [191, 192, 177],
areas of ischaemia or inflamma-
tion [200, 199], metabolic changes
due to diabetes [198]
[1,4-13C2]-fumarate [1,4-
13C2]malate 24 s Increased malate production as a
marker for necrosis [168, 201]
13C-bicarbonate 13CO2 10 s Measurement of pH [165, 202]
[1−13C]acetate [1-13C]- acetylcarnitine 15 s AcetylCoA synthetase activity in
cancer [205]
[5−13C]glutamine [5-13C]glutamate 20 s Indicator of tumour metabolism
[203]
13C-succinate 13C-glutamate
13C-glutamine
6 s Early detection of brain tumour
[208]
demonstrate metabolic changes. Ischaemia and inflammation are both obvious can-
didates for imaging with hyperpolarised pyruvate. Although imaging has been shown
feasible in a rat glioma model [209, 177], the abnormal vasculature and compromised
blood-brain barrier still left questions unanswered regarding use in the non-cancerous
brain. A proof of concept study in 2014 looked at the feasibility of imaging the healthy
primate brain prior to testing possible experimental set-ups for human studies [210].
Pyruvate was able to cross the blood brain barrier in cynomolgus healthy monkeys
and its conversion to lactate inside the brain was successfully imaged, opening up the
possibility of using [1-13C]pyruvate for studying neurometabolism further. A study to
image multiple sclerosis in patients is now under way at Addenbrooke’s hospital Cam-
bridge, where it is believed that the plaques visible during active disease will show
increased conversion to lactate, due to the inflammatory response that causes the
lesions. Human imaging in stroke patients is also planned, where the neuroprotective
production of lactate may indicate salvageable tissue in the ischaemic penumbra.
1.7.2 Advancement to the clinic: first human studies
In 2013, Nelson et el performed the first hyperpolarised 13C metabolic imaging study
in patients with prostate cancer [156]. The study used hyperpolarised dissolution
DNP of [1-13C]pyruvate in a pre-clinical Hypersense polariser and hyperpolarisation
carried out in clean room conditions, to assess the safety and feasibility of the tech-
nique. No dose limiting toxicity or adverse effects were seen in the initial tests and
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a weight-dependant dose of 0.43 mL/kg of pyruvate was chosen for the experiment.
A small number of the 31 patients were chosen to undergo 1D or 2D spatially lo-
calised dynamic hyperpolarised MRS. Spatial locations were chosen which included
both a region of known tumour and of healthy tissue for each patient so that com-
parisons could be drawn, and the rate kP of pyruvate to lactate flux was calculated
in each case by fitting of the dynamic data to a simple one-way kinetic model; this
parameter was shown to be lower in the healthy tissue. The majority of patient data
acquired consisted of single time-point MRS over a 9 voxel array. By analysing the
[1-13C]pyruvate/[1-13C]lactate ratios in each voxel, researchers were able to detect
bilateral cancers, later confirmed by biopsy, that were not detectable with the con-
ventional anatomical images that were also acquired. Their work provides an early
indication that the sensitivity of hyperpolarised imaging may be sufficient to allow
for very early tumour detection.
The difficulty of the clean-room approach taken by the UCSF team was one of
a number or reasons why publications on human imaging were halted for the next
four years. Although a number of conference abstracts were presented in the field,
some containing early human data [211, 212, 213] it was not until 2017 that the second
human study of 13C-pyruvate in the healthy human heart was published. Cunningham
et al imaged the metabolism of [1-13C]pyruvate to [1-13C]lactate and 13C-bicarbonate
in the healthy human heart in four volunteers at Sunnybrook Hospital Toronto [214].
Bicarbonate production was clearly observed in the myocardium whilst lactate signal
was more diffusely seen in the blood, muscle and tissues. The same dose as the
previous study of 0.1 mmol/kg was given with no adverse effects; a result echoed in
early unpublished human studies at other sites.
A very recent third publication from UCSF images one prostate cancer patient
before and six weeks after treatment with androgen deprivation therapy [215]. A
marked change in the kP value as derived from a single large tumour-containing
voxel is noted, with a pretreatment kP of 0.025 s
−1, dropping to 0.007 s−1 following
treatment. Although this is a single patient study and the time window of six weeks is
far longer than might be hoped for detecting treatment response with hyperpolarised
imaging, it nevertheless marks an important first demonstration of potential for the
technique.
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1.8 Quantitative analysis of dynamic 13C spectra
1.8.1 Enzyme kinetics and the Michaelis-Menten approach
The temporal resolution of many hyperpolarised imaging and spectroscopy techniques
is sufficient that dynamic data may be produced, describing the relative concentra-
tions of metabolites over time. This allows for a range of potential quantitative
analysis to be applied and for values of rate constants governing the dynamics to be
derived. By far the most widely investigated reaction is the reversible conversion of
pyruvate to lactate by the LDH enzyme, requiring one molecule of NADH for each
pyruvate molecule metabolised. The enzyme kinetics of the reaction have been well
probed with 1H NMR in vivo [216] and later also with hyperpolarised 13C NMR [217].
The reaction can be summarised as follows:
[P] + [NADH] + [LDH]
k12−−⇀↽−
k21
[P][LDH]
Enzyme complex
k23−−⇀↽−
k32
[L] + [NAD+] + [LDH] (1.11)
where letters in square brackets represent concentrations of metabolites and LDH
enzyme, and kij are reaction rates for each step. One simplifying assumption which
may be made is that the backwards reaction rate k32 = 0. In this case, the reaction
model simplifies to one-way conversion and obeys Michaelis-Menten dynamics if the
following assumptions are made. First, the formation of the pyruvate/LDH complex
is in fast exchange, or k12 ≈ k21  k23, and is also in steady state. Second, it must be
assumed that the pyruvate concentration is much greater than the LDH concentration
and can therefore be considered constant. The rate of lactate production kP is then
given by:
kP =
[LDH]Tk32[P ]
[P ] + ([k23 + k21]/k12)
=
Vmax[P ]
[P ] +KM
(1.12)
where Vmax is the maximum speed at which the reaction can occur and KM is the
Michaelis-Menten constant, representing the concentration of pyruvate at which the
reaction rate is half of its maximum. It is often desirable to reduce the complexity
of a reaction down to these simple parameters, which describe clear and measurable
quantities; many enzymatic reactions are very successfully described by this equation.
However, the numerous assumptions made do not necessarily apply to every exchange
reaction meaning such simplifications are not always possible or appropriate.
1.8.2 The modified Bloch equations
When dealing with hyperpolarised metabolites, it is not the concentrations that we
are able to measure but rather that fraction of each species which is polarised and
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thus visible. We are also unable to directly measure LDH in any way, so it is sensible
to simplify the equation 1.11 to:
P
kP−−⇀↽−
kL
L (1.13)
The polarisation is being lost over time at a rate defined by the T1,eff as described in
section 1.5.3. It is then possible to define two coupled differential equations, known
as the modified Bloch equations [218], to describe how the visible magnetisation of
these metabolites changes in time:
dP
dt
= kLL− kPP − ρPP (1.14)
dL
dt
= kPP − kLL− ρLL (1.15)
The ρi are equivalent to the inverse of the T1,eff for each species. This set of equa-
tions can be easily extended to include other metabolites, or to account for intra- and
extracellular compartmentalisation, and provide a starting point from which the ma-
jority of hyperpolarised 13C kinetic modelling approaches are derived. Both equations
have bi-exponential solutions, which tend to zero when t becomes large. These solu-
tions can then be fit to experimental data, generally by using a least-squares fitting
method to find values for each of the four parameters kP , kL, ρP and ρL. Generally of
greatest interest is the pyruvate to lactate conversion rate constant kP ; the tighter the
constraints placed on the other three variables, the more accurately the rate constant
can be determined.
By setting the backwards rate kL to zero, an approximation of the modified Bloch
equations can be made which allows analysis of hyperpolarised data via a Michaelis-
Menten model as described above. This simple and popular model has been applied
with some success by multiple groups [219, 220, 221, 222]. However, researchers have
at times underestimated the complexities involved, with both Harris and Whitney
concluding that the transport of pyruvate into the cell was in fact flux-limiting, con-
trary to implicit assumptions with the one-way model that this step is instantaneous.
Another example of the pitfalls of this approach is highlighted in a paper by Zierhut
et al [170], in which dynamic data from healthy rats and TRAMP mice (prostate
cancer model) is fit to a Michaelis-Menten type model with apparently good results.
However, when the T1 of pyruvate is estimated by the fit, the variance is enormous,
with data from two mice giving a three-fold difference. Since the T1 is a largely phys-
ical property of the molecule and the data were obtained in the same magnetic field
and roughly the same biological environment, these erratic values would indicate that
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their model is under constrained, most likely due to the use of separate equations pre-
and post-peak, which would explain the visually good fits. Additionally, the steady
state approximation necessary for Michaelis-Menten statistics is unjustified, as the
reaction is nowhere close to equilibrium. A paper reviewing this model found it to
provide the worst fits to data out of several models tested [223].
1.8.3 Two and three compartment models
There has been some debate over whether it is necessary to include contributions
from intracellular and extracellular lactate separately, giving rise to both two and
three-compartment models; the two-compartment model is described by equations
1.14 and 1.15 and has been used successfully in numerous papers without requiring
the assumptions detailed above [169, 222]. It was shown in a 13C diffusion study by
Schilling et al [224], that although it was a reasonable assumption to treat all pyru-
vate as extracellular, transport of lactate into and out of the cell produces separate
intracellular and extracellular pools which undergo exchange. With subscripts i and
e denoting intracellular and extracellular respectively, the three-compartment model
can be described by the rate equation:
P
kPi−−⇀↽−
kLi
Li
kie−−⇀↽−
kei
Le (1.16)
Which gives the following set of differential equations:
dP
dt
= kLiLi − kPiP − ρPP (1.17)
dLi
dt
= kPiP − kLiLi + keiLe − kieLi − ρiLi (1.18)
dLe
dt
= kieLi − keiLe − ρeLe (1.19)
Pyruvate may only be converted to intracellular lactate; it must first be transported
into the cell where NADH and LDH are available before the reaction can commence.
The intracellular pyruvate pool may be neglected due to the rapid speed at which
pyruvate is converted upon entering the cell. In a comprehensive review of six different
two and three compartment kinetic models [223], dynamic hyperpolarised data were
obtained from isolated glioblastoma cells as well as mass spectrometry (MS) data
from pyruvate exposed to cells taken at 0, 3 and 10 min. Pyruvate, intracellular and
extracellular lactate were measured and used for comparison. Both data sets were fit
simultaneously to the six models. Surprisingly, they found that all six models were
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able to provide good fits to the hyperpolarised data, with or without the MS data.
When the hyperpolarised and MS data were used together to calculate the kinetics,
it was only the bi-directional three compartment and bi-directional two compartment
models which were able to produce a good fit. When the hyperpolarised data were
fit to each model without the MS data, only the two-compartment bi-directional
model produced a fit compatible with the MS data. It is interesting that all of
the models with a uni-directional component were unable to describe both data sets
simultaneously; the implication here is that the fully bi-directional models fit the data
due to a more accurate description of the reaction, rather than simply by having more
fitting parameters.
1.8.4 Arterial input function
None of the above models account for the influx of pyruvate to the imaging site which
occurs clinically; each one assumes that the pyruvate is injected instantaneously. Al-
though this may be a reasonable approximation for in vitro data, in animals and
particularly in patients, a large volume of fluid must be injected over a finite time.
The pyruvate will then wash through the imaging site as a bolus after a few seconds,
with a flow profile known as an arterial input function (AIF). Mathematically, this
results in an extra term in equation 1.14 for the rate of change of incoming pyruvate,
with the simplest possible description being the addition of a constant represent-
ing constant inflow. For a more accurate description of the flow profile, a Gaussian
or gamma-variate function can be better used to model the pyruvate bolus moving
through the site. The gamma-variate is commonly used approximation of the AIF,
which describes a fast initial flux starting from zero with a slow tail off. One paper
uses a directly measured AIF from a catheter placed in the femoral artery of rats,
along with simultaneous pyruvate injection and dynamic hyperpolarised data acqui-
sition [225]. They then compare fits to the hyperpolarised data with a two-site model
incorporating the measured AIF, various box-car function AIFs (constant inflow for
a defined period) or using a simple precursor-product model. All of the box-car func-
tions gave poor fits. Additionally they find that unless the effects of blood flow and
substrate delivery are of direct importance, it is better to make no assumptions about
the shape of the AIF by using the precursor-product model. Although the measured
AIF gave an excellent fit to the data, and by fitting it to a gamma-variate function
parameters could be ascribed biological relevance, it would be very impractical to
use this method for AIF measurement on a patient since arterial catheterisation car-
ries potential risk. Non-invasive measurements of the AIF, or of parameters which
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could be used to build up a representative gamma-variate input, could yet be of
use to provide better models for more complicated reactions involving three or more
metabolites, or for situations when blood flow is of great importance to the results.
1.8.5 Model-free approaches
There has been much debate between groups over which kinetic model best describes
dynamic hyperpolarised data with no clear outcome. The two-site one-way model
is certainly the most popular, yet in comparison papers has been shown multiple
times to provide the worst fits [223, 225, 226, 227]. The three-site models would
appear to give a better scientific description, yet these too have been found lacking.
Arterial input functions are difficult to measure and modelling cerebral metabolism
brings further problems with regards to metabolites crossing the blood brain barrier
[209, 228] and the possibility of new models being required in order to account for
this slow transit. In the light of all this it would be highly desirable, particularly in a
clinical setting, to find some simple quantitative parameter capable of characterising
the observed reaction without the need for complicated models. There have been
several suggestions as to what this parameter could be.
In a paper by Hill et el, they suggest calculating the area under curve (AUC) for
each of lactate and pyruvate, then taking the ratio of these to provide a simple quan-
titative parameter [226]. They demonstrate mathematically that, providing that the
input function only depends on pyruvate, this AUC ratio is completely independent
of what exact function is used. They go on to prove that this ratio is also directly
proportional to the rate kP , and is equal to:
LAUC
PAUC
=
kP
ρl + kL
(1.20)
When compared to fits from both two and three compartment models, the AUC ratio
was found to correlate well with the kP values, providing a slightly better correlation
with those obtained from the two compartment model. This is an indication that
the AUC ratio may provide a simple and robust alternative to the derivation of rate
constants.
A different approach called FmRα analysis was developed by Page`s and Kuchel
[229]. This involves the determination of two geometric values from the data which
they call α and β. They begin with two assumptions; that the T1 is equal for pyruvate
and lactate and that the reaction is one-way, i.e kL = 0. From here, they define β to
be the ratio of the two curves at the maximum of the lactate signal, i.e. at t = tmax
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and show this to be β = L(tmax)/P (tmax) = kPT1. The next step is to determine
two points in the rise and fall of the lactate signal such that the width between
them is equal to T1; this is the fall-minus-rise time at height α, or FmRα, where
L(t1) = L(t1 +T1). α is defined as L(t1)/L(tmax). Since α varies slowly with β, it can
be approximated as 0.8. β/FmRα is then equal to the rate constant kP . The method
was tested against previously published in vivo data fitted to the same unidirectional
model. Correlation was reasonable but not good, possibly due to limitations in the
one-way model both sets of values were derived from.
Other researchers, particularly when the emphasis has been on collecting spectro-
scopic data, have used the ratio of lactate-to-pyruvate peak heights as determined
from the spectra [177, 156]. This is a good parameter to utilise in the absence of dy-
namic data and has been shown to correlate well with the Gleason grade of tumours
[193].
There are numerous other model-free approaches to hyperpolarised data analysis
which could prove clinically valuable for quick assessment of patient data. Whether
they will be able to provide biologically meaningful values, or just an arbitrary but
still clinically useful measure, is yet to be fully discussed. Also to be established
is the robustness of each approach and the correlation both to measured biological
parameters and to each other. It is highly desirable that a clinical standard of quan-
titative analysis presents itself so that patient data from different groups and sites
can be compared; it is clear that further investigation and comparison of the various
potential approaches is required.
1.9 Molecular imaging with 18F-FDG PET
The most similar imaging modality to hyperpolarised MRI with 13C-pyruvate is 18F-
Fluoro-deoxyglucose positron emission tomography (18F-FDG PET). The two tech-
niques may be thought of as complementary, providing similar yet distinct metabolic
data (see [230] for a full comparison). As PET/MR becomes a more widely avail-
able technology, the potential for simultaneous hyperpolarised 13C/18F-FDG PET is
becoming apparent and clinical feasibility studies are already being performed; for
example, Gutte et al successfully imaged 10 canine cancer patients using a clinical
“hyperPET” set-up [231]. 18F-FDG PET is a metabolic imaging technique which uses
uptake of a radioactive glucose-based tracer as a marker of abnormal metabolism. Tu-
mours and areas of inflammation are particularly glucose avid, showing up as areas
of bright contrast on the images. After the tracer is taken up into the cells by glucose
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transporters it is phosphorylated by the enzyme hexokinase, however the labelling
prevents the tracer from progressing any further through glycolysis, or being trans-
ported out of the cell. Instead, it remains in the cytoplasm and emits positrons (β+
radiation) which may meet an endogenous nearby electron and annihilate to produce
two 511 KeV photons. A cylinder of photo-detectors surrounding the scanner detects
simultaneous incidences as coming from the same annihilation event. By using a
technique called time-of-flight correction to account for the different journey times of
photons released simultaneously but detected in different locations, it is possible to
calculate their spatial origin and to generate a 3D map of glucose uptake through out
the whole body.
PET is intrinsically semi-quantitative in nature, as the image contrast is directly
based on the number of photons detected to have originated in each voxel. In standard
clinical practice, PET contrast is quantified by a parameter called the standardised
uptake value (SUV), which is defined for each voxel as the ratio of the observed
activity to the injected activity. These quantities are measured in MBq/ml or MBq/g
and are corrected for the radioactive decay of the tracer between injection and imaging
and the weight of the patient, such that the SUV can be read as the unitless deviation
of any particular voxel from the averaged expected uptake, assuming uniform tracer
uptake across the body. The SUVmax and SUVmean define the highest voxel within
and average over voxels within a region of interest respectively, and are the quantities
most commonly utilised clinically in the analysis of PET images. In most cases a single
static 3D image is acquired, however it is also possible to acquire multiple images over
time. Although the SNR is reduced with this approach, capturing the glucose uptake
timecurve at each voxel allows for the derivation of quantitative parameters by fitting
kinetic models to the 4D data [232].
PET imaging is generally combined with CT, or more recently MRI, taken on
the same machine in order to anatomically reference the images, particularly as the
resolution of PET itself is poor (5×5 mm) and images suffer from being very noisy.
There are several factors in the physics of PET which combine to produce this: the
emitted positron will travel a few millimetres from the source before annihilating;
the photons are not produced perfectly orthogonally and are subjected to further
scattering effects before reaching the detectors and the individual photodetectors
have a finite size within which they are not able to further spatially locate the point
of photon impact. The patient may also move during the scan, either voluntarily or
involuntarily, and normal uptake in the body organs, particularly in the brain, gut
and urinary system, often obscure nearby regions of pathological uptake. Although a
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wealth of approaches exist to reduce the effect of these sources of noise and error, any
attempt to derive quantitative results from PET images must bear these limitations
in mind.
1.9.0.1 18F-FDG PET in oncology
18F-FDG PET is an established clinical tool for the diagnosis, grading and treatment
response monitoring of many cancers [233]. The increased uptake observed to occur in
tumours of the glucose-analogue tracer 18F-FDG, is due to a combination of increased
rate of cellular glucose metabolism and an increased number of glucose transporter
proteins on the cell surface (primarily GLUT1 and GLUT4). The almost ubiquitous
occurrence of these factors in tumour cells make 18F-FDG PET feasible in most
cancers, however additional factors such as tumour size, anatomical location and the
availability of competing, cheaper means of detection mean that PET is only used
routinely for certain applications. Nevertheless, it still provides a highly sensitive and
specific tool for imaging a range of cancers.
18F-FDG PET has been successfully applied for diagnosis and staging in a wide
range of diseases. It has been shown to provide a significant benefit over CT alone
for distinguishing between benign and malignant pancreatic lesions [234] and offers
sufficiently sensitive detection of bone metastasis in Hodgkin’s lymphoma to negate
the use of an invasive bone marrow trephine biopsy [235]. Use of PET imaging for the
staging of lymphoma has been shown to be superior to other standard methodologies
including physical examination, radiography and laboratory testing [236]. It has also
demonstrated significant benefit over other means of cancer detection and staging for
non-small cell lung cancer [237], recurrent colorectal cancer [238] and head and neck
cancer [239].
18F-FDG PET offers a significant benefit for the imaging of gynaecological cancers
such as cervical and ovarian [240]. In recurrent metastatic ovarian cancer, PET
imaging has been shown to significantly aid the detection of lesions not visible on
anatomical CT or MRI alone [241] and to improve site-specific radiation planning, as
well as aid in the selection of optimal surgical candidates [242]. Furthermore, Avril
et al were able to accurately predict patient response to neoadjuvant chemotherapy
after just one cycle from sequential FDG PET [243]. They demonstrated the improved
accuracy of this approach over clinical or histopathologic response criteria including
changes in tumor marker CA125. The benefits of using 18F-FDG PET to detect early
treatment response have further been demonstrated in Hodgkin’s lymphoma [244],
non-small cell lung cancer [245] and esophageal squamous cell carcinoma [246].
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1.9.0.2 18F-FDG PET for imaging the immune response
Increased glucose uptake is known to occur in activated immune cells during an in-
flammatory response; 18F-FDG PET therefore provides a means of imaging such a
response. Often, the high metabolic activity of the immune cells is viewed as a hin-
derance which obscures signal from sites of oncological interest, however there are
several situations in which 18F-FDG PET may be usefully deployed for directly prob-
ing immune cells. Standard clinical applications range from autoimmune diseases to
infections, such as rheumatoid arthritis [247], sarcoidosis [248], HIV and AIDS related
infection [249, 250] and fever of unknown origin [251]. Recently, the role of glycolytic
metabolism in activated T-cells has been elucidated [252]. The rapid proliferation of
these cells initiates metabolic reprogramming remarkably similar to that seen in tu-
mours, demonstrating high levels of ATP production through glycolysis and elevated
glucose and glutamine uptake [253]. This clearly has profound implications for tu-
mour imaging with both 18F-FDG PET and hyperpolarised 13C-pyruvate, particularly
as the use of immunotherapies gains clinical popularity.
1.10 Image segmentation in PET and MRI
Clinical imaging research commonly makes use of regions or volumes of interest (ROI
or VOI) for delineating anatomical features, or for the analysis and quantification of
areas that are pathologically abnormal in comparison to normal tissue. For example,
radiation treatment planning relies heavily on accurate delineation of the tumour
volume to avoid damage to normal tissue, and many commonly used metrics for
assessing disease progression and treatment response rely on region determination
and the subsequently derived quantitative parameters based on these regions; the
SUVmean, commonly used in the clinical interpretation of PET images, is a good
example of such a metric. Accurate and robust quantification of imaging data is
imperative in order to make reliable inter- and intra-patient comparisons therefore
any ROI used in this analysis must be accurate, robust and repeatable.
There are four main approaches which are applied to the problem of image seg-
mentation, which vary considerably in complexity. The first is manual delineation;
this is used very commonly by clinicians for defining ROIs on anatomical images, how-
ever it is time consuming making it unsuitable for processing large date sets, prone
to human error and has poor repeatability [254, 255]. Also frequently applied, partic-
ularly in clinical PET analysis, is a thresholding approach whereby the user defines
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some inclusion criteria for the ROI based on image contrast [256]. Although itera-
tive and adaptive thresholding methods have been developed over the past decade
[257, 258], these methods are still ultimately quite susceptible to noise and variability.
Unsupervised image segmentation methods use a more complex, statistical decision
process, generally accounting for background noise and other user supplied informa-
tion when defining the ROI. They have the benefit of being completely repeatable
and require very little user interaction once the algorithm has been set up [259]. Fi-
nally, supervised segmentation methods using machine learning techniques have been
rapidly gaining popularity. Initially requiring very large data sets to train algorithms,
supervised methods can become very accurate over time and eventually require no
additional user input [260]. They are well suited to the detection of subtle anatomical
features on MRI or CT images which would not be possible with other methods.
Unsupervised and statistical segmentation techniques are particularly well suited
to molecular and functional imaging data due to their enhanced capability to appro-
priately handle the noise, partial voluming effects and artefacts which are common
to these modalities. The reminder of this section will therefore focus on unsupervised
segmentation in PET and functional MRI, motivated by the potential application of
these techniques to hyperpolarised 13C data.
1.10.1 Edge-detection approaches for image segmentation
Variational methods rely on detecting the location of gradients in image contrast to
determine the boundaries between regions. A common starting point is a Sobel edge
detection or watershed transform, which determine the lines of maximum gradient
across the whole image. The water shed transform treats the image contrast as a to-
pography with pixel intensity representing height; the transform can be thought of as
the dividing lines between different catchment basins for rain falling on the landscape.
Although an early study applying this technique to PET images found little benefit
over thresholding methods [261], Greets et al were able to produce more accurate
results by first applying denoising and deblurring edge-conserving filters, along with
constrained iterative deconvolution, to images [262]. Active contour methods are also
a means of edge detection which seek to iteratively minimise an objective function
defining the contour. Hsu et al demonstrate the success of this approach, combined
with a genetic algorithm for objective function parameter optimisation, for segmenting
the liver [263]; it has also been used to delineate PET tumour volumes in conjunc-
tion with an adaptive region-growing algorithm [264]. Known colloquially as “snake”
methods, many variational methods struggle with discontinuities and more recently,
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the level-set method was proposed to overcome some of these limitations [265]. Start-
ing with some initial contour, an evolutionary PDE is solved iteratively to balance the
forces between image gradient and contour curvature. The resulting segmentations
have been successfully utilised for both PET and fMRI [266, 267, 268, 269].
1.10.2 Clustering methods
Clustering methods are a form of unsupervised classification learning which have been
widely applied to medical image segmentation. The k-means algorithm is perhaps the
simplest; a known number K of initial cluster centres are chosen, either randomly or
manually, from the N image voxels. For each voxel, a vector of features xj such as
the intensity are defined based on which the algorithm will attempt to classify the
voxels. Voxels are initially assigned to the most similar cluster centroid, with the aim
to minimise the objective function for each cluster:
J(x, c) =
N∑
j=1
K∑
k=1
‖ xj − ck ‖2 (1.21)
where ck are the cluster centroid feature vectors. New centroids are then calculated
as the mean for each cluster and voxels are reassigned. This iterative process contin-
ues to convergence. Although this method has shown some successful applications in
MRI, [270, 271], an adaptation known as fuzzy c-means (FCM) clustering has been far
more widely applied in molecular imaging problems [272]. By incorporating fuzzy as
opposed to binary logic, large voxels, which may cover elements from more than one
real biologically distinct segment, are permitted to belong to multiple classes simulta-
neously during the iterative procedure. Fuzzy logic is a popular way of acounting for
poor image resolution and partial voluming; the fuzzy c-means algorithm has been
applied to many problems in PET imaging such as whole body attenuation correction
[273], brain lesion detection [274] and heterogeneous tumour quantification [275]. It
has also been successfully applied to brain tumour delineation in MR [276].
1.10.3 Statistical image segmentation
Statistical image segmentation methods generally make use of a Bayesian inference
to exploit statistical differences between the region of interest and the background.
These methods are particularly well suited to noisy data, as the noise can be explicitly
modelled for each segment and therefore taken into consideration when classifying
each voxel. Gaussian mixture models work on the principle that any distribution, such
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as image voxel intensities within an image, can be described as a mixture of Gaussian
(normal) distributions representing the image classes. The segmentation task is then
to use Bayesian expectation maximisation (EM) to determine as to which class each
voxel belongs. Aristophanous et al apply this approach, with three mixed Gaussian
distributions representing tumour, background and uncertain classes, to the definition
of lung tumor volumes from PET [277]. One notable approach for segmenting PET
imaging is suggested by Hatt et al. They use a Bayesian EM framework with two hard
classes and two fuzzy classes, which additionally accounts for the spatial relationship
between voxels based on the premise that voxels of the same class are more likely to
be adjacent that separate. They demonstrate the superiority of this approach over a
range of competing methodologies, particularly in the delineation of tumours <2 cm
in size [278].
An extension to the above approach uses the same Bayesian framework, but in-
corporates a specific form of prior called a Gibbs prior defined for each permutation
of the segmentation map x as:
p(x|β) = 1
Z
e−U(x|β) (1.22)
where β is a temperature parameter and Z is the partition function, defined as the
sum over all permutations of x. There are a number of key advantages to this ap-
proach; the term U(x|β) in the exponent may be made up of multiple additive terms,
making it possible to incorporate prior information from different sources. One of
these terms defines the spatial relationship between voxels; in 2D, this is known as
a Markov random chain (MRC) and in 3D, a Markov random field (MRF). As with
the Gaussian mixing model, normal distributions are used as the joint distributions
to model noise explicitly for each class. MRFs, and MRCs, have been extensively
applied to segmentation problems in MRI [279], [280], [281], [282], CT [283], [284]
and PET imaging [285], [286], [287]. More recently, studies have extended the ap-
proach to include a temporal component, notably to handle time activity curves in
PET [285] and in 4D MRI for both brain [288] and cardiac imaging [289]. Descombes
et al have a particularly interesting approach, utilising a 4D MRF model to examine
blood flow profiles in fMRI as a means of providing additional temporal information
to their segmentation process [290].
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Chapter 2
A comparison of quantitative
methods for clinical imaging with
hyperpolarised 13C-pyruvate
Dissolution dynamic nuclear polarisation (DNP) enables the metabolism
of hyperpolarised 13C-labelled molecules, such as the conversion of [1-
13C]pyruvate to [1-13C]lactate, to be dynamically and non-invasively im-
aged in tissue. Imaging of this exchange reaction in animal models has
been shown to detect early treatment response and correlate with tumour
grade. Early human DNP studies are now under way at multiple sites
worldwide, and for widespread clinical translation, simple and reliable
methods are necessary to accurately probe the reaction in patients. How-
ever, there is currently no consensus on the most appropriate method to
quantify this exchange reaction. In this study, an in vitro system was used
to compare several kinetic models, as well as simple model-free methods.
Experiments were performed using a clinical hyperpolariser, a human 3
T MR system, and spectroscopic imaging sequences. The quantitative
methods were compared in vivo by using subcutaneous breast tumours
in rats to examine the effect of pyruvate inflow. The two-way kinetic
model was the most accurate method for characterising the exchange re-
action in vitro, and the incorporation of a Heaviside-step inflow profile
was best able to describe the in vivo data. The lactate time-to-peak and
the lactate-to-pyruvate area under the curve ratio were simple model-free
approaches which accurately represented the full reaction, with the time-
to-peak method performing indistinguishably from the best kinetic model.
Finally, extracting data from a single pixel was a robust and reliable surro-
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gate of the whole region-of-interest. This work has identified appropriate
quantitative methods for future work in the analysis of human hyperpo-
larised 13C data.
2.1 Introduction
Functional and molecular imaging is increasingly used as a routine clinical tool in
many areas of oncology. The advent of molecularly-targeted drugs, combinational
therapies and personalised medicine has resulted in an increasing requirement for spe-
cific imaging methods to monitor drug efficacy; consequently, new imaging methods
to probe tumour biology are required that demonstrate both intra- and inter-patient
repeatability. Dissolution dynamic nuclear polarisation (DNP) is a new imaging test
which has the potential to image tissue biology. The technique increases the signal-to-
noise (SNR) of molecules containing one or more 13C nuclei by more than 10,000-fold
above thermal levels; this process is undertaken outside of the animal or patient,
and the hyperpolarised molecule is subsequently injected intravenously [152]. When
combined with 13C-magnetic resonance spectroscopic imaging (MRSI), this increase in
SNR allows real-time in vivo metabolism of the molecules to be imaged non-invasively
[291].
There are now many 13C-labelled probes which have been successfully hyperpo-
larised using DNP and these have been used to interrogate many aspects of tissue
biology and metabolism that occur in a wide range of disease processes [168, 165,
203, 204, 207, 208]. [1-13C]Pyruvate is the most extensively studied of these probes;
the major reaction of pyruvate is its conversion into [1-13C]lactate, which is catalysed
by the enzyme lactate dehydrogenase (LDH) and requires the reduced form of nicoti-
namide adenine dinucleotide (NADH) as a cofactor. Hyperpolarised [1-13C]pyruvate
may also form [1-13C]alanine, [1-13C]bicarbonate, and [1-13C]pyruvate-hydrate in a
pH-dependent reaction [173]. These reactions have been well characterised in vivo in
pre-clinical animal models of disease [193, 189, 191, 198, 200] and there are now a
number of sites worldwide that are developing the technique for human use [156].
The success of hyperpolarised 13C-labelled pyruvate as a cancer imaging biomarker
is largely dependent on the phenomenon of aerobic glycolysis within tumours known
as the Warburg effect [2]. There is a high lactate concentration within most cancers,
even in normoxic conditions, and the hyperpolarised 13C signal may rapidly exchange
between the injected [1-13C]pyruvate and the endogenous lactate pool. Imaging of
this exchange reaction in animal models has been shown to detect early treatment
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response [169, 177] and correlate with tumour grade [170]. The results from the only
clinical study performed to date, have shown that labelled lactate may be present in
small tumours that are not visible with standard proton imaging techniques [156].
The sensitivity of 13C-MRSI to small changes in metabolic rate offers the potential
to non-invasively monitor metabolic alterations in patients. However, for any novel
imaging technique to be widely adopted, it must be repeatable, reproducible and
will ideally utilise simple and robust quantitative methods for analysis. Current
clinical approaches for the analysis of dynamic contrast-enhanced MRI and positron
emission tomography (PET) can offer insight into quantitative imaging with DNP.
For example, the maximum standardised uptake value (SUVmax) is a very simple
and powerful routine clinical tool to quantify metabolism in PET imaging with 18F-
fluorodeoxyglucose [292]. For each voxel of a PET image, the SUV is defined as the
tissue radioactivity concentration divided by the injected radiation per unit body
weight, correcting for decay from the time of injection. The SUVmax is the voxel of
highest SUV within a region of interest while the SUVmean is the average over that
region. A number of methods have been employed to quantify the pyruvate-lactate
exchange reaction measured using DNP, many of which involve fitting kinetic models
of varying complexity to imaging or spectroscopy data to produce the forward reaction
rate constant kP as a quantitative marker [169, 170, 220, 219]. Simple methods for
estimating kP from the time course of pyruvate and lactate have been suggested [229],
as well as methods using model-free parameters such as the area under the metabolite
curve (AUC) [226], or ratios of the metabolite signal peaks [194, 178]. However, there
is currently no consensus on the best method to characterise the pyruvate-lactate
reaction, either for research purposes or for more routine clinical use.
In this chapter, both in vitro and in vivo dynamic hyperpolarised data are used to
comprehensively compare a range of kinetic models and simple analysis parameters.
A clinical hyperpolariser and imaging sequences were used with a 3 T MR system,
as well as a pyruvate concentration similar to the blood pyruvate concentration an-
ticipated in future patient studies. The aim was to determine which quantitative
parameters are most appropriate to describe the dynamic time-course data acquired,
testing for accuracy, simplicity and robustness in each case. Each analysis was also
applied in vivo to rats with subcutaneous tumours, which were imaged with the same
spectroscopic imaging sequence, to examine the effect of pyruvate inflow on kinetic
model accuracy.
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2.2 Materials and methods
2.2.1 In vitro experiments
Research grade fluid paths (GE Healthcare, Milwaukee, WI, USA) were filled with
100 µl of [1-13C]pyruvic acid doped with 15 mM of an electron paramagnetic agent
(EPA or Trityl radical AH111501, GE Healthcare, Milwaukee, WI, USA) and 30
ml of dissolution fluid containing 1 g/L ethylenediaminetetraacetic acid (EDTA, GE
Healthcare, USA). Samples were polarised using a clinical hyperpolariser (SPINlab,
GE Healthcare, USA) at approximately 0.9 K and 5 T for an average of 101 minutes
(range 83-149 min) to an average polarisation of 21% (range 10-38%) at the time of
measurement using a benchtop NMR polarimeter (Oxford Instruments, Abingdon,
UK). Following rapid dissolution, 1.4 ml of neutralisation medium containing 0.72 M
NaOH, 0.4 M TRIS buffer and 0.1 g/L EDTA (GE Healthcare, USA) was added to
the solution. The final pH ranged from 6.7-7.4 with an average of pH 7.2.
Imaging phantoms consisted of 15 ml Falcon tubes filled to 14 ml with 5-times
concentrated phosphate buffered saline at pH 7.2 and containing the coenzyme NADH
at 4.4 mM (Sigma-Aldrich, UK). L-lactate dehydrogenase from rabbit muscle (Sigma-
Aldrich, UK) was added in quantities varying from 0 to 120 U, a range chosen to
incorporate the expected range of kP in human blood based on the only published
study to date (mean ± SD of 0.045 ± 0.025 s−1) [156]. 1 ml of the above 60 mM
hyperpolarised solution was added simultaneously to the three tubes making up each
set immediately before imaging, giving a final pyruvate concentration of ∼4 mM. This
is similar to the final blood concentration in the rats (∼3 mM) and that expected
in patients (∼1.5 mM). If uniform distribution of this is achieved in the body in the
timescale of the half-life of hyperpolarisation, then the tissue concentrations would be
lower. Neither pyruvate nor NADH were rate limiting. The time between dissolution
and imaging was approximately 35 s.
2.2.2 In vivo experiments
Four adult female Fischer 344 rats (Charles River, Sulzfeld, Germany; 165 ± 6 g body
weight) bearing subcutaneous mammary adenocarcinomas were imaged [176, 293].
Tumours were induced by implanting 1×106 MAT B III cells (syngenic breast cancer
cell line), and imaging was performed 12-16 days after cell implantation. Animals
were anaesthetised with 1-3% isoflurane and monitored for ECG, breathing, and
temperature, and kept warm on a heating pad with circulating warm water. The
time delay between dissolution and injection was 15-20 s. The animal study was
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approved by the local governmental committee for animal protection and welfare
(Tierschutzbeho¨rde, Regierung von Oberbayern).
[1-13C]Pyruvic acid doped with 15 mM of the trityl radical OX063 and 1 mM gado-
teric acid (Guerbet, France) was polarised in a HyperSense DNP polariser (Oxford
Instruments, UK) for approximately 45 min at 1.4 K and 3.35 T to a polarisation of
approximately 25%. Dissolution fluid, containing 80 mM NaOH, 80 mM Tris buffer,
and 0.1 g/L EDTA dissolved in water, was heated to 185 ◦C and used to rapidly
dissolve the polarised sample. The final solution contained 80 mM [1-13C]pyruvate at
pH 7.6 and physiological temperature and osmolarity. This was injected into a tail
vein inside the MRI scanner at a rate of approximately 0.2 mL/s and at a dose of 2.5
mL/kg. Dynamic imaging was performed from the time of injection.
2.2.3 Spectroscopic imaging
All imaging was carried out on a clinical 3 T MRI system (Signa HDx, GE Healthcare,
USA) using imaging sequences from the multinuclear spectroscopy (MNS) research
pack version 2.0 (GE Global Research, Munich, Germany). Enzyme phantoms were
imaged in sets of 3 using a 13C-1H multi-nuclear receive/transmit coil (GE Coils,
Aurora, Ohio, USA). First, four 90◦ non-localised spectral-spatial pulses with TR
= 1 s centred on the lactate Larmor frequency were applied [176]; this was found
to be the optimum number for removing signal from any lactate labelling prior to
commencement of the experiment whilst retaining maximum pyruvate polarisation.
These were immediately followed by a 3 min IDEAL (iterative decomposition with
echo asymmetry and least-squares estimation) spiral chemical shift imaging (CSI)
acquisition [182] acquired using a single 20 mm axial slice. Each excitation is followed
by a single-shot spiral image encoding module, with echo-time shifting of 1.12 ms
between excitations. Seven time-shifted echoes plus a single free induction decay
(FID) spectrum are acquired in total for each time step, with the chemical-shift
information from the FID providing prior knowledge for the reconstruction. Other
parameters were TR 500 ms, flip angle 5◦, FOV 80 mm, nominal matrix resolution
32×32 and 4 s time resolution.
Animals were imaged on a similar clinical 3 T MRI system (Signa HDx, GE
Healthcare, USA) using a rat-sized 13C-1H multi-nuclear birdcage coil. The same
IDEAL spiral CSI acquisition was performed through four axial 10 mm slices over 1
min with a temporal resolution of 4 s. 13C-pyruvate is replenished by inflowing blood
in vivo, so a larger flip angle of 10◦ was used. All other parameters were consistent
with the in vitro experiments. Single metabolite k-space data was first reconstructed
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by matrix inversion with off-resonance correction, followed by Cartesian regridding
for spatial reconstruction [182]. Gaussian k-space filtering was applied during post-
processing on both data sets, resulting in an effective image resolution of 5×5 mm.
For anatomical reference, standard gradient echo proton images were acquired from
the same slice geometry and FOV (resolution 256×256, slice thickness 3 mm, spacing
7 mm, TE 10 ms, TR 500 ms).
2.2.4 Data analysis
Imaging data was exported into Matlab (Mathworks, Natick, Mass. USA) for analysis
using custom built software. Images were partially noise-corrected by subtracting the
average squared background noise from the power images [294]; the effect of this
correction on the images is demonstrated in figure 2.1. Dynamic time-course data
for pyruvate and lactate were extracted from the images, using two methods for
comparison. In the first, a region of interest (ROI) was defined by thresholding the
t = 0 pyruvate image at 40% of the maximum pyruvate signal within each phantom
for the in vitro data, or by outlining the tumour boundary based on the anatomical
proton image for the in vivo data. This ROI was applied to all subsequent images
in the series and the pixels within the ROI were averaged to produce the relative
signal strengths of each metabolite at each time point. The second method defined
a pixel-of-interest (POI) as the pixel within each phantom, or within the rat on
the tumour bearing image slice, which demonstrated the highest lactate signal after
averaging over all time points. Dynamic data from these two extraction methods was
separately analysed using each of the methods detailed below.
2.2.4.1 Kinetic modelling
The exchange reaction between pyruvate and lactate, along with the irreversible hy-
perpolarised signal loss due to spin-lattice relaxation and applied RF excitation, can
be characterised by the following coupled differential equations:
dP (t)
dt
= kLL(t)− kPP (t)− ρP (t) (2.1)
dL(t)
dt
= kPP (t)− kLL(t)− ρL(t) (2.2)
Where P and L are the relative pyruvate and lactate signal intensities, kP and kL are
the forward and backward reaction rate constants respectively and ρ is the effective
relaxation time given by:
ρ =
1
T1,eff
=
1
T1
− 1
tR
ln(cosθ) (2.3)
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Figure 2.1: The same 13C-lactate image before (left) and after (right) applying noise
correction for comparison. Image is taken from phantom experiments and shows an
axial slice through 3 phantoms containing 20, 40 and 60 U LDH at t = 6 s.
Where T1 is the relaxation time of pyruvate in the medium or tissue, tR is the known
repetition time of the applied RF pulses and θ is the flip angle. To reduce the number
of parameters to be fitted, it is assumed throughout that the pyruvate and lactate
relaxation rates are equal, which in the limit of fast exchange between metabolites can
be shown to be a good approximation [295], and use the above expression to correct
for RF flip angle. Each model variant was applied to yield the forward reaction rate
constant kP , the T1 decay constant, their standard errors and other fitting parameters
where appropriate. Constrained fits were carried out in Matlab using the fmincon
function unless otherwise stated. Solutions were found by minimising the negative
log of the maximum likelihood function, which for N data points is given by:
f(K, σ) =
N∑
i=1
(Li − Ldatai )2
2σ2
− ln(1− exp{−(Pi − P
data
i )
2
2σ2
}) + ln((Pi−P datai )2) (2.4)
Here K is the vector of free parameters to be fit, σ2 is the lactate variance, Li and Pi
are the model estimates of the metabolite signal strengths and Ldatai and P
data
i , the
measured values for the ith data points. This likelihood function is derived from a
Bayesian extension to least squares minimisation which addresses the disproportion-
ately large early pyruvate signal, as described by Hill et al [226]. It incorporates a
lower-bound prior on the pyruvate noise which acts to reduce the impact of any large
early pyruvate residuals which can otherwise dominate the fit. Due to the sensitivity
of the optimisation algorithm to the initial values of P and L, a Monte Carlo method
was used to randomly vary these inputs over 1000 runs for each model fit. Inputs
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were allowed to vary over a Gaussian distribution centred, with a standard deviation
of 5%, on the measured value of P or L at t=0.
The two-site exchange model For the two-way differential model, the above set
of differential equations were solved simultaneously to fit the pyruvate and lactate
time course data with kP , kL and ρ as free parameters. The equations may also be
solved analytically to give the following solutions:
P (t) =
1
kP + kL
{P (0)(kLe−ρt + kP e−(kP+kL+ρ)t) + L(0)(kLe−ρt − kLe−(kP+kL+ρ)t)}
(2.5)
L(t) =
1
kP + kL
{P (0)(kP e−ρt − kP e−(kP+kL+ρ)t) + L(0)(kP e−ρt + kLe−(kP+kL+ρ)t)}
(2.6)
These equations themselves may then be fit directly to the data in the two-way integral
model, which is computationally faster than applying the full differential fit but may
be more sensitive to the initial values of the parameters. For the in vitro data,
the latter two models are virtually identical apart from the fitting algorithms used,
however they require different approximations for metabolite inflow when used in vivo.
A popular simplification of the model is to set the backwards reaction rate constant
kL to zero [170, 220, 219, 221, 222]. This is argued to be a reasonable assumption since
kL is often around 10-fold smaller than the forward rate constant kP and, depending
on the model used, may not be a mathematically distinct parameter. To investigate
the validity of the one-way model, the above integral solutions with kL=0 were also
applied to the data.
Ratiometric model A ratiometric model has been suggested by Li et al [295].
Briefly, when the ratio is taken of the above integral solutions, ρ can be eliminated
as a parameter; this new model can be fit to the ratio of the lactate-to-pyruvate data
to solve for the rate constants kP and kL. Prior to fitting with the nlinfit function
in Matlab, ratio data was smoothed by averaging over every three data points. The
lactate data was used to weight the fit towards the region in which the rate constants
are stable and was subsequently derived as a single unknown by inputting the kP
and kL obtained from the ratiometric fit into the differential kinetic model.
2.2.4.2 Model-free methods
Fall minus rise at height α approach Page`s and Kuchel suggest a method for
estimating kP and ρ from graphical features of the time-course which they call the
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FmRα (Fall minus Rise at height α) approach [229]. They suggest parameter β to be
the ratio of the lactate-to-pyruvate signals for the time at which the lactate signal is
maximal, then show this to be mathematically equal to the product of kP and T1,eff .
Furthermore, they show that an estimate for T1,eff can be obtained from the width of
the lactate curve at a specific height α. Although they suggest it is sufficient to use
a consistent value of α = 0.8, α was calculated here explicitly in each case to avoid
incurring a non-physical correlation between kP and T1.
Lactate/pyruvate peak ratio The in vitro T1,eff is only affected by physical
factors such as magnetic field and temperature. Since these factors are controlled for,
the T1,eff is not expected to show a large variation. The above parameter β, which
will be refered to here as the L/P peak ratio, could therefore be expected to correlate
with LDH concentration and as such, was investigated as a potential parameter of
interest.
Area under the curve ratio The ratio of the lactate-to-pyruvate area under the
curve (AUC) has been shown by Hill et al. to be independent of the shape of the
pyruvate inflow [226] making it an excellent candidate for analysis of in vivo data.
If it is assumed that only the pyruvate has an explicit input function and that the
concentration of both metabolites is zero at t = 0, then using the two-way, two-site
model, the AUC ratio can be shown to be proportional to kP . For in vitro data this
ratio was calculated in two ways: firstly taking the AUC ratio of the available data
(AUC data) and secondly fitting bi-exponential solutions extrapolated back to t = 0
(AUC fit).
Time-to-peak measurements Finally, this work suggests a new approach that
examines the time difference from the start of the lactate build up to its peak, as has
been used in DCE-MRI. Starting from the two-way model, the rate equations can
be solved analytically to find the time at which the lactate reaches its maximum by
differentiating the lactate solution, and solving for t when this is zero. The time-to-
peak (TTP) is then given by:
TTP =
1
kP + kL
ln(1 + T1,eff (kP + kL)) (2.7)
The TTP should show a roughly inverse correlation with LDH concentration. A bi-
exponential function was fitted to the time-domain lactate data and extrapolated back
to find the predicted start time of the increase in lactate signal from zero. Schematic
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diagrams of each of the models and model-free methods described above are presented
in figure 2.2a-f.
Figure 2.2: Schematic diagrams for each of the models and model-free methods pro-
posed. a: Interactions accounted for in the two-way differential/integral models where
kP and kL are the forwards and backwards reaction rate constants respectively and ρ is
the inverse of the effective spin-lattice relaxation, T1,eff ; b: Interactions for one-way
integral model; c: Example metabolite timecourses demonstrating the ratiometric
model; d: FmRα approach and L/P ratio method; e: Lactate-to-pyruvate area under
the curve ratio; f: Lactate time-to-peak.
2.2.4.3 In vivo imaging
in vivo analysis of pyruvate metabolism is complicated by the flow of injected metabo-
lites in the bloodstream, tissue diffusion and cellular transport. For full modelling of
this data, a pyruvate inflow function (PIF) must be included to describe the large ini-
tial pyruvate peak as the injected bolus reaches the tissue of interest. In the interest
of simplicity, each of the four model variants was fitted only to data from the pyruvate
peak onwards, which in each case occurred at the third data point. Each of the model-
free methods was implemented on the entire dataset. A common way to approximate
the PIF is to use a box-car or trapezoidal function, and an alternative is to fit a
piece-wise integral solution. The latter involves splitting the pyruvate profile into two
segments described by separate equations; the first for constant pyruvate inflow, and
the second describing signal decay and conversion to lactate [170, 296, 297, 225]. Here,
a Heaviside-step function is used to incorporate a continuous PIF into the pyruvate
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two-way differential equation with the same characteristics as a box-car function:
dP (t)
dt
= ki
(
1− 1
1 + e−2(t−te)
)
+ kLL(t)− kPP (t)− ρP (t) (2.8)
Where ki is the pyruvate flow rate and te is the time at which the inflow ceases. This
was compared to the piece-wise one-way integral model described by Zierhut et al.
[170] in two ways: fixing te at the peak of the pyruvate curve or fitting for it as an
extra parameter.
2.2.5 Statistical analysis
The quantitative parameters derived using each method were tested for their corre-
lation with the known in vitro LDH concentration. These correlations were generally
linear. Both Pearson (linear) and Spearman (rank) correlation coefficients and their
two-tailed p-values were calculated, so that it was possible to compare all methods
directly whilst making no assumptions about the nature of the dependences. In order
to determine whether one analysis approach was significantly better than another,
Steiger’s z-test for dependant correlations was implemented pair-wise on both the
Pearson, then Spearman coefficients produced by each method, and the two-tailed p-
values calculated (significance p <0.05) [298]. In addition, a simple linear regression
model was applied in each case to calculate the adjusted R2 values both with and
without a robust bi-square weighting function applied to the data. The difference in
R2 with and without the weighting, denoted the ‘instability factor, provides a crude
indicator of how much the fit is dominated by outliers and therefore how robust a
particular method may be. The mean, range and standard deviation (SD) of T1 values
obtained from all phantoms taken together were also analysed for each quantitative
method to assess goodness of fit. Since the T1 is expected to be highly consistent in
vitro, a large range and high SD suggests that a model is not fully describing the data
or is under-parametrised.
To assess how well each model was able to fit the in vivo data, the corrected Akaike
Information Criteria (AICc) were calculated [299]. The AICc uses the minimised
likelihood function values to examine how well each model was able to describe the
data, whilst imposing a penalty for each extra free parameter to guard against over-
fitting; a low AICc denotes higher model accuracy. The relative likelihood that each
model is correct as compared to the model with the lowest AICc was then calculated.
To investigate model-free parameters in vivo, correlation coefficients and R2 values
were again calculated, however because the enzyme activity was an unknown, they
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were compared against kP values derived using the most likely model with ROI or
POI data as appropriate. The ROI and POI results were combined when calculating
correlation coefficients due to the small size of the dataset.
2.3 Results
2.3.1 In vitro modelling
Thirty-three 15 ml phantoms containing 0 U (n = 2), 20 U (n = 5), 40 U (n = 6),
60 U (n = 6), 80 U (n = 6), 100 U (n = 5) and 120 U (n = 3) of LDH enzyme were
imaged in sets of three, for which representative images can be seen in figure 2.3a.
Ringing artefacts, noise spikes and other interference were visible in some images,
however since it was of particular interest to test the quantitative analysis methods
for robustness against such common artefacts, none of the data was excluded. The
quantitative parameters obtained with each analysis method were tested for their
correlation with the known scale of phantom LDH concentrations. The two-tailed
p-values calculated from the Pearson and Spearman correlation coefficients were all
highly significant (p <0.001).
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Figure 2.3: Representative data from the in vitro study. a: IDEAL spiral CSI ax-
ial images of pyruvate and lactate in three phantoms, displayed at 24 s intervals.
Phantoms contain 40, 0 and 20 U of LDH enzyme (clock-wise from top), colour bar
shows arbitrary signal units scaled to the brightest point in the time curve for each
metabolite. b: Pyruvate and lactate time-courses (solid lines) extracted from the 40
U phantom using the ROI method and fitted using the differential two-way kinetic
model (dashed lines). c: Correlation with LDH enzyme concentration of the forward
reaction rate constants kP derived from four model variants (differential, integral,
ratiometric and one-way models). Note that the scale for kP varies between plots.
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Table 2.1: Summary of the analysis for the in vitro data are shown by comparing the
calculated exchange rate constants with the known enzyme concentration. Calcula-
tions have been performed using both the ROI and POI approaches.
Region of Pearson Spearman Adj. R2 Adj. R2 Instability T1 T1 T1
interest coeff. coeff. robust mean range SD
kP Differential 0.950 0.984 0.900 0.917 0.017 52.4 13.2 3.04
kP Integral 0.952 0.986 0.903 0.931 0.028 52.5 13.5 2.97
kP One-way 0.942 0.982 0.883 0.907 0.025 58.4 21.7 5.99
kP Ratiometric 0.896 0.986 0.796 0.891 0.095 57.3 26.9 5.46
kP FmRα 0.920 0.981 0.842 0.923 0.082 47.7 21.9 4.36
L/P ratio 0.854 0.969 0.721 0.905 0.184 - - -
AUC data 0.877 0.966 0.761 0.945 0.184 - - -
AUC fit 0.916 0.974 0.833 0.944 0.110 - - -
TTP -0.971 -0.964 0.940 0.946 0.006 - - -
Pixel of Pearson Spearman Adj. R2 Adj. R2 Instability T1 T1 T1
interest coeff. coeff. robust mean range SD
kP Differential 0.925 0.982 0.852 0.946 0.094 53.8 12.4 3.75
kP Integral 0.919 0.982 0.840 0.939 0.100 54.0 15.8 4.23
kP One-way 0.767 0.924 0.574 0.923 0.348 60.2 26.6 7.78
kP Ratiometric 0.915 0.984 0.831 0.852 0.020 58.6 30.4 6.63
kP FmRα 0.922 0.981 0.846 0.942 0.096 46.4 21.8 4.81
L/P ratio 0.858 0.976 0.727 0.921 0.195 - - -
AUC data 0.880 0.971 0.766 0.926 0.160 - - -
AUC fit 0.898 0.976 0.801 0.943 0.142 - - -
TTP -0.963 -0.964 0.926 0.921 0.005 - - -
The results of the analyses are summarised in table 2.1. For the model-based
approaches, application of Steiger’s z-test to the Pearson coefficients for the ROI
data demonstrated the ratiometric method to be significantly poorer than the other
three models, which were not found to be significantly different. However, the POI
data showed the one-way model to be worse than the other methods tested. In both
cases, the differential and integral models are better able to constrain the T1 compared
to the other three methods, which suggests that they are more closely modelling the
data. A fit with the differential model is shown in figure 2.3b. The variation in kP
between the integral and differential versions of the two-way model is a function of the
algorithm used for fitting the data, but this difference was shown to be insignificant
(p >0.2). Despite the simplicity of the FmRα approach, kP values obtained from
the FmRα analysis were not significantly different from those obtained by modelling
methods, other than the ROI integral model.
In contrast, the model-free methods showed greater variation with the TTP prov-
ing to be significantly better, and the L/P ratio significantly worse, than other meth-
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Table 2.2: Significance matrix for in vitro data from region-of-interest (ROI) data
(top) and pixel-of-interest (POI) data (bottom). Matrix shows p-values from ap-
plying Steiger’s z-test for comparing the relative strength of correlations pairwise
to Pearson coefficients; the Pearson coefficients test the correlation between quanti-
tative parameters produced by each method, and known enzyme concentration. *
indicates the better ranking (high 1-9 low) analysis method of the two is significantly
so (significance level p <0.05).
ROI analysis Pearson Raw kP kP kP kP L/P AUC AUC TTP
rank Integral One-way Ratiometric FmRα ratio data fit
kP Differential 0.9503 3 0.762 0.664 0.001* 0.075 0.001* 0.007* 0.098 0.156
kP Integral 0.9518 2 - 0.604 0.000* 0.050* 0.000* 0.005* 0.075 0.183
kP One-way 0.9415 4 - 0.032* 0.402 0.011* 0.051 0.336 0.219
kP Ratiometric 0.8956 7 - 0.380 0.322 0.643 0.539 0.001*
kP FmRα 0.9201 5 - 0.000* 0.010* 0.722 0.010*
L/P ratio 0.8541 9 - 0.078 0.000* 0.000*
AUC data 0.8766 8 - 0.000* 0.000*
AUC fit 0.9158 6 - 0.007*
TTP -0.9705 1 -
POI analysis Pearson Raw kP kP kP kP L/P AUC AUC TTP
rank Integral One-way Ratiometric FmRα ratio data fit
kP Differential 0.9254 2 0.206 0.000* 0.640 0.753 0.003* 0.073 0.173 0.054
kP Integral 0.919 4 - 0.000* 0.860 0.763 0.007* 0.129 0.303 0.035*
kP One-way 0.7666 9 - 0.002* 0.000* 0.048* 0.026* 0.003* 0.000*
kP Ratiometric 0.9147 5 - 0.780 0.173 0.375 0.647 0.020*
kP FmRα 0.9223 3 - 0.000* 0.024* 0.103 0.048*
L/P ratio 0.8575 8 - 0.103 0.001* 0.001*
AUC data 0.8795 7 - 0.074 0.003*
AUC fit 0.8983 6 - 0.010*
TTP -0.9633 1 -
ods tested. The AUC from the extrapolated fits also performed well, being indistin-
guishable from the modelling approaches. When p-values were calculated from the
Spearman coefficients, the results largely supported those from the Pearson coeffi-
cients with the exception of the TTP, which performed least well. Table 2.2 shows
full significance matrices for both ROI and POI data from the pair-wise application
of Steiger’s z-test.
The sensitivity of kP may be examined in terms of the offsets of the fit lines at the
origin. The cause of these offsets is two-fold; firstly there is a positive skew caused by
the divergent kP values produced at high LDH concentrations and secondly, sensitivity
limitations at very low concentrations cause an initial monotonic but non-linear rise
in kP with increasing LDH. The relative sensitivity of each model to these features is
characterised by the difference in the two correlation coefficients; they are accounted
for well by the Spearman coefficients, which allow regions of monotonic non-linear
increase, but will incur a penalty with the Pearson coefficients which enforce linearity.
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2.3.2 In vivo modelling
Figure 2.4: In vivo data from a rat (rat 1) with a subcutaneous implanted mam-
mary adenocarcinoma. a: proton anatomical reference image and hyperpolarised
13C-pyruvate and 13C-lactate images at t = 20 s; color bar in arbitrary signal units. b:
Pyruvate and lactate time-courses (solid lines) extracted from the thresholded tumor
ROI and fits (dashed lines) from the differential kinetic model with a Heaviside-step
PIF (left) and the fixed te piece-wise model (right) for comparison.
Each of the four models tested in vitro were fit to both ROI and POI derived time
course data from four rats with subcutaneously implanted tumours. An additional
three models were tested which incorporated a PIF. The corrected Akaike Information
Criterion scores (AICc) and the relative likelihood of each model correctly describing
the observed data were then calculated; the results of this, along with the T1 mean,
range and SD are shown in table 2.3. The T1 values obtained were slightly higher
than those previously estimated in healthy rats of ∼15 s, but consistent with other
rodent tumour T1 values [170, 187]. The in vivo results were similar to those found
in vitro, with the differential and integral models statistically indistinguishable from
each other, but significantly more likely than the one-way or ratiometric models to
accurately describe the data. Models incorporating a PIF were applied to a larger
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number of data points than the remaining models to include data prior to the pyruvate
peak. For this reason, the relative likelihood values for the PIF models were calculated
separately to compare just these three, as shown in table 2.3.
Table 2.3: Summary of statistical analysis from calculating the corrected Akaike
Information Criterion for each model, separately fitted to ROI and POI data from
four rats with subcutaneously implanted tumours. The relative likelihoods for models
incorporating a PIF were calculated separately against each other. The lowest section
shows correlation coefficients for model-free parameters against kP values from the
differential Heaviside-step PIF model. * p <0.05; ** p <0.001.
Region of interest Average AICc Relative likelihood T1 mean T1 range T1 SD
kP Differential 368.9 0.257 25.7 7.51 2.78
kP Integral 367.5 1 25.4 7.60 2.90
kP One-way 403.3 2.95×10−16 23.2 5.98 2.26
kP Ratiometric 388.8 5.87×10−10 27.1 8.54 3.03
kP Differential, PIF 469.0 1 24.6 6.90 2.61
kP Piece-wise, fixed te PIF 495.9 2.12×10−12 22.2 5.71 2.24
kP Piece-wise, variable te PIF 499.2 2.12×10−12 22.2 5.78 2.28
Pixel of interest Average AICc Relative likelihood T1 mean T1 range T1 SD
kP Differential 436.1 1 25.0 4.75 1.83
kP Integral 436.2 0.880 25.2 4.84 1.89
kP One-way 449.5 1.51×10−6 22.8 5.18 1.97
kP Ratiometric 469.0 5.28×10−15 27.6 2.47 0.91
kP Differential, PIF 527.8 1 23.9 4.59 1.73
kP Piece-wise, fixed te PIF 533.7 2.97×10−3 22.5 5.82 2.13
kP Piece-wise, variable te PIF 536.4 1.90×10−4 22.0 5.53 2.15
Combined ROI and POI Pearson Spearman Adj. R2 Adj. R2 robust
kP FmRα 0.797* 0.714 0.574 0.497
L/P ratio 0.636 0.548 0.305 0.637
AUC 0.888* 0.905* 0.754 0.733
TTP -0.970** -1.00** 0.930 0.920
The differential model with the Heaviside-step PIF provided the lowest AICc of the
three, fitting the data significantly better than the piece-wise models. Interestingly,
the penalty for allowing the end of inflow time te to vary as an extra free parameter
within the piece-wise model, was greater than the improvement this made to the fit.
It has been stated by previous users of the model that te should correspond to the
injection length starting from t0 [170, 297], which in the case of the rats was around 2
s. The fitted te calculated here was 8-10 s, which corresponded to the pyruvate peak
time instead. For this reason, te was then fixed at the pyruvate peak time, as was
the centre of the downslope for the Heaviside-step function used in the differential
model. Figure 2.4b shows fits of the differential PIF model as compared to the fixed
te piece-wise model to ROI time courses from one animal (rat 1).
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In the absence of a gold standard as a comparator, it was difficult to assess the
model-free parameters in vivo. However the differential model with a Heaviside-step
PIF was used as a surrogate standard given its low AICc. Based on comparison to
these calculated kP values, the TTP significantly out-performed the other approaches
and the L/P ratio performed least well, being the only method to produce no signif-
icant correlation coefficients. The AUC also correlated very well with kP , with both
correlation coefficients having p <0.005. Parameter maps for kP were generated for
each of the four rats and are shown in figure 2.5: in vivo parameter mapping derived
from the model-based methods were largely similar and two representative examples
are shown using the one-way and two-way non-PIF integral models. Unfortunately,
many of the model-free parameter mapping methods were very sensitive to noise in
regions of low lactate, rendering them difficult to interpret which is an inherent limi-
tation of some of these more simplified approaches. A visual inspection of the two sets
shows that both models were able to distinguish the implanted tumours from nor-
mal tissue, however the two-way maps appeared to better highlight the full tumour
and offered higher contrast-to-noise, showing increased sensitivity over the one-way
model. kP values were capped at 0.25 s
−1, a value chosen to be suitably above those
previously reported in rat tumours (∼ 0.1 s−1) [293]; only one rat (rat 4) had an
area of very high activity greater than this. The mean tumour kP and range were
both higher with the two-way than the one-way model, and in general, the kP maps
demonstrated significant intra-tumour heterogeneity.
2.4 Discussion
Metabolic imaging with hyperpolarised 13C-labelled molecules is an emerging clinical
tool to non-invasively detect real-time metabolism. In order to utilise this dynamic
data - either as a research technique or ultimately as a clinical tool - mathematical
analysis methods are required which are sensitive to detecting the small changes in
metabolism that occur during tumour growth and following treatment, whilst be-
ing insensitive to noise and artefacts. Many of the approaches used to analyse the
metabolism of hyperpolarised pyruvate are analogous to the methods used in other
areas of MRI research (such as DCE-MRI), as well as those used with PET. In this
work, a comprehensive analysis is performed of the main quantitative techniques used
to analyse hyperpolarised data, as well as some novel approaches, with the aim of
determining which are the most appropriate as research tools and which may have
potential for clinical application in the future. Imaging data is utilised for this study
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Figure 2.5: Functional parameter mapping in four rats with subcutaneous mammary
adenocarcinomas demonstrating intratumoural heterogeneity. a: Grey scale anatom-
ical proton images showing the outline of the implanted tumours defining the region-
of-interest (green) and pixel-of-interest (white cross) which were used for modelling.
b: False-colour functional maps of kP calculated using the one-way integral model
superimposed over the grey scale anatomical imaging. c: Similar colour maps using
a two-way integral model. The maximum kP has been limited to 0.25 s
−1 in both
cases.
rather than spectroscopic data, as this will be more applicable to patient studies
and two methods of extracting the dynamic time course data from these images are
compared.
The approaches studied can be divided into two groups: model-based and simpler
model-free analyses. Of the four kinetic model variants, the differential and integral
two-way models performed best, showing strong correlation with in vitro LDH enzyme
concentration and producing the most accurate modelling in vivo (as determined by a
low AICc). Furthermore, the T1 values produced by these models, which are expected
to be constant in vitro, had the smallest ranges and standard deviations of those tested
implying good parameterisation. The one-way model is a very popular approach
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because it allows for the use of Michaelis-Menten kinetics in order to solve for real, as
opposed to apparent, reaction rate constants. However, this requires an assumption
which is not fulfilled by the hyperpolarised exchange reaction: that the reaction has
reached chemical equilibrium [300]. The one-way model was found to be unstable at
higher enzyme concentrations within the physiological range, producing divergent kP
values almost three times higher than those given by the two-way models (figure 2.3c).
This divergence was also seen in some of the in vivo data sets (figure 2.5, rat 4), and is
likely to be a consequence of the approximation kL = 0 which becomes less valid with
increasing enzyme activity or in the presence of large pools of lactate which are freely
exchanging with the pyruvate. A previous comparative study by Harrison et al. [223]
demonstrated the shortcomings of the one-way model by showing that results from
fitting to hyperpolarised data were incompatible with those from mass spectrometry
data. This suggests an inconsistency between the model and the underlying biology;
the breakdown of the model at high enzyme activity that is observed here provides
further evidence against the use of the one-way model.
The effect of explicitly modelling the pyruvate inflow within both the differential
and integral (piece-wise) models was examined. Kazan et al suggest modelling the
PIF with a gamma-variate function which, although an excellent descriptor for the
flow profile, requires accurate measurement of the arterial input function either with
an invasive arterial line, or by image acquisition from a large vessel which may be
difficult to obtain from human hyperpolarised data [225]. The choice was made here
to look at incorporating simpler functions. From calculations of the AICc, the dif-
ferential model with a Heaviside-step PIF was significantly more likely to correctly
describe the data than either variant of the piece-wise model. The fitted pyruvate
inflow end-time te in this model correlated poorly with the measured injection length;
this mismatch is indicative of the difficulty in fitting theoretical arterial input func-
tions to hyperpolarised data with a low SNR and temporal resolution. Complicated
inflow functions introduce several additional free parameters which over-fit noisy data
and increase the error of the derived rate constants. With the current resolution limi-
tations for clinical hyperpolarised imaging, simple approximations for pyruvate inflow,
such as those used in this study, are therefore required.
The above methodologies are desirable when accurate fitting is required for re-
search purposes, however kinetic modelling can be computationally intensive and time
consuming. Four model-free methods were tested as potential candidates for provid-
ing simple, robust parameters that are fully representative of the metabolic exchange
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reaction. Such approaches may allow easy intra-patient and inter-patient compari-
son across clinical sites. The FmRα method described by Page`s and Kuchel [229]
provided a better correlation with LDH concentration and tighter constraints on T1
than two of the modelling methods. However in this study it was necessary to calcu-
late α explicitly in each case, rather than using a constant value as suggested by the
authors, to produce realistic results. Simpler still, and producing similar statistical
results, is the AUC ratio described by Hill et al. [226], which is independent of the
PIF. The lactate-to-pyruvate ratio at the time of maximum lactate signal was con-
sistently the poorest method for describing the data. The final approach using TTP
showed the strongest correlation with enzyme concentration in vitro of any analysis
and the strongest correlation with kP values derived using the differential PIF model
in vivo of any model-free method. The small size of the in vivo dataset means it is
not possible to claim significance of the TTP over the AUC and so further testing of
these two methods on larger in vivo data sets is required. Nonetheless, these prelim-
inary results along with the in vitro results suggest that the TTP may prove to be a
very robust quantitative marker which is able to provide an equivalent assessment of
metabolism to fitting a full PIF kinetic model.
Finally, two methods for extracting dynamic time course data from the images
were defined and assessed for their effect on quantification. Data extracted using the
region-of-interest (ROI) method provided universally stronger correlations with the
in vitro enzyme concentrations than the pixel-of-interest method, although this was
not significant in the majority of cases. Averaging results over a tumour ROI may
provide a more sensitive measure of metabolic change in that region which is robust
to experimental noise, however it tells nothing of the local heterogeneity nor allows
for tumours outside the region to be detected in the way that pixel-by-pixel analysis
could. Furthermore, determining the anatomical limits of a tumour is subjective, and
therefore difficult to reproduce accurately, even if performed by the same operator
using the same dataset [301, 302]. These findings suggest that extracting data from
a single POI is sufficiently robust to provide a metric that reports on the whole
area, and may provide a simple and reproducible method for analysing the data
objectively over time. This approach is analogous to the SUVmax used routinely in
the analysis of clinical PET data. Under normal conditions, the POI (representing
the highest lactate concentration over time) will lie within the boundaries of the
tumour. Although unlikely, theoretically the POI could lie outside the tumour margin
if it was so poorly vascularised that the time required to perfuse the tumour was
long compared to the half-life of the polarised pyruvate signal, or if the systemic
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lactate level was very markedly elevated. Since single pixel analysis was shown to
be sufficiently robust, parameter mapping of kP was performed in the rats. This
showed marked intratumoural heterogeneity with some areas of low exchange within
the tumours and regions of high activity extending beyond the tumour boundary. Due
to the spatial resolution of the 13C images, it is not possible to determine whether
these findings are due to artefact from partial voluming or whether there is underlying
biological heterogeneity due to changes in metabolism or vascularity, although a highly
heterogeneous vasculature is a known feature of the subcutaneous tumour type studied
here [303]. Future human studies comparing histology to these kP maps will be
required to further understand this heterogeneity.
The rate constant kP is generally considered to be the gold standard for quantifi-
cation of hyperpolarised data, but several of the simpler non-model based approaches
used here appeared to provide a good approximation to the reaction. A good probe
for tumour biology should be repeatable, reproducible, quantitative, highly sensitive
and highly specific. The results of this study show that kP is a robust biomarker of
LDH activity. However, at low LDH concentrations the modelling is more suscepti-
ble to noise, and at high LDH concentrations greater divergence was demonstrated
which may relate to undersampling. Importantly, this work has shown that these
modelling methods performed well in the physiological range and further research is
required from human studies to validate this. Variation in kP may occur secondary
to other factors such as SNR, which is dependent on polarisation [304, 305], pyru-
vate concentration [297] and imaging protocol [306]. Therefore the optimisation and
standardisation of each of these is an important step for multi-center comparison, or
if kP is to be considered as a clinical tool.
2.5 Conclusion
For accurate kinetic analysis of the hyperpolarised pyruvate-lactate exchange reaction
in vivo, the two-way differential model with a Heaviside-step PIF centred on the
pyruvate peak was best able to characterise the data with the fewest free parameters.
If the data prior to the pyruvate peak are not included in the analysis, the two-way
differential and integral models performed equally well and were significantly better
than the one-way model in the presence of high enzyme activity or when applied
to the pixel-by-pixel analysis. As a simple parameter for clinical quantification of
hyperpolarised imaging data, the TTP performed best both in vitro and in vivo,
providing excellent correlation with model-derived kP values. Extracting data from
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an averaged ROI may provide the most sensitivity to small changes in metabolism,
however the POI approach is sufficiently robust to be applied pixel-by-pixel allowing
tumour heterogeneity to be probed. This work provides a basis for analysing data
from future human trials in hyperpolarised 13C imaging.
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Chapter 3
Unsupervised segmentation of 5D
hyperpolarised 13C MRI data using
a fuzzy Markov random field model
Hyperpolarised MRI with 13C-labelled compounds is an emerging clinical
technique allowing in vivo metabolic processes to be characterised non-
invasively. Accurate quantification of 13C data, both for clinical and re-
search purposes, typically relies on the use of region-of-interest analysis to
detect and compare regions of altered metabolism. However, it is not clear
how this should be determined from the five-dimensional data produced
and most standard methodologies are unable to exploit the multidimen-
sional nature of the data. In this chapter, a solution to the novel problem
of 13C image segmentation using a hybrid Markov random field model
with continuous fuzzy logic is proposed. The algorithm fully utilises the
multi-dimensional data format in order to classify each voxel into one of
six distinct classes based on its metabolic characteristics. Bayesian priors
fully incorporate spatial, temporal and ratiometric contextual information
whilst image contrast from multiple spectral dimensions are considered
concurrently by using an analogy from colour image segmentation. Per-
formance of the algorithm is demonstrated on in silico data where the
superiority of the approach over a reference thresholding method is con-
sistently observed. Application to in vivo animal data from a pre-clinical
subcutaneous tumour model illustrates the ability of the MRF algorithm to
successfully detect tumour location whilst avoiding image artefacts. This
work has the potential to assist the analysis of human hyperpolarised 13C
data in the future.
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3.1 Introduction
With the increasing use of functional and molecular imaging techniques in medicine,
there has been a significant increase in the size and the complexity of the data ac-
quired. A major challenge in medical imaging is to determine the optimal use of
these large data sets. For example, automated lesion identification and segmentation
could greatly assist the interpretation of radiological images but is often hampered by
the intrinsically noisy nature of most molecular imaging techniques when compared
to conventional anatomical imaging. Hyperpolarised imaging with 13C-labelled com-
pounds is an emerging clinical technique allowing in vivo metabolic processes to be
characterised and quantified non-invasively. The method is based on dynamic nuclear
polarisation (DNP); endogenously occurring metabolites labelled with one or more
13C atoms are hyperpolarised at a cryogenic temperature and within a high magnetic
field, before being rapidly dissoluted using a heated fluid [152]. The molecules are
able to retain liquid state polarisation for a sufficient length of time to spectroscopi-
cally image both the substrate and its metabolic breakdown products with magnetic
resonance spectroscopic imaging (MRSI), following their intravenous injection into
an animal or human [187].
The conversion of hyperpolarised [1-13C]pyruvate to [1-13C]lactate is the most
intensively studied exchange reaction to date and the first molecule to be translated
into the clinic. Preclinical oncological studies have shown increased lactate exchange
correlating with tumour grade [170], a change in this exchange rate to be a marker of
treatment response [169] and a first-in-man study in prostate cancer has demonstrated
the feasibility for human imaging [156]. [1-13C]pyruvate may also be metabolised
to produce [1-13C]alanine and 13C-bicarbonate. The ability to rapidly detect small
changes in metabolism in vivo can be applied to a number of areas within medicine
including oncology, neurology [209] and cardiology [196], with a recent pilot study
successfully imaging pyruvate metabolism in the healthy human heart [214].
By utilising the change which occurs in the 13C frequency as metabolites inter-
convert, multiple metabolites can be simultaneously imaged in 3 spatial dimensions
and at multiple time points with a resolution of a few seconds to generate intrinsi-
cally co-registered 5-dimensional data. Accurate and robust quantification of multi-
dimensional 13C data is imperative in order to make reliable inter- and intra-patient
comparisons and many methodologies have been suggested for this purpose. Most
commonly, the forward exchange rate constant kPL is derived by fitting variations on
the following coupled differential equations to pyruvate and lactate timecourse data
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[169], [170], [219]:
dP
dt
= I(t)− kPLP + kLPL− ρPP (3.1)
dL
dt
= −kLPL+ kPLP − ρLL (3.2)
where I(t) is a function describing the pyruvate inflow, kLP is the backwards exchange
rate constant and ρ describes the polarisation loss for each metabolite due to both
thermal T1 decay and through radiofrequency excitation during sampling. Simple
model-free analyses have also been shown to accurately quantify lactate exchange
[226], [307]. Both the lactate/pyruvate area under the curve (AUC) ratio and the lac-
tate time-to-peak show excellent correlation with the exchange rate model approach,
albeit by producing parameters less easily linked to the underlying biological reaction
[307].
Clinical imaging research has conventionally made use of regions or volumes of
interest (ROI or VOI) for the analysis and quantification of areas that are pathologi-
cally abnormal in comparison to normal tissue. A VOI must be accurate, robust and
repeatable, however commonly used manual delineation and thresholding techniques
both often suffer from high variability, as well as susceptibility to noise and image
contrast [254], making statistical segmentation methods important for the reliable
processing of large imaging datasets.
Unsupervised segmentation of 13C data offers a unique challenge due to its low spa-
tial resolution, high noise, susceptibility to artefacts and its inherent 5-dimensionality,
making analysis of this data using spatial contrast alone very difficult. Simple seg-
mentation methods such as thresholding are made unsuitable by the rapidly changing
temporal dynamics and spectral interdependency, whilst supervised learning methods
are hampered by the lack of clinical data currently available to enable training. The
use of a fuzzy Markov random field (MRF) model is proposed here, which provides
a framework for segmentation which fully incorporates spatial, temporal and spec-
tral information whilst effectively handling the low image quality currently associated
with hyperpolarised MRI.
Image segmentation describes the problem of sorting a set of image pixels or voxels
into a number of distinct classes. For a set S = {1, 2...s} of image pixels, indexed
by j, the MRF model considers two random fields; the observed, noise-corrupted
field Y = (Yj)j∈S and the underlying ground-truth field X = (Xj)j∈S. Here, the
vector of real, positive image pixel intensity values is a realisation, defined here as a
particular observed configuration, Y = y of Y and the objective is to uncover the field
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X = x representing the “true” image by means of iteratively optimising an objective
function. Here, the realisation x represents the assignment vector of one of the set
Ω = {1, 2..., q} of classes to each pixel j.
In addition to being an efficient approach for many problems, a main advantage
of using an MRF model for medical image segmentation is the ability to formally
incorporate multiple forms of contextual information. Modelling of local interactions
between spatially and/or temporally adjacent pixels vastly reduces the influence of
noise on the segmentation, as each pixel is classified based not only on its own con-
trast, but on the contrast of its neighbours. MRFs, and the closely related Markov
random chains, have been extensively applied to segmentation problems in MRI [282],
computed tomography (CT) [283] and positron emission tomography (PET) imaging
[287].
A powerful way of accounting for poor image resolution is to incorporate fuzzy
logic into the segmentation process. Rather than pixels being assigned to a ‘hard’
Boolean class, i.e. definitely tumour or definitely background with xj = 0 or 1, pixels
are assigned a fuzzy membership level to each class. This is similar to, although dis-
tinct from, the probability of belonging to each class and instead provides a measure
of uncertainty on the true content of the pixel. Similarities between PET and hyper-
polarised 13C imaging include low resolution and large partial volume effects [202].
Incorporation of fuzzy logic into PET segmentation algorithms proved successful in
handling these challenges by providing a more realistic description of the blurred
boundaries between regions of different classes when compared to a hard Boolean
approach. This is particularly apt for both PET and 13C, as each large pixel is likely
to contain elements of both tumour and background.
Two methodologies for applying fuzzy logic in medical image segmentation have
dominated the literature; the fuzzy c-means (FCM) approach [273], [274] and the
Markovian approach [308], [287]. Chatzis et al have proposed a hybrid FCM-MRF
which combines the flexibility of the FCM model with the capacity to incorporate
higher dimensional prior information of an MRF model [309]. Their framework is
used as a starting point, with this work extending it to handle the 5D data produced
by hyperpolarised 13C MRI, using an analogy with colour image segmentation to
fully incorporate the spectral dimension, in order to segment and quantify regions
of interest. The primary focus is to detect the metabolism of [1-13C]pyruvate to [1-
13C]lactate, however the capability of identifying [1-13C]alanine and 13C-bicarbonate
production is also included.
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The performance of the algorithm is initially demonstrated here on an in silico
dataset as well as in vivo animal data from rats with subcutaneously implanted
tumours. This work demonstrates the feasibility of applying a fuzzy MRF approach
to the novel and challenging problem of hyperpolarised 13C image segmentation in
order to automatically detect regions of altered metabolism, thereby providing a useful
tool to delineate tumour from normal tissue.
3.2 Theory
3.2.1 The MRF framework
Given a set of 2D or 3D image voxels S = {1, 2, ...s}, the objective of the MRF seg-
mentation algorithm is to find the correct classification for each voxel which minimises
a Bayesian-derived objective function, separating the image into segments displaying
similar features. The input information is the observed data; the measured voxel in-
tensity values are a realisation Y = y, where Y is the set of all possible measurements,
and the desired output is to find the correct configuration X = x of assigned class
labels. Y and X are the ‘emitted’ and ‘hidden’ random fields respectively, where a
random field is defined as having a strictly positive probability distribution:
p(x) > 0 ∀x ∈ X (3.3)
An MRF is defined as any random field for which the joint probability distribution is
a Gibbs (Boltzmann) distribution:
p(x|β) = 1
Z
e−U(x|β) (3.4)
Here β is the inverse temperature parameter, which is maximised at each iteration
of the algorithm; in physical terms, this is equivalent to actively ‘cooling’ the system
such that it converges to a state of minimum energy. In further analogy to statistical
mechanics, Z is the partition function, defined as the sum of the numerator over every
possible realisation of x ∈ X.
Exact computation of the partition function becomes computationally expensive
to the point of being intractable for systems with a large number of sites; it is therefore
simplified here by the commonly used mean-field approximation [310]. Under this
approximation, the site of interest is decoupled from the field by averaging over its
external interactions with each other site to produce a single mean effect and p(x|β)
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Figure 3.1: Graphical depiction of image pixels x as nodes in a Markov random field
and the connections between them. A. shows the 8-neighbourhood in 2D (shown in
gray) and B. the 10-neighbourhood for 3D segmentation which form the cliques on
which the state of each pixel xj will depend.
is given by:
p(x|β) =
s∏
j=1
p(xj|xˆcj , β) (3.5)
where xˆcj is an estimate of the class labels in the clique cj obtained from the previous
iteration of the algorithm.
The term U(x|β) in (3.4) is the energy function containing the contextual prior
information. For the set of voxels S = 1, 2, ...s, it is possible to define a set of cliques
cl such that for each site j ∈ S, j ∈ cl if and only if j 6= l and l ∈ cj. This
sets up the network of two-way interactions to be considered at each site; figure 3.1
depicts the 8- and 10-connectivity neighbourhoods which form the cliques considered
in the 2D and 3D contexts respectively. A main advantage of MRF models is the
straightforward incorporation of additional prior information by linearly adding terms
to form the energy function U(x|β). Three terms are considered here with equal
weighting: a spatial term US(x|β) utilising the network discussed above; a temporal
prior UT (x|β) testing for an expected shape profile; a ratiometric prior UR(x|β) which
tests for expected metabolite ratios. In accordance with Bayes’ theorem, the joint
probability of the Gibbs prior distribution for the hidden field p(x), and the emitted
field distribution p(y) is given by:
p(x,y) = p(y|x)p(x) (3.6)
It is reasonable to assume that the full conditional distribution can be written as the
product of contributions from each individual site and that the distributions are of
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multivariate Gaussian form:
p(y|x) =
s∏
j=1
p(yj|xj) = e
(yj−µxj )TΣ−1xj (yj−µxj )√
(2pi)n|Σxj |
(3.7)
where yj is the vector of measured intensity values of dimensionality n, µxj is the
vector of means over each dimension of yj defined for a given class xj and Σxj is the
corresponding covariance matrix.
Substituting (3.5) and (3.7) into (3.6), then taking the negative log, provides a
convenient form of the posterior probability as the objective function to be minimised.
Given the set of possible classes Ω = {1, 2, ...q} where each xj may take values 1 to
q, the full negative log-likelihood function under the mean-field approximation takes
the form:
L(x|y) = −
s∑
j=1
log p(yj|xj,µxj ,Σxj)−
s∑
j=1
log p(xj|β) (3.8)
where the voxel-wise priors are given by:
p(xj|β) = e
−U(xj |β)∑q
i=1 e
−U(xj=i|β) (3.9)
3.2.2 The hybrid fuzzy c-means MRF model
Fuzzy c-means clustering is a simple and commonly used algorithm for separating a
set of s voxels into q partitions by minimising the objective function:
Lλ =
s∑
j=1
q∑
i=1
Rλi,jDi,j (3.10)
The ‘dissimilarity function’ Di,j describes the likelihood of voxel j belonging to a given
class i, and Ri,j is the ‘fuzzy membership function’, which describes the certainty of
j belonging to each class i and exhibits the following properties:
Ri,j = ]0, 1[
q∑
i=1
Ri,j = 1 (3.11)
The parameter λ controls the level of fuzziness. Following the rationale set out by
Chatzis et al [309], it is instructive to consider a variant of the above function which
is regularised by relative entropy [311]:
Lλ =
s∑
j=1
q∑
i=1
Ri,jDi,j + λ
s∑
j=1
q∑
i=1
Ri,jlog
(
Ri,j
Pi,j
)
(3.12)
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This version of the fuzzy objective function reverts to hard partitioning when λ=1
and the fuzzy membership function is redefined with Ri,j = {0, 1}. In this special
case, it is possible to make a direct comparison with equation (3.8) and thus to define:
Di,j = −log p(yj|xj = i,µi,Σi) (3.13)
Pi,j = p(xj = i|β) (3.14)
In this way it is possible to incorporate the MRF multivariate conditional distribution,
as well as the MRF priors containing the desired contextual information, into the
clustering framework provided by the fuzzy c-means objective function. This hybrid
model can be iteratively minimised over the parameters β,µ and Σ in order to find
an optimal solution for R; the hard classification field x is then defined simply as the
class for which R is maximised at each voxel.
3.2.3 Application to hyperpolarised 13C data
The novel approach proposed in this chapter is to adapt and apply the hybrid fuzzy
clustering MRF framework described above to the problem of segmenting the 5D
data produced by hyperpolarised 13C MRSI. Although the exact form of the data
may differ depending on the imaging sequence used, it will in general consist of a set
of 2D (single slice) or 3D (multi-slice) images, acquired at multiple time points and at
multiple frequencies. The spectral dimension may either be acquired as a continuous
spectrum, or at a number of discrete frequencies corresponding to target metabolites.
The second case is considered here, which provides a separate series of images for
each metabolite.
Four metabolites are considered; pyruvate (P ), lactate (L), alanine (A) and bi-
carbonate (B), therefore at each voxel j in the 3-dimensional imaging volume, the
observed intensity vector yj is given by:
yj(t) = [Pj(t), Lj(t), Aj(t), Bj(t)] (3.15)
To reduce the dimensionality of yj(t) from [4× T ] to [4× 1], where T is the number
of imaging time points, the data were time-averaged. Only images from time points
at which the total carbon signal present was greater than the minimum value plus
0.2 times the standard deviation were included in the time average. This protocol
effectively removed noise images whilst retaining as much useful signal as possible.
Based on the animal data, total carbon SNR was approximately 4 at this cut-off with
individual metabolite SNRs considerably lower. The overall objective of the segmen-
tation was to automatically identify regions of differing metabolism, therefore the set
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of classes Ω = {1, 2, 3, 4, 5, 6} into which voxels were sorted was defined as follows:
1. background (no pyruvate inflow); 2. no conversion of pyruvate; 3. low conversion
rate of pyruvate into lactate; 4. high conversion rate of pyruvate into lactate; 5.
conversion of pyruvate into alanine; 6. conversion of pyruvate into bicarbonate. If
at any point during the iterative minimisation process membership of one of these
classes falls to zero, then it is removed from further calculations and q → q − 1.
In conventional colour image segmentation, a multivariate Gaussian conditional
distribution, as in equation (3.7), may be used to describe the separate intensities
from each of the relevant dimensions of a chosen colour space; e.g. red, green and
blue. Analogous with this approach, the time-averaged data here is treated as a
single image with intensity contributions from four different ‘colours’, i.e. the four
different metabolites. The conditional distribution at each voxel is then modelled by
(3.7), where yj = [Pj, Lj, Aj, Bj], µi is the vector of corresponding means for each
metabolite in relation to class i and Σi is their covariance matrix. For a given voxel
j, its weighting in the calculation of the noise parameters µi and Σi is dependant on
its fuzzy membership to class i as given by Ri,j.
The energy function U(xj|β) in equation (3.9) is comprised of three parts incor-
porating the spatial, temporal and parametric prior information respectively:
U(xj|β) = −β {US(xj) + UT (xj) + UR(xj)} (3.16)
It is in general possible to incorporate any number of terms into the energy function;
the three included in this work are described below.
3.2.3.1 Spatial priors
The first term in the energy function US(xj) describes the spatial dependency of the
MRF system, and the connectivity between voxels. An 8 or 10-connectivity network
is used depending on whether the image to be segmented is 2D or 3D as depicted in
figure 3.1. The spatial energy is calculated as follows:
US(xj) = −
∑
l∈cj δ(xj − xl)
card(l ∈ cj) (3.17)
where δ is the Dirac delta function defined as follows:
δ = { 1 if xj=xl
0 otherwise
(3.18)
The function card is simply the count of voxels in the clique cj. As xj takes each
class label 1, 2, ...q, US will take a minimum value of -1 when the labels of all voxels
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in clique cj match that of xj = i and a maximum value of 0 when no labels coincide.
For the purpose of this calculation, the hard class labels of each voxel in the clique are
defined as that which maximises the current value of the fuzzy membership function:
xl = arg
q
max
i=1
(Ri,l) (3.19)
This results in imposing a penalty on xj = i for not being of the same class as
its immediate surroundings, therefore reducing the influence of random noise and
fulfilling the requirement that voxels containing similar tissue types or metabolic
features are more likely to be adjacent than separate. The spatial priors also prevent
small regions of noise being picked up as false positives by making it energetically
unfavorable to have many small ROIs.
3.2.3.2 Temporal priors
Although the algorithm uses a time-averaged version of the data, the temporal in-
formation is preserved through its incorporation into the prior on each voxel. The
changes in the local concentrations of each of the four metabolites of interest can be
described by the following set of ordinary differential equations:
dP
dt
=I(t)− (kPL + kPA + kPB)P + kLPL− ρPP (3.20)
dL
dt
=− kLPL+ kPLP − ρLL (3.21)
dA
dt
=kPAP − ρAA (3.22)
dB
dt
=kPBP − ρBB (3.23)
where I(t) is the pyruvate inflow profile, kAB is the rate of metabolic conversion form
metabolite A to metabolite B, and ρA is the rate of polarisation loss of metabolite
A. Values for ρ can be estimated from the known thermal decay rates and imaging
parameters, whereas the k terms are unknowns to be solved. Nevertheless, the so-
lutions to these equations have distinct expected forms, which are of similar shape
regardless of the exact values of the conversion rates.
Measured temporal profiles for the relative concentrations of each metabolite at
voxel j are stored in yj(t). To assess whether these time profiles are likely to rep-
resent real signal, their shape is compared to a set of trial functions which form the
solutions to the above differential equations [307]. Six trial functions are used for
each metabolite, varying the kAB and, for pyruvate, the inflow speed contained in the
function I(t). Both the measured signal and trial functions are normalised to [0,1],
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the positions of the peaks are aligned and the R2 is calculated to test goodness of fit
to each of the six trial functions. The highest R2 is then selected for inclusion in the
temporal prior function.
For a given voxel j, the priors for each class i for metabolite X can then be defined
as follows:
PX,i,j =
fi(R
2
X,j)∑q
i=1 fi(R
2
X,j)
(3.24)
Here, the function fi(R
2
X,j) takes two different forms dependant on the expectation of
that metabolite in each class. When no signal is expected from a particular metabo-
lite, f−X,j = 1 − (R2X,j)3, whereas f+X,j = (R2X,j)3 if signal is required for inclusion of
a voxel into a particular class. The cube is used to produce a sharper distinction
between signal and noise. Explicitly, where each column in the row vector is a class
1 to 6, then the following apply:
PP,j = [f
−
P,j, f
+
P,j, f
+
P,j, f
+
P,j, f
+
P,j, f
+
P,j] (3.25)
PL,j = [f
−
L,j, f
−
L,j, f
+
L,j, f
+
L,j, f
−
L,j, f
−
L,j] (3.26)
PA,j = [f
−
A,j, f
−
A,j, f
−
A,j, f
−
A,j, f
+
A,j, f
−
A,j] (3.27)
The polarisation decay rate of bicarbonate is too fast to define appropriate test
functions, therefore only pyruvate, lactate and alanine are included in the temporal
prior. Finally, the normalised contribution to the energy function is given by:
UT (xj = i) = − PP,i,jPL,i,jPA,i,j∑q
i=1 PP,i,jPL,i,jPA,i,j
(3.28)
3.2.3.3 Parametric priors
The final contribution to the energy function considers ratios of the metabolites ob-
served at each voxel and also utilises the full temporal data set. Using the time curve
for each metabolite, it can be shown that the ratio of Areas Under the Curve (AUC)
for lactate and pyruvate is equal to [226]:
RLP =
AUCLactate
AUCPyruvate
=
kPL
kLP + ρL
(3.29)
What is striking about this result is that it is completely independent of the pyruvate
inflow function I(t). Furthermore, since kPL  kLP and ρL is expected to be consis-
tent, this simple metric correlates reasonably well with the forward rate conversion
constant kPL [307].
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AUC ratio maps were calculated for lactate, alanine and bicarbonate, relative to
pyruvate. Values >2 were set to this maximum value, the upper limit expected from a
true signal, to avoid random noise in the background region skewing the results. Each
map was then normalised by dividing by its maximum value. Individual metabolite
priors were then constructed from the ratio maps:
PXP,i,j =
fi(RXP,j)∑q
i=1 fi(RXP,j)
(3.30)
The following main changes to the functions fi used in the temporal case are noted.
Firstly, the background class 1 is noise so does not depend on the AUC ratios; this
was set such that PXP,1,j = 1/6 after normalisation. Secondly, the low lactate class,
class 3, requires a negative quadratic response as the lactate/pyruvate AUC increases.
The normalised ratiometric contribution to the energy function is given by:
UR(xj = i) = − PLP,i,jPAP,i,jPBP,i,j∑q
i=1 PLP,i,jPAP,i,jPBP,i,j
(3.31)
Although there are multiple parametric approaches which could be included as prior
information, the AUC ratio was chosen because of its rapid calculation speed, insen-
sitivity to pyruvate inflow profile, full usage of temporal data and its dual treatment
of metabolite signals, which separates metabolic conversion from perfusion. It is
the latter of these which provides the most important additional information for the
segmentation process.
3.2.4 Initialisation
Given that each class in the 13C segmentation is required to exhibit specific pre-
defined metabolic properties, initialisation was performed using a Bayesian maximum
posterior likelihood method using thresholded, time-averaged metabolite images to
estimate initial class means and variances and incorporating previously calculated ra-
tiometric and temporal maps for the Bayesian priors. Estimates for the background
class noise parameters µ1 and σ1, the 4-metabolite mean and standard deviation vec-
tors respectively, were obtained from the final metabolite images in the time series,
by which time all the signal has decayed. These parameters were then used to deter-
mine whether each voxel in the time-averaged data set, with measured signal intensity
yj = [yP,j, yL,j, yA,j, yB,j], contained signal significantly above the noise level.
The following initial thresholding was used to find mean and variance estimates for
each class, where Lmax is the maximum lactate signal intensity in the time-averaged
image:
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1. Background class: yP,j < µP,1 + 5σP,1
2. No exchange: j /∈ 1, 5, 6 and yL,j < µL,1 + 5σL,1
3. Low lactate exchange: j /∈ 1, 4 and yL,j ≥ µL,1+ 5σL,1
4. High lactate exchange: j /∈ 1 and yL,j ≥ µL,1 + 5σL,1+ 0.8(Lmax − µL,1 + 5σL,1)
5. Conversion to alanine: j /∈ 1, 3, 4 and yA,j ≥ µA,1 + 5σA,1
6. Conversion to bicarbonate: j /∈ 1, 3, 4, 5 and yB,j ≥ µB,1+ 5σB,1
From these initial voxel groupings, mean µ′i and covariance Σ
′
i are calculated
for each class as the inputs into a multivariate normal distribution, N (µ′i,Σ′i). The
final initialisation is given by the class which for each voxel maximises the Bayesian
posterior:
x′j = arg
q
max
i=1
P ′i,jNj(µ′i,Σ′i)∑q
k=1 P
′
k,jNj(µ′k,Σ′k)
(3.32)
Where P ′i,j is an initial prior constructed in the same way as Pi,j but with the spatial
term omitted. An initial estimate of 3 was used for the temperature parameter β and
the fuzziness parameter λ was set to 3 throughout. This value was chosen to provide
a satisfactory trade-off between underestimating the region size and producing false
positives; λ may be optimised further when additional clinical data becomes available.
3.2.5 Iterative determination of the hidden field x
Having defined the constituent parts of the objective function (3.12) and the procedure
for initialisation in the context of the segmentation of 13C imaging data, it is possible
to define the iterative process with which the hidden field x is determined. The
procedure for the most part follows that described by Chatzis et al [309] and is
outlined below.
The full objective function to be minimised at each iteration w is given by:
L
(w)
λ =
1
2
s∑
j=1
q∑
i=1
R
(w)
i,j {n log(2pi) + log(|Σ(w)i |) + (yj − µ(w)i )TΣ(w)
−1
i (yj − µ(w)i )}
+ λ
s∑
j=1
q∑
i=1
R
(w)
i,j log
(
R
(w)
i,j
P
(w)
i,j
)
(3.33)
Therefore at each step, the priors Pi,j, the noise parameters µi and Σi, the fuzzy
membership function Ri,j and the temperature parameter β must all be updated.
Given some initial estimate of the hidden field x(w) at iteration w, the priors P
(w)
i,j are
calculated as follows:
P
(w)
i,j =
eβ
(w){US(xj=i|c(w)j )+UT (xj=i)+UR(xj=i)}∑q
k=1 e
β(w){US(xj=k|c(w)j )+UT (xj=k)+UR(xj=k)}
(3.34)
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Here c
(w)
j denotes the current estimate of the hard class labels for voxels in the clique
cj. These are determined by choosing the value for each xl ∈ cj which maximises the
fuzzy membership function R
(w)
i,j according to equation (3.19). Only the spatial term
in the energy function U(xj|β) is updated, along with the temperature parameter β,
at each iteration.
Given initial estimates of the noise parameters at w, D
(w)
i,j is defined as the
negative-log of the multivariate Gaussian conditional distribution, equation (3.7):
D
(w)
i,j =
1
2
{n log(2pi) + log(|Σ(w)i |) + (yj − µ(w)i )TΣ(w)
−1
i (yj − µ(w)i )} (3.35)
The value of the fuzzy membership function can now be computed for the subse-
quent iteration w + 1:
R
(w+1)
i,j =
P
(w)
i,j e
−D
(w)
i,j
λ∑q
k=1 P
(w)
k,j e
−
D
(w)
k,j
λ
(3.36)
This function is derived by minimising the objective function Lλ with respect to Ri,j
subject to the constraint:
q∑
i=1
Ri,j = 1 ∀j ∈ S (3.37)
This can be achieved by introducing a Lagrange multiplier ψj to enforce the constraint
at each voxel j ∈ S and then setting the partial derivative of the resulting Lagrangian
equal to zero:
∂
∂Ri,j
{Lλ −
s∑
j=1
ψj(
q∑
i=1
Ri,j − 1)} = 0 (3.38)
Similarly, setting the partial derivative of Lλ with respect to each of µi and Σi to
zero, yields the following update functions for the noise parameters at w + 1:
µ
(w+1)
i =
∑s
j=1 R
(w)
i,j yj∑s
j=1R
(w)
i,j
(3.39)
Σ
(w+1)
i =
∑s
j=1 R
(w)
i,j (yj − µ(w)i )(yj − µ(w)i )T∑s
j=1 R
(w)
i,j
(3.40)
The final step is to find the new value for the inverse temperature β(w+1) according
to:
β(w+1) = arg max
β
s∑
j=1
q∑
i=1
R
(w)
i,j log(P
(w)
i,j ) (3.41)
Maximising β in this way fine-tunes the system to become maximally sensitive to
the value of the energy function U(x|β), therefore globally forcing the system into
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the state of lowest energy based on the definition of U(x|β). There is now sufficient
information to calculate the updated value of the objective function L
(w+1)
λ . This was
compared at each step with the value of L
(w)
λ and convergence was defined as having
reached a stable value of ∆Lλ = |L(w+1)λ − L(w)λ |/L(w)λ < cT with cT , the convergence
threshold, set at 0.1.
In summary, the full iterative procedure for the segmentation of 13C imaging data
is as follows:
1: Input: 5D 13C imaging data
2: Calculate temporal coherence maps and value of temporal energy function UT (x)
for each voxel j in the 3D volume
3: Calculate AUC ratio maps and parametric energy function UR(x)
4: Use initialisation procedure to establish initial estimates of R
(0)
i,j , x
(0)
j , µ
(0)
i and
Σ
(0)
i , and thus calculate L
(0)
λ
5: Set iteration number w = 1
6: while ∆Lλ > cT or w < 150 do
7: Calculate the new temperature parameter β(w) using R
(w−1)
i,j and P
(w−1)
i,j with
equation (3.41)
8: Update the values of fuzzy membership function R
(w)
i,j from D
(w−1)
i,j and P
(w−1)
i,j
using the formula given by (3.36)
9: Calculate the updates to the noise parameters µ
(w)
i and Σ
(w)
i using (3.39) and
(3.40) respectively
10: Calculate the current realisation of x
(w)
j from fuzzy membership function R
(w)
i,j
using equation (3.19)
11: Calculate the current value of voxel-wise priors P
(w)
i,j using x
(w)
j and β
(w)
12: Find the new value of the objective function L
(w)
λ
13: Calculate |L(w)λ − L(w−1)λ |/L(w−1)λ and test for convergence
14: w → w + 1
15: end while
16: Return: Hidden field x of voxels segmented into q classes
The fuzzy MRF algorithm was written and implemented in Matlab (MathWorks,
Natick, MA, USA). The algorithmic runtime is dependent on the image size, number
of image slices and number of classes detected during the initialisation process. For
128×128 single slice images, the computational runtime is 42-117 s for 4-6 classes as
measured with a 2.2 GHz Intel Core i7 processor and 8 GB RAM. This stated time is
for processing the raw reconstructed 5D image tensor, including all parametric map
calculations. Computational complexity scales linearly with the number of image
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slices but in practice, this is rarely greater than 4. The algorithm was not optimised
for speed, so further reductions in this runtime will be possible.
3.3 Data acquisition and analysis
3.3.1 In silico data generation
In order to quantitatively assess the accuracy of the segmentation algorithm, an in
silico 13C dataset consisting of 27 sets of images was generated. Each set had the
following properties, chosen to resemble those of the animal data: 2 spatial dimen-
sions, with 128×128 voxels in each image; 16 time points and 4 s temporal resolution;
4 metabolites. Each set contained regions corresponding to classes 1-6. Metabo-
lite signals were generated by solving equations (3.20-3.23) at each voxel location
over time with the following parameterisation; ρP = ρL = ρA = 0.064; ρB = 0.131;
kPL = 10kLP ; and the pyruvate inflow function:
I(t) = kI
(
1
1 + e−(t−ts)
− 1
1 + e−0.4(t−te)
)
(3.42)
Where ts is the inflow start time and te the inflow end time. These were set to increase
gradually with distance from a main ‘supply vessel’ with a fixed difference of 4 s, and
the inflow rate kI decreased from a maximum value at this same point. To evaluate the
performance of the segmentation under different conditions, three parameters were
varied across the dataset. Firstly, to assess the detection of differently sized metabolic
regions of interest, the mean radius of the high lactate conversion region was ascribed
values of 3, 6 and 9 voxels and the surrounding low conversion zone mean radius set
to be 2.4 times larger. Alanine and bicarbonate regions had a variable size between
these two. Secondly, to assess the effects of variable metabolic conversion rates, each
kPX was varied across the entire image, decreasing outwards from a centre point
which took values; kPL,max = 0.01, 0.03, 0.05; kPA,max = 0.008, 0.012, 0.016; kPB,max
= 0.01, 0.014, 0.018. kPX maps were set to zero everywhere except within the test
regions. For the lactate map, the outer low conversion region had a multiplier of 0.14
applied to the kPL. Finally, the effect of varying the SNR, qualitatively equivalent
to differing initial polarisation, was investigated by varying the inflow rate kI over
arbitrary units of 9000, 12000 and 16000, corresponding to a mean pyruvate SNR of
approximately 20, 30 and 40 within the high conversion zone. To mimic the partial
voluming and noise corruption characteristic of in vivo data, image resolution was
first reduced to 32×32, the nominal matrix resolution of the imaging, by grouping
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the pixels into 4×4 bins and taking the mean. Random Gaussian noise with a variable
random mean of 220-410 and variance of 1.1-6.3×104 was then applied to each image,
before artificially increasing the resolution to 128×128 using the imresize() function
in MATLAB with the default bicubic interpolation kernel. The noise parameters were
chosen by measuring the mean and variance of pixels in real images containing only
noise such as those from the end of an acquisition. This procedure produced signal
spread and patterns of noise similar to the in vivo data.
3.3.2 In vivo data acquisition
The segmentation algorithm was tested on previously published data from four tumour-
bearing adult rats with subcutaneous mammary adenocarcinomas [293], [176]. Briefly,
[1-13C]Pyruvic acid was hyperpolarised to approximately 25% in a Hypersense hyper-
polariser (Oxford Instruments). The final solution contained 80 mM [1-13C]pyruvate
at pH 7.6 and physiological temperature and osmolarity. This was injected into a tail
vein inside the MRI scanner at a rate of approximately 0.2 ml/s and at a dose of 2.5
ml/kg and dynamic imaging was performed from the time of injection.
Animals were imaged in a clinical 3 T MRI system (Signa HDx, GE Healthcare)
using a 13C-1H multinuclear birdcage coil. IDEAL spiral CSI acquisition [182] was
performed through four axial 10 mm slices over 1 min with a temporal resolution
of 4 s and a flip angle of 10◦. Other parameters were: repeat time (TR) 500 ms;
field of view 80 mm and nominal matrix resolution 32×32. Gaussian k-space filtering
was applied during post-processing, interpolating from a real resolution of about 5×5
mm2 to an effective image resolution of 0.625×0.625 mm2. For anatomical reference,
standard gradient echo proton images were acquired from the same slice geometry
and FOV (resolution 256×256, slice thickness 3 mm, spacing 7 mm, echo time (TE)
10 ms, TR 500 ms).
3.4 Results
3.4.1 Statistical results on in silico data
The fuzzy MRF segmentation algorithm was applied to each of the 27 4-dimensional
in silico image sets described above. The data set was designed to test the limits
of the algorithm and asses its ability to distinguish two separate regions: region A
was defined as the total area of lactate production (class 3 + class 4); region B, high
lactate production region only (class 4). In both cases, all other classes are considered
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background with the known input kPL map for each in silico image providing the
gold standard for comparison. Performance of the algorithm was compared to that
of thresholding the time-averaged lactate image at 40, 50, 60, 70 and 80% of the
maximum lactate value; a comparison standard chosen for its clinical applicability.
The same time-averaging as for the MRF segmentation was applied. To quantify
performance, the Precision (positive predictive value) and Recall (sensitivity) for this
binary case were calculated; these can be combined to produce the balanced F-score
for the segmentation as follows:
Precision =
tp
tp+ fp
(3.43)
Recall =
tp
tp+ fn
(3.44)
F =
2PR
P +R
(3.45)
where tp stands for “true positives”, the count of voxels correctly identified as tumour
when compared to the gold standard, fp are “false positives” and fn are “false
negatives”. The F-score for the full segmentation into six classes was calculated
using the averages of the precision and recall over each class, with instances where
the algorithm failed to detect a region still included in this score. As an additional
measure of accuracy, the classification error (CE) was calculated in addition to the
F-score. It is defined as:
CE =
100(fp+ fn)
no. pixels in region
(3.46)
where fn are “false negatives”, pixels incorrectly labelled as background, and a CE
closer to zero denotes a more accurate segmentation. The results from calculating
both metrics over each region A and B for all segmentations are shown in table 3.1.
The mean values for all 27 images, as well as the maximum and minimum in each
set, are given.
In every instance, the MRF segmentation performs, on average, better than
thresholding for binary segmentation of both tumour regions A and B. In almost
every case, the MRF method produced the highest minimum and maximum F-scores,
as well as the lowest minimum and maximum classification errors, suggesting that it is
a more robust methodology than thresholding the lactate image at any level. Excep-
tions to this are the maximum lower CEs produced by the high threshold levels for the
small region B. In general, both the MRF algorithm and the reference thresholding
methods were better able to detect region B than A due to class 3 being very close to
the noise floor as evidenced by figure 3.2C and I. Considering the full segmentation
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Table 3.1: Comparison of performance between MRF algorithm and different thresh-
olding levels (as % of maximum lactate) for the detection of two separate regions A
and B.
MRF 40% 50% 60% 70% 80%
F-score Mean 0.694 0.490 0.402 0.329 0.251 0.155
(A) Min 0.284 0.028 0.048 0.247 0.182 0.081
Max 0.938 0.840 0.630 0.548 0.462 0.317
F-score Mean 0.895 0.758 0.864 0.870 0.788 0.571
(B) Min 0.613 0.006 0.011 0.120 0.692 0.355
Max 1.000 1.000 0.997 0.982 0.949 0.844
CE Mean 43.70 497.8 214.4 89.98 85.65 91.54
(A) Min 12.09 29.87 62.64 63.32 72.73 82.25
Max 83.47 6795 3662 344.6 90.02 95.80
CE Mean 27.30 2157 700.5 71.95 34.814 59.42
(B) Min 0.000 0.000 0.694 3.472 9.722 28.57
Max 126.5 32030 17230 1463 47.14 78.45
Table 3.2: F-scores and classification errors for each of the six classes, excluding
instances where a class is empty. Exclusions by class; class 4, 8; class 5, 1; and class
6, 7 out of 27 images.
F-score Class 1 Class 2 Class 3 Class 4 Class 5 Class 6
Mean 0.947 0.975 0.475 0.400 0.583 0.812
Min 0.919 0.932 0.011 0.000 0.527 0.714
Max 0.974 0.991 0.598 0.552 0.639 0.921
CE Class 1 Class 2 Class 3 Class 4 Class 5 Class 6
Mean 10.41 5.053 58.84 75.91 43.62 45.31
Min 5.157 1.839 20.14 31.31 15.99 16.92
Max 17.49 14.37 246.9 136.7 79.41 80.23
into 6 classes, the mean F-score was 0.798 with a range of 0.547-0.882. Figure 3.2A
illustrates the variation in calculated F-score as the simulation parameters are varied.
Low scores indicate that one or more classes failed to be detected. In 8 instances,
only the inner high lactate region was detected and marked as class 3 with class 4
empty. Although this is damaging to the statistical results, it is technically not an
incorrect result to see low lactate production labelled as such; the kPL was just 0.01 in
all but one of these cases. In a clinical setting, it is advantageous that the algorithm
can correctly detect a area of low conversion to lactate whilst separating the region
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from a noisy, very low conversion background. Background lactate is often present,
particularly in organs such as the brain or in the muscles, but should be ignored by
the segmentation. There were no cases in which region B was not detected at all and
no false positives. In 1 case the alanine class and in 7 cases the bicarbonate class
failed to be detected. Lower sensitivity to these metabolites has been chosen to avoid
false positives which, although not detected in the in silico data, are common for in
vivo data. Table 3.2 shows class by class F-score and CE results. Empty classes are
omitted from the mean calculations.
3.4.2 In vivo results
Application of the MRF segmentation algorithm to in vivo imaging was demonstrated
on 5D data from four rats with subcutaneous implanted tumours. Figure 3.3 shows
the single-slice segmentation results for three rats alongside the corresponding 13C-
pyruvate, 13C-lactate and 1H anatomical images. The same time-averaging is used
for these images as for the segmentation algorithm. In each case, the tumour lo-
cation is correctly detected and dual-labelled between low and high lactate classes
demonstrating the feasibility of the algorithm to identify tumour heterogeneity.
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Figure 3.3: A single axial image slice centred on the tumour is shown for 3 rats.
A. Time-averaged pyruvate over each slice; B. Time-averaged lactate; C. Anatomical
reference image with tumour location outlined in green; D. MRF segmentation results
showing background class 1 (no colour) no-conversion class 2 (blue), low conversion
class 3 (yellow), high conversion to lactate class 4 (green) and alanine class 5 (orange).
Class 6 is empty. Lactate phantom in upper left corner.
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Figure 3.4: Three consecutive tumour-bearing slices from rat 4 are shown, with slice
1 cranial in orientation. A. Time-averaged pyruvate over each slice; B. Time-averaged
lactate; C. Anatomical reference image with tumour location outlined in green; D.
MRF segmentation results showing background class 1 (no colour) no-conversion class
2 (blue), low conversion class 3 (yellow), high conversion to lactate class 4 (green)
and bicarbonate class 6 (orange). Class 5 is empty. Lactate phantom in upper left
corner.
The only false positives to be detected were the lactate phantoms; the close prox-
imity to the large tumour in rat 1 has caused joining of these regions, highlighting a
current limitation of the algorithm. Although the alanine detected in rat 1 is likely to
be a false positive from an overlying artery, in rat 3 it points to real signal from the
muscle. Four image slices were acquired for each animal, however only one rat had a
tumour which spanned multiple slices allowing for a demonstration of the 3D capa-
bilities of the algorithm. The resulting segmentation of the three tumour-containing
slices for this rat are shown in figure 3.4. Poor image quality due to artefacts is a
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common problem with current 13C imaging methods; it is therefore crucial to demon-
strate the ability of the proposed MRF algorithm to distinguish high contrast artefacts
from real tissue metabolism. Despite the low spatial resolution and spiral artefact,
particularly in the lactate image where the artefact intensity is comparable to that
of the tumour, the algorithm performs well and correctly identifies the tumour in
each slice with no false positives. A small area of bicarbonate production was also
detected (shown in orange on figure 3.4D); while this may be real, it may also be
artefactual, caused by signal overspill from the very high pyruvate signal in the over-
lying artery. Finally, it is worth noting that the lactate phantom, seen as the bright
circle in the top left of figure 3.4C-D, has been correctly classified as part of the
background despite the increased lactate signal it generates. Taken together, the in
silico and in vivo results suggest that the model is able to distinguish areas of low
from high metabolism. Future correlation of hyperpolarised images with histology
will determine how accurately this variation corresponds to true biological variation.
3.5 Conclusion
A fuzzy Markov random field approach has been presented as the first example of
a segmentation algorithm designed for handling 5D hyperpolarised 13C data. The
method fully utilises the multi-dimensional format of the data in order to classify
each voxel into one of six distinct classes based on its metabolic characteristics. Con-
version of 13C-pyruvate into downstream metabolites 13C-lactate, 13C-alanine and
13C-bicarbonate, in addition to no-conversion and no-perfusion regions, are consid-
ered in this work, however the approach could be applied to other hyperpolarised
13C-labelled molecules in the future. Unlike a hard classification algorithm, the sug-
gested approach uses continuous fuzzy logic to effectively analyse the low resolution,
noisy images by retaining information about the true contents of each voxel through-
out the segmentation process. Contextual information on each voxel is handled by
Bayesian priors describing spatial, temporal and ratiometric dependencies, whilst the
use of a multivariate Gaussian conditional distribution allows image contrast from
multiple spectral dimensions to be considered concurrently.
When tested on an in silico dataset which varied parameters such as the SNR,
metabolic conversion rate constant and lesion radius, the MRF approach significantly
out-performed the reference thresholding methodology at all five thresholding levels
tested. There were no cases in which the algorithm failed to detect the region of high
metabolic conversion of pyruvate to lactate and only a small number in which the
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low conversion region was not detected despite the lactate signal being barely visible
above the noise floor in these image sets. Application to in vivo data from rats
with subcutaneously implanted tumours demonstrated the ability of the algorithm to
successfully segment regions of varying metabolic activity in three spatial dimensions.
The anatomical tumour location was correctly identified in each occasion, whilst
detection of high lactate signal from imaging artefacts was avoided.
Since the algorithm takes imaging parameters including the TR, temporal reso-
lution and flip angle as inputs, it should be robust to changes in these parameters.
Future work will look more closely at these and other dependencies by testing the
algorithm for robustness against different spatial resolutions and image sequences, as
well as developing the capability to effectively handle sequences with multiple or vari-
able flip angles. Another avenue for future development will be incorporating prior
information from the co-registered anatomical 1H images into the segmentation pro-
cess to improve accuracy. In the anatomical rat images used in this work, background
and lactate phantoms form clearly defined regions which may be detected using ex-
isting segmentation algorithms tailored to proton MRI. Although this may not be
appropriate for all human applications, (deep tissue imaging of the liver or ovaries for
example) there are certainly areas such as the brain where the clear division between
tissue and background would allow for easy incorporation of proton image derived
priors. The capability to automatically detect and exclude phantoms as part of the
MRF segmentation is a further point for development.
The method of applying Gaussian white noise to corrupt the in silico dataset is
intended to be as general as possible, thereby making the results applicable to multiple
imaging sequences. However, this comes at the expense of generating artefacts more
closely aligned to those produced by the IDEAL spiral sequence used to collect the
in vivo data. A useful extension of this work would be to examine the effects of the
spiral artefact on the segmentation by generating data in the following way. Begin by
Fourier transforming the uncorrupted metabolite data generated into the frequency
domain; add Gaussian noise; Fourier transform back and zero-fill the truncated data
to artificially increase the resolution back to 128×128. This methodology should
better simulate the effects of the point spread function and spiral artefact and would
provide a controlled means of testing the accuracy of the MRF segmentation in the
presence of these effects.
Hyperpolarised imaging with 13C-labelled compounds is an established research
field and an emerging clinical technique allowing metabolism to be characterised in
vivo. Highly accurate quantification of the multidimensional data produced is an
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ongoing research objective and the success of this technique as a clinical tool depends
on the ability to detect and quantify these changes in metabolism. ROI or VOI
analysis is an integral part of this process and the fuzzy MRF approach presented
here is capable of efficiently providing this analysis in a way that is repeatable and
accurate. This novel methodology for analysing pyruvate metabolism could be applied
to other metabolites and clinical imaging in the future and provides a first solution
to the problem of hyperpolarised 13C image segmentation.
104
Py
ru
va
te
 tim
e-
av
er
ag
ed
Gr
ou
nd
 tr
ut
h 
se
gm
en
ta
tio
n
M
RF
 se
gm
en
ta
tio
n
F-
sc
or
e 
va
ria
tio
n
A	
La
cta
te
 tim
e-
av
er
ag
ed
k P
Lk I
2
1
Al
an
ine
 tim
e-
av
er
ag
ed
Bi
ca
rb
. t
im
e-
av
er
ag
ed
A.
B.
C.
D.
E.
F.
G.
H.
I.
J.
K.
M
.
L.
F
ig
u
re
3.
2:
P
er
fo
rm
an
ce
of
th
e
M
R
F
al
go
ri
th
m
on
in
si
li
co
d
at
a.
P
ar
t
A
.
V
ar
ia
ti
on
in
F
-s
co
re
as
th
e
in
ow
co
n
st
an
t
k
I
an
d
ra
te
co
n
st
an
t
k
P
L
ar
e
in
cr
ea
se
d
fo
r
a
m
ea
n
in
n
er
le
si
on
ra
d
iu
s
of
3
(t
op
),
6
(m
id
d
le
)
an
d
9
(b
ot
to
m
)
im
ag
e
vo
x
el
s.
F
u
rt
h
er
im
ag
es
fr
om
tw
o
re
p
re
se
n
ta
ti
ve
se
ts
la
b
el
le
d
1
(B
-G
)
an
d
2
(H
-M
)
on
p
ar
t
A
ar
e
sh
ow
n
.
T
h
es
e
ar
e:
th
e
ti
m
e-
av
er
ag
ed
p
y
ru
va
te
(B
,
H
);
ti
m
e-
av
er
ag
ed
la
ct
at
e
(C
,
I)
;
ti
m
e-
av
er
ag
ed
al
an
in
e
(D
,
J
);
ti
m
e-
av
er
ag
ed
b
ic
ar
b
on
at
e
(E
,
K
);
gr
ou
n
d
-t
ru
th
se
gm
en
ta
ti
on
(F
-L
)
an
d
M
R
F
se
gm
en
ta
ti
on
(G
,
M
).
T
h
e
n
u
m
b
er
s
1-
6
la
b
el
li
n
g
th
e
la
tt
er
tw
o
of
th
es
e
d
en
ot
e
th
e
si
x
cl
as
se
s.
105
Chapter 4
A mathematical model of
tumour-stroma metabolic coupling
in metastatic ovarian cancer
Ovarian cancer is a highly heterogeneous and metabolically active disease
which is often already metastatic by the time of diagnosis. Metastatic
patterns are predictable, but the common locations are varied in terms
of their microenvironmental conditions and cellular composition. The in-
teraction between stroma and tumour cells in ovarian cancer has been
shown to dramatically affect outcome, with cancer associated fibroblasts
repeatedly implicated as an important driver of invasive and aggressive
behaviour. Furthermore, it has been suggested that metabolic coupling
may exist between these two cell types, resulting in a symbiosis which aids
cancer growth. Ovarian cancer has been the subject of a number of 18F-
FDG-PET studies to date and is due to be imaged with hyperpolarised
13C-pyruvate as part of a study at Addenbrooke’s Hospital in Cambridge.
In order to accurately interpret metabolic imaging data, it is crucial to un-
derstand the way lactate is used and produced by both tumour cells and
fibroblasts in this complex disease. This chapter presents a mathematical
model of tumour growth in a range of tissue environments, focusing on the
role of cancer associated fibroblasts and the different metabolic coupling
regimes which may exist between them and the tumour. Platinum-based
chemotherapy is simulated to explore how the metastatic environment may
affect treatment response and the subsequent presentation of the tumour
on metabolic imaging data.
106
4.1 Introduction
The increased production of lactate which is observed in the vast majority of cancers
forms the basis of metabolic imaging techniques such as 18F-FDG-PET and hyperpo-
larised 13C-pyruvate MRI. These imaging modalities rely on the detection of regions
exhibiting abnormally high metabolic conversion or cellular uptake of the exogenous
tracer in order to make quantitative estimates of changes in metabolism compared to
that of surrounding healthy tissue. Previous chapters have focused on defining the an-
alytical techniques required to accurately and robustly quantify the pyruvate-lactate
exchange reaction from reconstructed hyperpolarised 13C images. However, there is
an implicit assumption that the observed lactate originates solely from the tumour
cells and any observed changes to the metabolic exchange rate represent a fundamen-
tal change in the tumour, either due to treatment response or progression. Although
18-FDG-PET is a less direct measure of glycolytic metabolism, detecting glucose trans-
port and phosphorylation, it is frequently deployed clinically as a means of monitoring
treatment response [312, 243, 242, 313]. Preclinical studies with 13C-pyruvate have
similarly showed that a drop in the observed labelled lactate is indicative of a positive
response to treatment [169, 177].
Recently, the notion that lactate in the tumour environment is produced solely
by the tumour cells has been challenged by many studies examining the interaction
between tumour cells and the surrounding stroma, and the metabolic coupling which
can occur between them [314, 315]. Cancer associated fibroblasts (CAFs) may be par-
ticularly interesting in this regard due to a phenomenon termed the “reverse Warburg
effect” which describes the observation that fibroblasts are capable of producing and
utilising lactate in a symbiotic relationship with the tumour cells [44, 316, 49, 317].
Understanding the mechanism by which lactate is both generated and utilised by the
tumour and surrounding stroma, before, during and following treatment, is crucial
for the successful interpretation of metabolic imaging data; this work uses a mathe-
matical model in order to investigate the dynamics and consequences for treatment
response and imaging of tumour-stroma metabolic coupling.
Ovarian cancer has been chosen here as a model system for this study for a number
of reasons. Firstly, it is a heterogeneous and metabolically active cancer which has
been the subject of a number of PET studies of treatment response [241, 243, 242, 318];
secondly, a clinical study imaging hyperpolarised 13C-pyruvate in ovarian cancer is
also under way which will shortly provide detailed insight into the metabolism of
pyruvate and lactate in these tumours. Thirdly, the importance of CAFs and the
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stromal microenvironment in the development and progression of ovarian cancer has
been repeatedly demonstrated [75, 69, 319, 320]. Finally, ovarian cancer commonly
metastasises to a range of heterogeneous tissue environments, making it a good can-
didate disease for such an environmental diversity study.
Ovarian cancer is a complex and heterogeneous disease with poor survival. Early
stage disease can often be effectively managed through a combination of drug and
surgical treatments, however early detection remains problematic and symptoms are
generally ambiguous with common gastrointestinal and genitourinary conditions [53].
Therefore, many patients are already at an advanced stage with widespread metas-
tases at the time of diagnosis, making ovarian cancer the eighth highest cause of
cancer-related mortality in women [321]. Current standard-of-care treatment for ovar-
ian cancer involves the administration of platinum-based chemotherapy followed by
de-bulking surgery. Allthough most patients will generally relapse, they may be again
treated with the same drug in an unusual phenomena known as platinum-sensitive
recurrence [79]. The mechanism behind this, and indeed behind the gradual build up
of platinum resistance which follows, are not well understood; however explanations
favour post-platinum re-population by quiescent tumour stem cells [83], or by cells
which resist treatment though entering a quiescent state triggered by unfavourable
microenvironmental factors [84].
Despite the histological diversity present in ovarian cancer, metastatic patterns
are highly predictable and common amongst all subtypes. The peritoneum has a
natural circulation of fluid, facilitating transcoleomic metastasis by transporting de-
tached malignant cells throughout the cavity [62]. The most frequently involved site
is the peritoneum and in particular the omentum, a large fat pad extending from the
stomach across the bowel, which has metastases present in 80% of all serous ovarian
cancer cases [63]. This is followed by the lymph nodes, genitourinary and gastroin-
testinal systems and the liver [64], which together provide a diverse range of tissue
compositions and microenvironmental conditions into which malignant cells in the
form of exfoliated tumour spheroids from the primary site can implant and develop.
The stromal microenvironment has been shown to play a critical role in deter-
mining the clinical outcome of many cancers including ovarian [314]. The propor-
tion of stromal cells found in ovarian tumours is highly variable, and ranges from
around 10-80% [69]; this stromal abundance has been shown to have significant prog-
nostic value, correlating negatively with overall survival. Fibroblasts are the most
commonly observed intratumoural stromal cell type and may be recruited and phe-
notypically altered by adjacent tumour cells to become CAFs through the action of
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microRNAs and TGFβ signalling [319, 320]. CAFs have been shown to increase in-
vasiveness and tumour cell motility by degradation of extracellular matrix proteins
[67, 73], and to drive angiogenesis [72]. There is abundant evidence that CAFs also
produce factors promoting adhesion, lymphangiogenesis and other growth factors im-
portant for metastasis and the subsequent development of an aggressive phenotype
[322, 319, 72, 73, 74].
Metabolic coupling is a form of symbiosis between CAFs and tumour that has
recently been gaining attention. The propensity of tumour cells to undergo glycolytic
metabolism has been well documented [2] and has the effect of acidifying the extra-
cellular environment by the fermentation of glucose into lactate. Microenvironmental
acidification has been shown to promote tumour invasion and aggressiveness [3], mak-
ing tumour pH and anaerobic glycolysis popular targets when considering potential
therapies [38]. Upregulated glycolysis also forms the target of molecular imaging tech-
niques such as 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET)
which detects cellular glucose uptake and hyperpolarised imaging with 13C-pyruvate,
a more specific probe for lactate production.
Excess lactic acid creates a favourable environmental niche for the tumour, how-
ever it may be also used as an energy source when nutrients are scarce. This phe-
nomenon, termed ‘cell-cell lactate shuttle’ theory, is already known to occur frequently
in healthy tissue and describes how cells with insufficient oxygen supply, such as ex-
ercising muscle fibre, may produce lactate which is then transported out of the cell
via monocarboxylate transporter 4 (MCT4), a membrane protein which is widely ex-
pressed in glycolytic tissues [35]. This lactate can be taken up by neighbouring cells
to be utilised as a fuel source; lactate produced by astrocytes for example, is taken
up by neurons for rapid energy production in the brain where it can be used instead
of glucose as a substrate for oxidation [36]. The same process has been suggested to
occur in cancer, creating a coupled metabolism between heterogeneous regions of the
tumour.
Peripheral CAFs have also been shown to take up lactate produced by hypoxic
tumour cells; this deacidifies the tumour microenvironment but reduces competition
for glucose, aiding tumour glycolysis [41]. Computational and evolutionary game the-
ory models have shown this type of tumour-stroma lactate shuttle to be energetically
favourable under a broad range of conditions given simple physiochemical constraints
[42, 43, 129]. Furthermore, tumour cells may induce increased anaerobic glycolysis
in the surrounding CAFs, generating a two-way lactate shuttle which allows hetero-
geneous tissue regions to make optimal use of available nutrients [44]. The process,
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often called the ‘reverse Warburg effect’, has been shown to be mediated by the loss
of stromal caveolin 1, a protein involved in cell cycle progression and metabolism and
the expression of which has been shown to negatively correlate with histological grade
and aggressiveness in serous ovarian carcinoma [48].
Figure 4.1: Histology data from the primary tumours of four ovarian cancer patients,
with good responders (top) and poor responders (bottom). Four stains are shown,
where brown staining shows positive regions and blue indicates background. Stains
shown from left to right: CA125 (ovarian cancer marker); Alpha-smooth muscle actin
(active fibroblasts); GLUT1 (glucose transporter protein 1); CD34 (vessels).
Tissue composition is clearly an important driver of tumour outcome and one
which may be probed clinically through histological analysis of biopsy-derived tis-
sue. Histology data was obtained from the primary tumours of 15 ovarian cancer
patients at Addenbrooke’s hospital and although this cohort is too small to make any
quantitative claims, it is instructive to discuss here some observed trends. Figure
4.1 shows data from two good and two poor responders to re-treatment with plat-
inum chemotherapy following relapse with ovarian cancer. The good responders show
greater tissue homogeneity, with diffuse but even staining for ovarian cancer marker
CA125, little infiltration of active fibroblasts (ASMA) and weakly elevated GLUT1.
In contrast, the poor responders show very high levels of GLUT1 over and around
ovarian cancer cells, with dense active stroma tightly surrounding the tumour, clearly
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indicating a much more metabolically active tissue. Perhaps the most striking dif-
ference between the two sets is in the CD34 staining, a marker of vasculature. The
good responders show well-spaced, homogeneously distributed vessels throughout the
tissue, whereas the poor responders have both regions of very dense staining and large
areas with no staining. These tumours are likely to have both hypoxic and highly
metabolically active regions; it is likely that the more aggressive coupled metabolic
phenotypes emerge as a response to heterogeneous vasculature such as this.
By its mechanistic nature, cellular metabolism lends itself well to study through
computational and mathematical approaches which make it possible to explore a
broad range of physiological conditions and constraints in a simulated tumour. Sim-
ple spatial differential equation models have been successfully utilised to investigate
glycolytic metabolism in tumour spheroids [119, 118], and the effects of tumour acid
production and microenvironmental pH on growth dynamics [121, 122, 120]. Such
models generally use reaction-diffusion type equations to model the movement of acid
and nutrients through the cellular environment. More complicated partial differential
equation (PDE) models with many cellular and chemical compartments have been
used to demonstrate various aspects of metabolic or environmental dynamics; no-
tably, Kim et al model the recruitment of fibroblasts via the release of cytokines by
the tumor [323]. Further examples of PDE models studying the tumour-stroma in-
teraction have focused on angiogenesis [107] and tumour response to chemotherapy
[324].
Although there have been numerous mathematical modelling attempts to demon-
strate either the advantages of metabolic coupling or the spatial interaction between
the tumour and host cells, there is currently no work in which these two approaches
are combined. This work presents a spatial mathematical model to investigate the role
of CAFs under differing environmental and metabolic regimes in ovarian cancer, with
the objective of understanding qualitatively how the tumour environment may affect
treatment response on both a cellular and metabolic level. Growth of a small tumour
‘seed’, such as that which remains following standard-of-care debulking surgery for
ovarian cancer, is allowed to grow to a clinically detectable size before platinum-based
chemotherapy is simulated. Multiple environments are simulated for the same seed
in order to examine how different metastatic locations may effect outcome. Several
vascular densities are considered as well as four metabolic environments: in the first,
no fibroblasts are recruited by the tumour; secondly, CAFs are recruited but may
only respire aerobically; thirdly, recruited CAFs are able to utilise lactate as a fuel
source in partial metabolic coupling with the tumour; finally, CAFs are allowed to
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produce, metabolise and exchange lactate with the tumour cells in metabolic sym-
biosis. Although this model was built with ovarian cancer as a model system, the
findings are more widely applicable to other solid tumours.
4.2 Methods
A mathematical model was built to explore in silico the effects of metabolism and
tissue environment on growth and treatment response in metastatic ovarian cancer.
The reactive stroma has been demonstrated in the literature to play an important
part in modulating the microenvironment to promote angiogenesis, aggressiveness
and invasiveness in ovarian cancer, with CAFs repeatedly implicated as the primary
driver. For this reason, it was decided that the interaction between the tumour, CAFs
and vasculature should be the primary focus of the model. It was also important
to include a detailed treatment of cellular metabolism in the model, with separate
equations for the three important metabolites: oxygen, glucose and lactate.
For this purpose, a 1D spherically symmetric partial differential equation (PDE)
model was chosen, which models the tumour growing in the centre of a sphere sur-
rounded by normal tissue. Interactions between tumour cells, CAFs, non-reactive
stromal cells and vascular endothelium are considered, with dead cells also included
in the equations. Concentrations of three nutrients - glucose, oxygen and lactate -
are modelled explicitly in addition to the cell densities, as well as the concentration
of the drug cisplatin; a platinum-based chemotherapy agent used frequently for the
treatment of ovarian cancer. The scale of the model was chosen to correspond to that
of metabolic imaging data to enable future comparison, with growth simulations per-
formed over a sphere of tissue 6 cm in diameter. Simulations for growth were run over
200 days. Simulations incorporating treatment were run until the tumour reached a
clinically detectable size of 2×108 cells, followed by an additional 400 days from the
start of treatment. Treatment was simulated as 6 cycles of cisplatin chemotherapy,
each cycle consisting of a single 4 hour infusion, spaced 21 days apart.
4.2.1 Model assumptions
Interactions between five cellular compartments are included in the model: tumour,
reactive stroma/CAFs, non-reactive stroma, vasculature and necrotic/dead tissue.
Given the scale of the model, vasculature is not modelled as discrete vessels, but
approximated as a vascular density of epithelial cells with the surrounding nutrient
concentrations proportional to this density. Cell densities are set to zero if they drop
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below a single cell. Figure 4.2 demonstrates the form of the interactions between each
of the cell compartments and the applied chemotherapy drug.
Figure 4.2: Visual representation of the interactions between different cellular com-
partments and cisplatin chemotherapy. Green arrows represent positive feedback and
red denote inhibitory effects on linked compartments. Arrows marked by an asterisk
represent interactions dependent on ATP production rates and those with a dagger
are pH dependant; both the removal of acid from the system and the level of available
nutrients for ATP production are mediated by the vascular compartment.
The following assumptions are used in this model:
• In the presence of tumour cells, CAFs may be recruited from the normal stroma
population.
• In the presence of CAFs, tumour cells have increased motility and the vascular
proliferation rate increases [72].
• Excluding the vasculature, cells must be producing ATP at 60% of the maximum
rate in order to proliferate, and will die if this falls to 20%. Cells between these
two thresholds are considered quiescent.
• Lactic acid produced by the tumour changes the local pH, with the change in
protons calculated according to [H+] = kpH [cl] where kpH = 2.5× 10−4 is taken
as the buffering constant and cl is the lactate concentration [128].
• Stromal cells begin to die if the pH drops below 6.65, the vasculature below
pH 6.6 and CAFs below pH 6.5. Cancer cells are assumed to have adequate
resistance to acidic conditions.
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• Stromal cells use aerobic respiration only, while tumour cells have an altered
metabolic phenotype which allows them to both use and produce lactate. CAFs
may take either of these metabolic phenotypes or an alternative third approach
which allows lactate to be used in addition to aerobic metabolism.
• Vascular endothelial cells are not included in metabolic calculations as it is
assumed they always have access to sufficient nutrients.
• Where available, tumour cells will take up all available glucose up to a maximum
allowed rate.
• All cellular metabolism is constrained by the stoichiometry of ATP production.
4.2.2 The PDE system
The full PDE system comprises ten equations with 1D spherical symmetry to describe
the change over time in the cell densities of the tumour (m), CAFs (f), non-reactive
stroma (s), vasculature (v) and dead cells (n). Additionally modelled are the molar
concentrations of oxygen (co), glucose (cg), lactate (cl) and platinum-based chemother-
apy drug (p). In the following equations, the parameters D are diffusion or motility
coefficients, µ are proliferation rates, η are acid induced or nutrient deficiency in-
duced death rates and δ are basal death rates. Cells may proliferate only when there
is sufficient space, where Ω is the maximum cell density, and ω = m+ f + s+ v + n
is the current local cell density. The functions of the form H(qAA − θ+) are continuous
step functions normalised to [0,1]; these smoothly but rapidly turn on or off terms
dependant on threshold concentrations of lactate, or threshold ATP production rate,
with the mid-point of the transition from zero to one occurring when the argument
equals zero.
Tumour cells are considered to move with a non-directional mobility coefficient
Dm which may be modulated by the presence of CAFs. Cells proliferate if there is
sufficient space and ATP production and may die if ATP production is insufficient,
as well as at their basal rate, according to:
∂m
∂t
= ∇ · {(Dm +Dmff)∇m}︸ ︷︷ ︸
Motility
+µmm(Ω− ω)H(qCA − θ+)︸ ︷︷ ︸
Proliferation
− ηmmH(θ− − qCA)− δmm︸ ︷︷ ︸
Cell death
(4.1)
Up to 50% of the local healthy stroma may be recruited to produce CAFs at a
rate ksf in the presence of tumour cells. CAFs are subject to the same growth and
death assumptions as the tumour cells and may additionally die if the pH drops below
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a threshold level. The qXA in this equation represents ATP production rates for the
three possible metabolic phenotypes the CAFs may take, denoted by the superscript
as qAA, q
B
A or q
C
A . The full equation governing the behaviour of CAFs is given by:
∂f
∂t
= ∇ · {Df∇f}︸ ︷︷ ︸
Motility
+ m(s− f)ksf︸ ︷︷ ︸
CAF recruitment
+µff(Ω− ω)H(qXA − θ+)︸ ︷︷ ︸
Proliferation
− ηffH(θ− − qXA )− ηlfH(cl −Hf )− δff︸ ︷︷ ︸
Cell death
(4.2)
The non-reactive normal stroma obeys the same basic behaviour as the reactive
stroma above, with the corresponding equation:
∂s
∂t
= ∇ · {Ds∇s}︸ ︷︷ ︸
Motility
−m(s− f)ksf︸ ︷︷ ︸
CAF recruitment
+µss(Ω− ω)H(qAA − θ+)︸ ︷︷ ︸
Proliferation
− ηssH(θ− − qAA)− ηlsH(cl −Hs)− δss︸ ︷︷ ︸
Cell death
(4.3)
The vasculature is modelled as a vascular density which is able to proliferate at a
rate µv provided the local oxygen concentration is below the maximum allowed and
there is sufficient space. This rate increases in the presence of CAFs. Vasculature
may preferentially diffuse, or chemotax, down the oxygen concentration gradient to
supply oxygen-starved regions with additional vessels, and vessels will begin to die
above their basel rate when the pH drops bellow a threshold level. The full equation
for the vascular compartment is given by:
∂v
∂t
= ∇ · {Dv∇v}︸ ︷︷ ︸
Motility
+ (µv + µvff)v(Ω− ω)(co,max − co)︸ ︷︷ ︸
Proliferation
+ χv∇ · (v∇co)︸ ︷︷ ︸
Chemotaxis
− ηlvH(cl −Hv)− δvv︸ ︷︷ ︸
Cell death
(4.4)
The final tissue compartment is that of dead or necrotic cells. When the other
four cell types die, they move to this compartment where they remain to take up
space until they are eventually reabsorbed:
∂n
∂t
= ηmmH(θ− − qA) + (ηff + ηss)H(θ− − qAA)︸ ︷︷ ︸
Nutrient deficiency death
+ δmm+ δvv + δff + δss︸ ︷︷ ︸
Basal cell death
+ ηl(sH(cl −Hs) + fH(cl −Hf ) + vH(cl −Hv))︸ ︷︷ ︸
Acid induced death
− δnn︸︷︷︸
Clearance
(4.5)
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Chemical concentrations of three metabolically important molecules - oxygen (co),
glucose (cg) and lactate (cl) - are modelled. These molecules are provided or removed
by local vasculature, may diffuse and also be used or produced by cells. The equations
for nutrient concentrations over the tissue domain are as follows:
∂co
∂t
= ∇ · {Do∇co}︸ ︷︷ ︸
Diffusion
+ vαo(co,max − co)︸ ︷︷ ︸
Vascular supply
− qAo s︸︷︷︸
Stromal uptake
− qXo f︸︷︷︸
CAF uptake
− qCo m︸︷︷︸
Tumour uptake
(4.6)
∂cg
∂t
= ∇ · {Dg∇cg}︸ ︷︷ ︸
Diffusion
+ vαg(cg,max − cg)︸ ︷︷ ︸
Vascular supply
− qAg s︸︷︷︸
Stromal uptake
− qXg s︸︷︷︸
CAF uptake
− qCg m︸︷︷︸
Tumour uptake
(4.7)
∂cl
∂t
= ∇ · {Dl∇cl}︸ ︷︷ ︸
Diffusion
− vα¯lcl︸ ︷︷ ︸
Vascular removal
− qXl f︸︷︷︸
CAF uptake
− qCl m︸︷︷︸
Tumour uptake
(4.8)
The parameters α (α¯) are vascular supply (removal) rates, and the metabolite up-
take parameters qXo , q
X
g , and q
X
l are defined by the stoichiometry of metabolism and
the local nutrient concentrations according to the rules of the particular metabolic
regime being played out. Three metabolic phenotypes are considered: aerobic metabolism
denoted by the superscript qA; aerobic or lactate metabolism qB; aerobic, lactate or
glycolytic metabolism qC . The stromal cells always metabolise aerobically as type A
and tumour cells always as type C whereas CAFs may take any of the three pheno-
types. Where more than one metabolic pathway is available to a cell, the relative
contributions from each type of energy production depends on the local nutrient con-
centrations according to a set of rules.
In the aerobic type A case, it is assumed that the uptake of both glucose and
oxygen is rate limited by the nutrient in scarcest supply, and that near the maximum
uptake rate qi,max the cell produces sufficient ATP for proliferation. For the aerobically
respiring cells, the mass balance equations for the rate of ATP production qAATP are
given by:
qAo = min{
qo,maxco
Ko + co
,
6qg,maxcg
Kg + cg
}, qAg =
1
6
qAo (4.9)
qAATP = 7q
A
g +
25
6
qAo (4.10)
Nutrient uptake takes a Michaelis-Menten form, with Ki representing the half-
max concentration constants. Although aerobic respiration has a theoretical ATP
yield of 38 ATP molecules per glucose, this process is not perfectly efficient due to
losses as molecules are transported into the mitochondrial matrix. Here, P/O ratios
of 2.5 and 1.5 have been assumed for NADH and FADH2 respectively based on the
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most recent experimental evidence [325]; this corresponds to an actual aerobic ATP
yield of 32 molecules per glucose.
The second metabolic phenotype, type B, is only exhibited by the CAFs and
models the lactate shuttle effect whereby CAFs may metabolise the lactate produced
by the tumour cells as a carbon source when glucose is scarce. It is assumed that cells
will take up oxygen and lactate where available with the rate limited by the scarcer
of the two, and that any additional oxygen may be utilised for glucose metabolism.
In this case, the oxygen uptake rate is given by:
qBo = min{
qo,maxco
Ko + co
, 6
qg,maxcg
Kg + cg
+ 3
ql,maxcl
Kl + cl
}, qBg =
1
6
qBo −
1
2
qBl (4.11)
qBl = min{
ql,maxcl
Kl + cl
,
1
3
qBo }, qBATP = 7qBg +
5
2
qBl +
25
6
qBo (4.12)
In the type C metabolic state, cells are permitted to maximise their energy pro-
duction through a combination of aerobic, glycolytic and lactate metabolism. In this
case, it is assumed that cells will consume glucose where available, and that the rate
of aerobic metabolism will then be limited by the available oxygen, with the remain-
ing glucose converted into lactate. However, if sufficient oxygen is available but little
glucose, lactate may be metabolised as an alternative carbon source according to the
following equations:
qCo = min{
qo,maxco
Ko + co
, 6qCg + 3
ql,maxcl
Kl + cl
}, qCg =
qg,maxcg
cg +Kg
(4.13)
qCl =
1
3
qCo − 2qCg , qCATP = 7qCg +
5
2
qCl +
25
6
qCo (4.14)
Constraining qXl = 0 gives the equivalent relations for the aerobic case. It should
be noted here that ql,max and q
X
l are both uptake rates, however q
C
l can be, and gen-
erally is, negative, indicating an overall net production of lactate. Figure 4.3 depicts
schematically the four different tumour-CAF coupling conditions being simulated.
4.2.3 Application of treatment
After 200 days, 6 simulated cycles of chemotherapy are implemented. In accordance
with the standard of care treatment offered to the ovarian cancer patient cohort,
treatment is modelled as a single intravenous infusion for 1 hour every 3 weeks. The
equation for the cisplatin concentration is:
∂p
∂t
= ∇ · {Dp∇p}︸ ︷︷ ︸
Diffusion
+ vαp(t)(pmax − p)︸ ︷︷ ︸
Vascular provision
− qppm︸ ︷︷ ︸
Tumour uptake
− γpp︸︷︷︸
Elimination
(4.15)
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Figure 4.3: Schematic showing the use and production of metabolites in each of the
four test conditions for tumour-CAF metabolic coupling. The control condition with
no CAFs (top left); aerobic CAFs with no metabolic coupling (top right); partial cou-
pling via lactate a shuttle (bottom left); fully metabolically coupled (bottom right).
Where qp and γp are constant uptake and decay rates respectively and αp(t) de-
fines the inflow of the drug via the vasculature over time; the temporal flow profile is
modelled as a series of six four-hour ‘on’ periods spaced three weeks apart. The corre-
sponding modification to the tumour cell and dead cell populations under treatment
are as follows:
∂m
∂t
= ...−mpH(qCA − θ+)qpηp,
∂n
∂t
= ...+mpH(qCA − θ+)qpηp (4.16)
Here ηp is the chemotherapy-induced death rate, and the drug is assumed to kill only
those cells which are proliferating; explicitly, the cells which have an ATP production
rate qCA above the critical value required for proliferation θ+.
4.2.4 Non-dimensionalisation
By transforming all variables and parameters into dimensionless form, the set of
equations can be scaled such that each variable may vary between a minimum of
zero and a maximum of one, corresponding to the maximum allowed value. This
not only confines the system to a more numerically tractable space, but allows for
easier estimation of any unknown parameters by making clear the scale on which
they must operate. By defining new dimensionless parameters as indicated by a tilde,
and making appropriate substitutions, the differential equations can be written in
dimensionless form. The following non-dimensional variables are defined:
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c˜o =
co
co,max
, c˜g =
cg
cg,max
, c˜l =
cl
cl,max
p˜ =
p
pmax
m˜ =
m
Ω
, n˜ =
n
Ω
, v˜ =
v
Ω
, f˜ =
f
Ω
, s˜ =
s
Ω
Additionally, characteristic time and length scales T and L respectively can be
defined, such that:
τ =
t
T
, ρ =
r
L
, ∇˜ = L∇, D˜i = DiT
L2
, D˜mf =
ΩTDmf
L2
A value of 1 hour was chosen for T and of 1 cm for L. Substituting into the equations
for nutrient concentrations, the following are obtained:
q˜i
j =
ΩTqji
ci,max
, q˜p = ΩTqp, α˜i = ΩTαi
Where i represents the subscript for each of the three nutrients oxygen, glucose and
lactate, and j denotes the type of metabolism, aerobic or abnormal. For the cell
concentration equations, the following can be defined for each of the general growth,
decay and death rates:
δ˜k = Tδk, µ˜k = TΩµk, η˜k = Tηk, γ˜p = γpT
And for the following which take a slightly different form to the general case:
µ˜v = TΩco,maxµv, µ˜vf = TΩ
2co,maxµvf , µ˜mf = TΩ
2µmf , δ˜p =
δppmax
Ω
Finally, the chemotaxis, recruitment and Michaelis-Menten constants are given by:
χ˜v =
χvco,maxT
L2
, k˜sf = ksfΩT, K˜i =
Ki
ci,max
These new dimensionless parameters are substituted into the original equations.
If the tildes are omitted from each of the variables and parameters, this leads to
equations of very similar form to those described above.
4.2.5 Parameterisation
The PDE system was built in the knowledge that any free parameters would have to
be derived from the literature. Although the model is comprised of a very large system
of equations, it contains few quantities which are not biologically measurable with
well documented values. Parameter values were obtained where possible from human
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studies, although it is noted that in some instances only animal or in vitro data was
available. In the interest of internal consistency, similar parameters were obtained
from as few sources as possible; for example, all chemical diffusion parameters are
derived from the same study which ensures values are correctly distributed relative
to one another.
There were a small number of parameters which were not directly measurable.
Firstly, the vascular transport parameters αo, αg and αl were picked to produce
the correct observed tissue concentrations of the respective nutrients under steady
state conditions with no tumour cells present; it is these tissue concentrations that
are referenced for these parameters. The CAF enhanced tumour motility Dm,f was
chosen such that the motility of tumour cells was doubled at a relative CAF density
of 20% in line with experimental observations. The vascular basal death rate δv was
varied to produce different vascular densities, taking values of 1.25×10−7, 3.60×10−9
and 2.56×10−9 s−1 to produce tissues with 4%, 8% and 12% vasculature by volume at
steady state respectively. Finally, the rate of CAF recruitment rate ksf was chosen to
produce a qualitatively similar proportion of CAFs as the tissue vascular density was
varied, with the objective to produce a CAF density of around 30% at the tumour
periphery in accordance with clinical histological findings. ksf values of 2×10−15,
6.2×10−14 and 1.82×10−13 were chosen for tissue vascular densities 4%, 8% and 12%
respectively to achieve this.
Table 4.1 shows the full list of parameters used in the tissue model, with their
descriptions, symbols, units, values and literature references given. Parameters de-
scribing the behaviour of both the platinum and alkalysing drugs are shown in a
separate table 4.2. Values for these parameters were derived from the known phar-
macokinetics of cisplatin.
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Table 4.1: Descriptions of all parameters used in the tumor growth model, or in the
non-dimensionalisation process, with their symbol, unit, value and literature refer-
ences where appropriate.
Parameter description Symbol Units Value Ref
Oxygen diffusion Do cm
2s−1 1.32× 10−5 [326]
Glucose diffusion Dg 3.62× 10−6 [326]
Lactate diffusion Dl 6.08× 10−6 [326]
Tumour cell motility Dm 1.0× 10−9 [326]
Vascular motility Dv 1.0× 10−10 [327, 324]
CAF motility Df 1.7× 10−9 [328, 323]
Stroma cell motility Ds 1.7× 10−10 [329, 330]
CAF enhanced tumour motility Dmf cm
2s−1cell−1cm3 4.0× 10−17 [323, 72]
Vascular provision of oxygen αo cm
3cell−1s−1 1.82× 10−8 [331, 332]
Vascular provision of glucose αg 6.06× 10−11 [333, 332]
Vascular removal of lactate αl 1.00× 10−10 [333, 332]
Tumour proliferation µm cm
3cell−1s−1 1.20×10−13 [334, 335]
Vascular proliferation µv 8.02×10−14 [336]
CAF proliferation µf 1.26×10−14 [323, 337]
Stroma proliferation µs 4.38×10−14 [323], [337]
CAF enhanced tumour proliferation µmf (cm
3cell−1)2s−1 1.93×10−24 [323, 72]
CAF enhanced vascular proliferation µvf 1.75×10−20 [72]
Tumour nutrient-mediated death ηm s
−1 4.0×10−8 [128]
CAF nutrient-mediated death ηf 4.0×10−6 [128]
Stroma nutrient-mediated death ηs 4.0×10−6 [128]
Acid-mediated cell death rate ηl 2.24.0×10−6 [338]
Tumour cell death rate δm s
−1 1.0×10−9 [334, 335]
Vascular cell death rate δv Variable
CAF cell death rate δf 2.42×10−9 [330]
Stroma cell death rate δs 2.42×10−9 [330]
Dead cell re-absorption δn 2.47×10−7 [108]
Vascular chemotaxis χv cm
2cm3mol−1s−1 9.10× 10−5 [108]
Stroma to CAF conversion ksf cm
3cell−1s−1 Variable [323]
Max tissue O2 concentration co,max mol cm
−3 1.1×10−7 [128], [339]
Max tissue glucose concentration cg,max 5.5×10−6 [128, 340]
Max tissue lactate concentration cl,max 4.0×10−5 [332, 341]
O2 Michaelis-Menten constant Ko mol cm
−3 4.8×10−9 [332, 341]
Glucose Michaelis-Menten constant Kg 4.0×10−8 [332, 341]
Lactate Michaelis-Menten constant Kg 5.5×10−10 [332, 341]
Max O2 transport rate qo,max mol cell
−1s−1 1.76×10−16 [332, 341]
Max glucose transport rate qg,max 1.33× 10−16 [332, 341]
Max lactate transport rate ql,max 1.00×10−14 [332, 341]
Max ATP production rate qATP,max 9.39×10−16 Calculated
Max cell density Ω cell cm−3 1× 108 [332, 128]
Stromal acid-death threshold pH Hs pH 6.65 [342]
Vascular acid-death threshold pH Hv 6.60 [342]
CAF acid-death threshold pH Hf 6.50 [342]
ATP proliferation threshold θ+ mol cell
−1s−1 0.6 qATP,max [343]
ATP death threshold θ− 0.2 qATP,max [343]
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Table 4.2: Parameter values for simulated cisplatin treatment.
Parameter description Symbol Units Value Ref
Cisplatin diffusion Dp cm
2s−1 2.10×10−6 [326]
Drug vascular provision rate ap(t) cm
3cell−1s−1 2.78×10−11 [344]
Max. cisplatin concentration pmax mol cm
3 Variable [344, 345]
Tumour cell uptake rate qp cell
−1cm3s−1 6.50×10−16pmax [344, 345]
Tumour cell kill potency ηp cell mol
−1 6.00×1022 [80, 344]
Cisplatin decay rate γp s
−1 1.50×10−6 [344, 345]
4.2.6 Numerical methods
The system of nine coupled partial differential equations was solved numerically using
a semi-implicit finite-difference scheme. Reaction-diffusion equations of this type are
hard to treat due to the inhomogeneous reaction terms and the fact that the processes
being described act on very different time scales, making this particular system stiff
in both the reaction and diffusion terms. This results in a system which requires
impractically tiny time steps to be taken if a standard explicit finite difference scheme
is used, else the solution will become unstable as the Fourier modes of the system grow
and generate oscillations. On the other hand, using a fully implicit method requires
vast matrix manipulations and is extremely computationally demanding. One way
of dealing with such a system is to use an implicit integration factor (IFF) scheme
in which the linear diffusion terms are treated exactly, and the stiff reaction terms
are treated implicitly. Several possible methods are compared by Nie et al [346],
however they find only the 2nd order IFF method (or weighted combinations with
other methods) to be unconditionally linearly stable with increasing time step. The
method is further developed in [347] and will be briefly described below.
The system of reaction-diffusion equations in one spatial dimension r, for time
t > 0 may be written concisely as:
du(r, t)
dt
= Cu(r, t) + f(u(r, t)), u(r, 0) = u0 (4.17)
Where u is a vector containing the values of each variable at each radial point r, u0
is a set of given initial conditions, C is a matrix operator describing the action of the
diffusion (all spatially dependant) terms and f(u(r)) is a vector containing the non-
linear (non-spatially dependant) reaction terms. Multiplying the above expression
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by an integrating factor e−Ct and rearranging (dropping the dependence on r for
convenience), the following is obtained:
d
dt
(ue−Ct) = f(u)e−Ct (4.18)
The vector u is known at time tn and its value at the next time step tn+1 must be
found, where tn+1 = tn + ∆t. First, both sides of equation 4.18 are integrated from
tn to tn+1:
u(tn+1)e
−Ctn+1 − u(tn)e−Ctn =
∫ tn+1
tn
f(u(t))e−Ctdt (4.19)
Then, making the substitution τ = t− tn:
u(tn+1) = u(tn)e
C∆t + eC∆t
∫ ∆t
0
f(u(τ + tn))e
−Cτdτ (4.20)
in order to continue, some discrete approximation is needed for the expression under
the integrand, g(τ) = f(u(τ + tn))e
−Cτ . The Lagrange polynomial for any set of k+1
discrete points tn and set of numbers gn is defined as the polynomial of lowest order
which is able to connect each of the k + 1 points to their corresponding numerical
values and is always a unique solution. Using this particular notation, the Lagrange
interpolating polynomial is defined:
p(τ) =
k+1∑
j=0
gjlj =
k+1∑
j=0
gj(τ)
k+1∏
m=0,m 6=j
τ − tm
tj − tm (4.21)
The 2nd order solution should be used since it is universally stable, so only two terms
are required in the interpolation at g(0) = f(u(tn)) and g(∆t) = e
−C∆tf(u(tn+1));
g(τ) is therefore being approximated by a polynomial which passes through the two
limits of the integral, with a solution which will have a truncation error of the order
∆t3. Then:
p(τ) = f(u(tn))
∆t− τ
∆t
+ e−C∆tf(u(tn+1))
τ
∆t
(4.22)
Substituting into equation 4.20 and integrating over p(τ) gives the final equation to
be used in the finite difference scheme:
u(tn+1)− ∆t
2
f(u(tn+1)) = e
C∆t(u(tn) +
∆t
2
f(u(tn))) (4.23)
The known quantities are on the left of the equation and the unknowns to be found
for the next time step are on the right. All terms with any spatial dependence, i.e.
all those incorporating a spatial derivative, are contained within the matrix C. If
we were only considering diffusion, which acts independently of other variables, the
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matrix exponential eC∆t would only need to be calculated once making this algorithm
extremely efficient, however since terms such as chemotaxis are included which must
be updated at each time step to account for the current local oxygen concentration,
this needs to be recalculated each time. Luckily, the fact that C is sparse can be ex-
ploited for speed, using the function expv.m [348], which calculates an approximation
of the matrix exponential for sparse matrices when the input is of the form vetC, with
v some vector and t a constant.
A central difference approximation was used for discretisation of the spatial terms.
For the diffusion terms, the finite difference discretisation of the spherically symmetric
Laplacian is of the form:
∇ ·Dk∇u = Dk{∂
2u
∂r2
+
2
r
∂u
∂r
} ≈ Dk{uj+1 − 2uj + uj−1
∆r2
+
2
r
uj+1 − uj−1
2∆r
} (4.24)
Where here the index j on the vector u represents the discrete spatial coordinate
on r, where j = 1, 2, 3...(N − 1) with N the total number of spatial grid points with
separation ∆r. Zero flow boundary conditions (Neumann) were implemented at r = 0
and r = R, where the spatial derivative of u goes to zero, as no flow conditions are
assumed through the centre of the tumour and steady state at the edge of the tissue
boundary where r = R. This leads to boundary approximations of the form:
∇ ·Dk∇u|r=0 ≈ 6Dkuj+1 − uj
∆r2
, ∇ ·Dk∇u|r=R ≈ 2Dkuj−1 − uj
∆r2
(4.25)
The discretisations and boundary conditions for the other spatially dependant terms,
chemotaxis and fibroblast induced motility, were implemented in the same way. Note
that the dependence on r in the Laplacian due to the geometry of the problem drops
out if we assume zero flux at the tumour core, meaning there is no issue of the solution
blowing up at the centre as r → 0.
The simulation was run for 360 days with a time step of ∆t = 0.5 hr and a spatial
grid size of ∆r = 0.02 cm. The full finite difference algorithm is as follows:
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Data: Input initial conditions for tissue composition u0(r, 0);
Define all parameter values;
Define treatment dynamics;
Define matrix C to incorporate all spatially dependant terms and boundary
conditions which will act on the vector u;
for n = 1; n < No. time steps; n++ do
Update dynamic terms in matrix C;
Calculate new chemical uptake rates qi,n;
Calculate reaction vector f(u(tn);
Calculate RHS of equation 4.23: X = eC∆t(u(tn) + ∆t2 f(u(tn))) ;
Make starting approximation u′(tn+1) = u(tn);
// Begin fixed point iteration
while Solution not converged || No. iterations <25 do
Calculate chemical uptake rates q′i,n+1;
Calculate reaction vector f ′(u′(tn+1));
Set up function to be minimised: Y = X + ∆t
2
f ′(u′(tn+1)− u′(tn+1) = 0;
Calculate Jacobian matrix Ji,j = ∂Yi∂u′(tn+1)j ;
Then using Newton’s method: ∆u = u′′(tn+1)− u′(tn+1) = −Y/J ;
Update working value of u(tn+1);
u′(tn+1)← u′′(tn+1);
Has solution converged? (∆u ∼ 0?)
end
u(tn+1) = u
′(tn+1)
end
Algorithm 1: Finite difference algorithm for numerical solution of PDE system
4.3 Results
In order to determine normal tissue conditions, the model was first run over 3000 days
with the initial tumour cell and CAF populations set to zero and the vascular density
fixed. In the absence of these cell populations the model behaved appropriately and
quickly reached a steady state for integer vascular densities of 4-12% of the maximum
tissue capacity Ω. In order to produce long-term stability at each of these nine fixed
vascular densities, the vascular basal death rate was required to vary; the optimal
value of this parameter for each tissue condition was found by solving the steady
state system of equations under appropriate constraints. The resulting set of stable
normal tissues provided initial conditions to input into the full model. In each case,
the tissue was perturbed with an identical tumour of ∼1 mm radius and 5.65×106
cells at the centre of the simulated tissue sphere. The initial conditions for tumour
growth in tissues of 4, 6 and 12% vasculature are shown in figure 4.4.
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Figure 4.4: Initial cell densities (top row) and metabolite concentrations (bottom
row) for used in the PDE model. Initial conditions for three different tissues are
shown with vascular densities 4% (left), 6% (centre) and 12% (right). Cell densities
are as a proportion of the carrying capacity Ω and metabolites are as a proportion of
their respective maximum values co,max, cg,max and cl,max.
4.3.1 Growth phase results
Tumour growth was simulated over 200 days from an identical initial population
in nine different tissue types with vascular densities from 4-12%. For each tissue,
four conditions were tested. In the first, no CAFs are recruited by the tumour with
ksf = 0; second, CAFs are recruited and respire aerobically with type A metabolism;
third, CAFs and tumour are partially metabolically coupled via a lactate shuttle with
CAFs exhibiting type B metabolism; finally, CAFs and tumour are fully metaboli-
cally coupled, with CAFs showing type C metabolism in analogy with the ‘reverse
Warburg’ effect. Figure 4.5 shows the growth curves for tumours in six representative
tissues; results for a vascular density of 8%, and for 10% and 11%, are omitted as
they are qualitatively very similar to those of 7% and 12% respectively. As vascular
density increases, different metabolic phenotypes of the CAFs become advantageous
for maximal growth. Furthermore, there appear to be critical cell numbers at which
the most advantageous strategy switches, or at which two previously similar strategies
diverge. At around 2×107 cells in tissue with 6% vascularity, the partially coupled
type B CAFs are overtaken by the tumour with no CAFs present. Despite providing
an initial advantage by redistributing nutrients when they are scarce, the removal of
lactate from the tumour environment eventually hinders the invasiveness and there-
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Figure 4.5: Tumour growth over 200 days in tissues with six different representative
vascular densities. For each tissue, four metabolic regimes are shown: no CAFs
present; aerobically respiring CAFs (type A); partial coupling of tumour and CAFs
via a lactate shuttle (type B); full metabolic coupling between tumour and CAFs
(type C).
fore growth potential of the tumour. The type B phenotype is the most successful
in the tissue with 4% vascular density, and at early times in the 5% tissue, for a
similar reason. With insufficient nutrients for growth, it is most beneficial to have
CAFs recycle lactate, however as vascular density increases, having CAFs which also
produce lactate drives invasion and the type C metabolic coupling becomes by far
the most successful once the tumours become established. The higher the vascular
density of the tissue, the bigger the advantage of the reverse Warburg phenotype is
over the other metabolic regime, with the 12% tissue showing the biggest percentage
difference in growth between this and the next most successful phenotype.
The hierarchy of vascular densities is well conserved across conditions, with the
9% vascularity tissue condition clearly optimal for tumour growth across all metabolic
conditions. At early times, the tissue conditions are generally comparable; the 4%
condition even outperforming other higher vascularity tissues as the poor health of
the surrounding stroma offers an initial invasive advantage. Two clear growth stages
are evident in figure 4.5; an early ‘establishment’ stage where growth is slow and
tumour vasculature is developing, followed by an exponential growth phase, the onset
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Figure 4.6: Total lactate after 200 days growth in tissues of 4-12% vascular density
and under four different metabolic conditions: no CAFs present; aerobically respiring
CAFs (type A); partial coupling of tumour and CAFs (type B); full metabolic coupling
between tumour and CAFs (type C). The total lactate in the 3 cm radius tissue sphere
is shown (left), along with the same total lactate normalised by tumour cell count
(centre) and tumour volume (right).
time of which is heavily dependant on tissue vasculature and metabolic phenotype.
In the 6% tissue condition for example, exponential growth begins at around 80 days
for the type C system and at 160 days for the system without CAFs, whereas at 9%
both begin exponential growth at around 40 days. The type B system seems to be
the exception to this, producing slower, steadier growth with no clear transition.
It is also of interest to examine the acidity of tumours growing in each different
environment. Figure 4.6 shows the total lactate in the tumour environment, summed
over the 3 cm radius simulation domain, after 200 days of growth. The total lactate
in the tumour environment increases with tissue vascularity rather than with growth
rate or tumour size as might be expected, with the type C condition increasing faster
with vascularity than the other conditions, followed by the type A, the no CAF and
finally the type B condition. When the lactate is normalised by tumour size, either by
cell count or by tumour volume, this hierarchy is preserved at low vascularities which,
in general, have the highest normalised lactate levels. Although metabolic strategies
cross over with slightly noisy trajectories, the general trend is a drop in normalised
lactate to a minimum at the optimal tissue condition of 9%, followed by an increase.
The order of the four strategies also stabilises and diverges at this point; figure 4.6
(centre) shows almost a clean reversal at high vascular densities compared to that at
low. The 9% vascular density mark is clearly a critical point at which the behaviour
of the system switches The increase in tumour acidity as vascular density rises may be
caused by glycolytic metabolism rising due to increased glucose access, whilst at the
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same time, peripheral lactate being carried away by the vasculature limits growth rate
by slowing invasion. There are small differences between the graphs in the central
and right portions of figure 4.6 depicting different normalisations by cell count or
volume respectively. The disparity is due to differences in tumour density that each
metabolic regimes produces; while the type B tumours are quite sparse at 200 days,
the type A and C are much denser.
4.3.2 Application of treatment
Four representative tissue types were further investigated to examine the tumour
response to simulated chemotherapy with cisplatin. Vascular densities of 4% (low),
6% (medium), 9% (optimal) and 12% (high) were chosen, as it was believed that these
four were sufficient to represent the full range of vascularities studied in the growth
phase in terms of their behaviour. In order to study how the tissue environment may
affect treatment response, tumours in each tissue were grown until they reached 2×108
cells, corresponding to a clinically detectable tumour of between 2-4 cm diameter
depending on conditions. When the tumour reached this critical mass, 6 cycles of
cisplatin spaced 3 weeks apart were simulated at a starting dose of 0.90 g. Figure 4.7
shows the tumour response to this treatment in the four tissues.
It is immediately clear that treatment response is at least partly dependant on
growth rate; the faster growing tumours in the higher vascularity tissues regrow
quickly after treatment, whereas the slower tumours in the 4% tissue are eradicated.
The dose required to remove a tumour of a particular metabolic type increased with
tissue vascularity; steeply at first, then more slowly past 6% vasculature. As with the
total lactate produced, (figure 4.6) it is surprising that the dose required for tumour
eradication scales with the vascularity of the tissue rather than with the growth rate
of the tumour. The two results together indicate that high acidity offers a protective
advantage. As further confirmation that growth rate is not the the most important
feature, the top right of figure 4.7 shows the 4% tissue where the type C tumour is
the only one to make an, albeit small, recovery despite having the slowest growth
rate. To examine the effect of a given metabolic phenotype on treatment response,
the tissues were treated at variable doses of cisplatin. Figure 4.8 shows the results of
treating tumours in 6% tissue with doses from 1.00 to 1.10 g of cisplatin; a dose range
chosen simply to highlight the dynamics. Although the type A tumour has a faster
growth rate than the no CAF condition, it is less treatment resistant. Since these two
tumours are metabolically similar, it is most probable that the additional vasculature
that the CAFs stimulate works against the tumour to increase drug delivery. The
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Figure 4.7: Tumour response to treatment at a dose of 900 mg in four different tissues
with vascular densities of 4, 6 9 and 12%. Four metabolic conditions are shown for
each tissue. Tumours are grown to 2×108 cells over various times; dashed lines of
matching colour indicate the start of the growth curves for each metabolic condition,
with the black dotted line indicating the onset of treatment at day 0 and lasting 126
days.
same order of resistance between metabolic types is seen in the 4% tissue at lower
doses, although all of the tumours regrow extremely slowly. Order is also preserved
in the 9% tissue; the no CAF and type C tumours can survive a dose of 1.10 g, only
the type C survives at 1.20g.
Repeating the above experiment in 12% tissue a very different result is achieved.
Since the vasculature is too high for optimal growth, any increase by the CAFs
is a disadvantage to the tumour through the angiogenesis they promote. The no
CAF condition was therefore the most resistant to treatment despite its slow growth
rate. For the remaining three metabolic conditions, a number of competing factors
determine their resistance. A poor vascular supply within the tumour provides a
niche in which less drug is delivered and more cells are protected through quiescence,
however it also slows the regrowth rate so the tumour is less able to repopulate
between treatment cycles. CAFs do still offer an advantage in some cases; as both the
most acidic and fastest growing tumour, the type C tumours have a large advantage
over both type A and B. With the highest inter-tumour vascularity, the type A tumour
has the lowest resistance and the type B falls in between.
Figures 4.10 and 4.11 show the spatial distribution of cells and lactate in tumours
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Figure 4.8: Tumour response to increasing doses of cisplatin of 1.00 g (left), 1.05 g
(centre) and 1.10 g (right) in 6% vascularity tissue. Tumours are grown to 2×108 cells
over various times; dashed lines of matching colour indicate the start of the growth
curves for each metabolic condition, with the black dotted line indicating the onset
of treatment at day 0 and lasting 126 days.
Figure 4.9: Tumour response to increasing doses of cisplatin of 1.25 g (left), 1.30 g
(centre) and 1.35 g (right) in 12% vascularity tissue. Tumours are grown to 2×108
cells over various times; dashed lines of matching colour indicate the start of the
growth curves for each metabolic condition, with the black dotted line indicating the
onset of treatment at day 0 and lasting 126 days.
in tissues of 4%, 6% and 12% vascular density. Again, tumours grow to 2×108 cells
before treatment is simulated. Although the number of cells at the onset of treatment
is the same in each case, the distribution of tumours and CAFs are qualitatively very
different between tissues. In the 4% tissue, there is no distinct tumour area. Instead,
the tumour grows out into the stroma as a diffuse, homogeneous and mixed popula-
tion comprising tumour, CAFs stroma and vasculature, regardless of the metabolic
phenotype of the CAFs. Although the two 4% tumours look similar in terms of their
size and density, they are quite different metabolically. In the type B tumour, lac-
tate produced by the tumour sustains the CAFs, aiding growth and motility. In the
type C, the two cell types are in direct competition and, since the cell distribution
is so homogeneous, there is no real advantage to the coupling and the tumour grows
slowest of the four metabolic types. Much of the lactate in this tumour is produced
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Figure 4.10: Tumour growth and response to a 1.05 g dose of cisplatin over a 3
cm radius sphere of tissue for the four metabolic conditions. Spatial distribution of
tumour, CAFs, stroma, vasculature, (as fraction of maximum cell density Ω), lactate
(as fraction of cl,max) and net lactate production QLac are shown.
by the CAFs as can be seen by the matching space that the CAFs and lactate fill, as
well as the lack of change to the lactate during the treatment window, as compared
to in the type B tumour where there is a significant change.
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Figure 4.11: Spatial view of tissue distribution and lactate production over the tumour
region for the type B and C metabolic phenotypes in 4%, and all phenotypes in 12%
vascularity tissue. Spatial distribution of tumour, CAFs, stroma, vasculature (as
fraction of maximum cell density Ω), lactate (as fraction of cl,max) and net lactate
production QLac are shown. White dashed lines show treatment window for treatment
with 0.40 g and 1.30 g of cisplatin for the 4% and 12% tissues respectively. Lactate
and QLac images are scaled differently between 4% and 12% images.
All four metabolic phenotypes are shown in figure 4.10. The tumours are more
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dense with some visible heterogeneity, however CAFs still spread quite far into the
tumour and there is a small population of stromal cells within the tumours also.
Again, there is little contrast between the tumour and outside tissue in terms of
vascularity, although in the no CAF and type C conditions a gap with very low
cell density has opened up at the tumour periphery due to a build up of lactate.
It is clearer from this image how the hierarchy of treatment response occurs in the
sub-optimal vascularity tissues; the no CAF and type C tumours both utilise this
vascular-poor region to resist the treatment. Both also leave large pools of lactate
when cells are killed which in turn further damages the vasculature. The bottom
row of figure 4.10 clearly shows the tumour regrowing from cells remaining where
the vasculature has been destroyed. The same can be seen in the no CAF condition,
although it is less obvious. In each tumour, slightly more lactate is produced at the
periphery as would be expected from increased access to glucose in this area.
The equivalent set of images is shown for the 12% tissue in the lower half of
figure 4.11. The change to the composition of the tumours is remarkable, with clear
regions of both tissue and metabolic heterogeneity visible. The acidity of the tumours
confines the CAFs fully to the periphery, however their impact on the dynamics of
the tumour is by no means marginalised. Metabolic heterogeneity can be seen in the
QLac images; a leading edge of CAFs with highly glycolytic metabolism produces an
advancing front of acid, which kills healthy stroma and vasculature clearing space for
invasion. The lactate produced here is used as an energy source for the next layer
of the tumour where the blood supply is very poor, then finally low-rate glycolysis
occurs again at the core. This layer structure can be seen most clearly in the type
B tumour where the peripheral CAFs free up even more glucose for glycolysis. The
tumour vascular density is significantly lower than that of the surrounding tissue,
varying around 1-7%.
Resisting treatment in high vascularity tissue appears to be more about main-
taining an acidic tumourgenic niche than about the level of vasculature. The most
resistant no CAF tumour has the highest intratumoural vasculature of the four during
the treatment window, however it is the only tumour in which the surrounding stroma
does not rebound. The least resistant type A tumour sees the surrounding stromal
cells grow quickly to fill the space meaning the few surviving tumour cells are unable
to compete. The same thing happens, slightly less quickly, in the type B tumour and
very slightly in the type C tumour as well; the regrowth of both the stromal cells and
vasculature can be seen surrounding the fibrotic outgrowth of CAFs in the bottom
row of figure 4.11, despite the glycolytic acid production from the CAFs. The very
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high surrounding vasculature is efficient at removing acid from the system, allowing
other cell types to thrive when tumour cells die during the treatment window.
4.4 Discussion
The poor survival rate of ovarian cancer can be largely attributed to the fact that most
patients are already metastatic at diagnosis. Since screening programmes have been
unsuccessful at aiding the early detection of the disease, it has very poor prognosis.
A deeper understanding of tumour growth and its reliance on metabolic phenotype
is important to model and predict tumour development. Identifying and exploiting
altered metabolism in cancers may allow for the development of new targeted thera-
pies and patient specific treatment strategies. With this objective in mind, this work
presents a spatial mathematical model capable of simulating the interaction between
the tumour and surrounding tissue on both a cellular and metabolic level. The model
has the potential to reproduce the dynamics of human disease in silico, allowing for
the direct comparison of tumour growth and treatment response outcomes under a
wide range of environmental conditions. There are two main factors that have been
considered in the model; the vascular density of the tissue in which the tumour grows
and the behaviour of CAFs recruited by the tumour, which may engage in different
types of metabolic coupling with the tumour cells. Although previous studies have
utilised mathematical models to study the tumour interaction with its environment,
this is the first model of its kind which fully integrates a cellular tissue interaction
model with a detailed study of multiple possible metabolic regimes.
Although metastasis to multiple locations is common in many cancer types, there
are a number of features which make ovarian cancer an ideal model system for this
study. Metastatic locations are common between patients, yet very diverse in terms
of their tissue composition; tumours arriving from the same primary will implant in
tissues with high variation in stromal composition and vascularisation such as the
omentum and lymph nodes display. Following standard-of-care debulking surgery,
small amounts of tumour remain. These fragments may then regrow, simultaneously
beginning repopulation of multiple environments such as occurs in the model. Finally,
the common phenomenon of platinum sensitive recurrence means that ignoring the
gradual build up of genetic resistance, in order to study instead environmentally
conferred resistance, is a reasonable first approximation in this instance. Despite
these features, the model remains general enough for its predictions to be applicable
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to many other metastatic solid tumours in which the involvement of CAFs is known
to occur.
One of the key early predictions of this model is that there is an optimal tissue
vascularity for tumour growth, which occurs here in the 9% vascular density con-
dition. This is a somewhat arbitrary measure of vascularity for the purposes of the
model; treating vascularity as a cell density rather than modelling discrete vessels is a
simplification only possible due to the large scale of the simulation domain compared
to that of the individula cells. Nevertheless, it clearly demonstrates the trade-off
between access to nutrients and the accumulation of acid at the invasive edge, which
together, dictate the growth rate of the tumour. This optimal tissue vascularity has
been predicted previously in a mathematical modelling study by Patel et al [125], has
been discussed in a mathematical oncology review of acid-mediated invasion [120] and
is seen clinically in the preference of particular cancers for specific metastatic sites
which may be particularly well vascularised, such as the omentum. The existence of
both anti- and proangiogenic treatments is also indicative of this phenomenon. The
model showed that the intratumoural vascularity only correlated with external tissue
vascularity up the 9% vascular density condition, after which it anticorrelated. Al-
though many studies exist comparing intratumoural vascularity to proliferation rate,
there are none which quantitatively compare tumour growth rate to the vascularity
of the external tissue environment. This observation may be relevant for therapies
where pro- or antivascular agents are used alone or in conjunction with other thera-
pies, as there is the potential to unintentionally push the tumour vasculature towards
a more optimal growth condition.
The tumours can be seen to grow in stages, with growth accelerating following the
establishment of vascularity with in the tumour. After 200 days of growth, the total
lactate in the tumour area was found to positively correlate with tissue vascularity
rather than growth rate, suggesting the most important factor for acid production is
access to glucose. The higher the tissue vasculature, the more this lactate production
is seen to concentrate at the tumour periphery. Normalising for tumour size at 200
days, it becomes clear that both very high and low vascularity tumours accumulate
more lactate per tumour cell; this is likely due to a lack of ability to remove acid at low
vascularity and the glycolytic exploitation of plentiful glucose at high vascularity. It is
worth emphasising an interesting prediction with regards to 13C metabolic imaging;
the tumours with the highest lactate turnover may not necessarily be the fastest
growing due to competing environmental constraints. In this case, even though their
lactate turnover rate is higher, the 12% vascularity tumours grow slower than the
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9% tumours because their invasive potential is reduced through increased removal
of acid from the system. Additionally, although the total lactate is high in the low
vascularity tissue tumours, figure 4.11 demonstrates that it is at low concentration as
the tumours in these tissues are of extremely low cell density compared to tumours
in more vascular tissues. Such tumours would likely produce low lactate conversion
rates on 13C images despite being quite acidic overall.
The CAFs, through their metabolic coupling with the tumour cells, have a re-
markable impact on the growth rate of the tumour, despite being comparably small
in number to the other cell types, the effect of which is most clearly visible in figures
4.5 and 4.7. In the very low 4% and 5% vascularity tissues, the type B metabolism,
where lactate produced by the tumour may be used by the CAFs as an energy source,
provides a huge advantage over the other phenotypes. When nutrients are scarce this
phenotype removes competition from the other cells, but at the expense of removing
lactate from the system and deacidifying the microenvironment, thereby preserving
the healthy tissue and reducing invasion. For this reason, the type B coupling very
quickly becomes by far the least efficient, producing the slowest growing tumours in
almost all tissues, even though it has a slight advantage when tumours are very small
for the 5-6%. In each case, the type A (no metabolic coupling) CAFs demonstrate
a small advantage over the no CAF condition due the increased angiogenesis and
motility they provide. This growth advantage is stable across all tissues, even when
vascularity is higher than optimal.
The type C CAFs with full metabolic coupling, which may both use and pro-
duce lactate, offer the biggest growth advantage in every tissue above 4% vascularity;
the size of this benefit grows with increasing vascularity. It is clear from these results
that a ’reverse Warburg’ effect would have very poor outcome for patients in virtually
every situation as these tumours grow 2-4 times faster than every other phenotype.
This type of metabolism not only allows the cells to perform the most efficient pos-
sible metabolism heterogeneously across the tumour, but since the CAFs are largely
peripheral, the lactate they produce penetrates deeper into the healthy stroma than
with any other phenotype, clearing the path for invasion. The high vascularity tu-
mours have more peripherally concentrated CAFs which in turn, have the most access
to glucose, explaining the increasing efficiency of this strategy with tissue vascularity.
By allowing tumours to grow to the same number of cells before simulating
chemotherapy, it was possible to examine the differences in treatment resistance
caused by the different environmental growth conditions. Although growth rate was
a factor in determining resistance, it was not the most important one in this model.
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Resistance scaled, almost counter-intuitively to some extent, with tissue vascularity
rather than with growth rate, despite the greater drug delivery ability of high vas-
cularity tissues. One reason for this is that above the optimal 9% vascularity tissue,
the vascular density within the tumour volume drops, as the increased acid present
damages the vessels. In general, the increased angiogenesis conferred by the CAFs
reduced treatment resistance, with the no CAF condition proving the most resistant
in high vascularity tissues and second to type C in all other tissues. In tissues up to
and including the optimal 9% vascular density, survival was largely determined by
a trade off between growth rate and drug delivery. Concentrated regions of acidity
reduce drug delivery, while angiogenesis increases it, therefore creating the order of
resistance seen in figure 4.8. The picture is slightly different above 9% however; since
drug delivery is strong, survival of the tumours relies on the creation and maintenance
of a tumorigenic niche. The most resistant no CAF case demonstrates this; by main-
taining a intertumoural vascular structure as well as an acidic environment, the space
remains free for a very small tumour cell population to repopulate unchallenged. The
role of the fibroblasts in normal tissue as wound healers suddenly becomes evident;
in the other three phenotypes they rebuild vasculature and allow healthy stroma to
regrow during the treatment phase. Although the type C CAFs also promote healing,
they simultaneously maintain the tumour niche through the acid they produce which
provides a resistive advantage over the other two CAF metabolic phenotypes.
There are several further predictions of the model which are worth mentioning for
their reproduction of real clinical phenomena. As already alluded to, the normal role
of fibroblasts is in healing damaged tissue following injury, a behaviour that can be
seen to occur also in the model results. This behaviour applies equally to a tumour
site, with cancers often being described as a ‘wound that will not heal’. Fibrosis is the
growth of active fibroblasts which may often follow cancer treatment, causing large
growths at the site; despite the very slow CAF turnover rate, such fibrotic growths
can be seen in figures 4.10 and 4.11 in cases where the tumour is completely or
partially healed. The type C CAFs in particular cause very large regions of fibrosis,
filling the space left behind by the tumour, which raises the question as to whether
lactate production may have a role in this particular pathology. A second interesting
feature of the model are the regions of both tissue and metabolic heterogeneity which
spontaneously emerge, an effect more pronounced in the higher vasculature tissues.
These regions, which appear as concentric layers into the tumour, provide evidence for
metabolic coupling within the tumour itself regardless of the behaviour of the CAFs.
Highly glycolytic cells on the periphery have access to the most glucose, producing
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large quantities of lactate which is then used as an energy source by cells in the next
layer. The cells in the centre of the tumour are again slightly glycolytic, but far less
so than those on the leading edge. The emergence of such structure adds significant
weight to the lactate shuttle theory of tumour metabolism [4, 349, 350] and provides
insight into the potential benefit the CAFs, particularly type C CAFs, could provide
by enhancing further the glycolytic activity at the tumour rim.
There are several predictions of this model which have implications for the use
of hyperpolarised [1-13C]pyruvate imaging as a means of determining treatment re-
sponse. The net lactate output rate of the tumour, QLac, is seen to drop during
treatment; however for those tumours which are not eradicated, it remains high at
the periphery and rises in the core during treatment, even though there is little or
no visible mass. If this prediction is correct, probing the tumour with hyperpolarised
[1-13C]pyruvate and spatially mapping the conversion rate to lactate should be able
to distinguish between tumours which respond and those which regrow, even when
anatomical imaging shows little difference. Another interesting result is the build
up of lactate that occurs following treatment; an effect best seen for the no CAF
and type C conditions in figure 4.10. This release of lactate following treatment is a
commonly observed clinical effect; what is perhaps interesting here is that it occurs
far more prominently in cases where the tumour is not removed, and is only observed
for certain metabolic phenotypes. In each case where this lactate build up occurs,
it is accompanied by a drop in QLac, at least initially, which then slowly rises for
tumours which will regrow following treatment. Monitoring both this extracellular
lactate pool size and the metabolic lactate turnover rate simultaneously, may give
greater insight into treatment response than is currently available. Although cur-
rently not clinically approved, measurements of this type may be available through
imaging patients injected with co-polarised [1-13C]pyruvate and 13C-bicarbonate, a
marker of extracellular pH, at some time in the future.
Returning to the example histology data from good and poor responders shown
in figure 4.1, it is encouraging to observe visual similarities between these images
and the model outputs. Considering first the histology data of tissue from the good
responders, tumours appear fairly homogeneous with low but even staining for CA125.
Vessels are sparsely but evenly distributed and there is some fibroblast infiltration
which again appears quite uniform throughout the tissue. The simulation results
from the 4% vascular density tissue, which demonstrated the best treatment response,
echoes this pattern; figure 4.11 shows each cell type distributed homogeneously within
the tumour region. In contrast, simulations of tumours growing in the 12% vascularity
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tissue, the poorest responders to treatment, can be seen in 4.11 to produce far more
heterogeneous tissue compositions. Tumour cells and vessels form distinct domains
and the fibroblasts are densely clustered on the periphery of the tumour; both of
these effects are also seen in the histology data for the bad responders.
It is worth noting that the method of varying the vascular basal death rate δv is
an arbitrary fix to control the target tissue density. This method was used because
δv proved to be the only single parameter capable of generating a range of stable
conditions as it was varied; it is not an accurate model of the physiology. In reality,
normal tissue densities are likely to be controlled by VEGF production, which is
in turn controlled through HIF1 stabilisation by hypoxia in tissues where oxygen
availability is too low. In tumour tissue, vascular growth may be accelerated by HIF1
over-expression resulting in higher levels of VEGF than is warranted by hypoxia
and elevated tissue lactate concentration alone. It would therefore be expected that
the dynamics governing vascular proliferation and death would be very different in
tumour and normal tissue; the simplifying assumptions made here and in controlling
the tissue density are noted as limitations of the model.
Although the model is capable of reproducing realistic simulations of human dis-
ease, there are a number of limitations to such an approach. The main consideration
is the size of the model and the large number of free parameters which have been
calculated, derived from the literature or in some cases estimated. Models of this
complexity are difficult to parameterise and validate, however this does not necessar-
ily invalidate the results if they are used carefully. Very few parameters are varied
between the tissue conditions- only the vascular turnover rate δv and the CAF recruit-
ment rate ksf - which allows for comparative if not completely objective conclusions
to be drawn. Another limitation is the lack of human data available for validation of
the model, with many parameters being drawn from animal or even in vitro studies.
As more data become available, particularly from in vivo human studies of tumour
metabolism, it may be possible to refine the model and its parameters to the point
where it provides a useful clinical tool for predicting treatment response. A final and
more subtle limitation of the model worth mentioning is in the form of its lactate
production output metric QLac. The way that the model is designed means it is only
possible to track the net lactate production rate, but not the rates of use and produc-
tion individually. Given that the type C tumours are so acidic, it is highly likely that
both of these metabolic processes are occurring simultaneously across heterogeneous
regions on both the tumour and CAFs. Although the spatial distribution QLac is
useful in making predictions of how such tumours would present on hyperpolarised
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[1-13C]pyruvate images, it is worth noting that future versions of the model could
be better able to spatially localise the movement of lactate in the system, thereby
improving predictions for metabolic imaging.
4.5 Conclusion
This work presents a spatial mathematical model of tumour growth and treatment
response, in which an identical initial tumour population is exposed to a range of
different tissue and metabolic environments. The model is unique in its ability to
simulate multiple metabolic conditions for comparison, and is capable of reproduc-
ing many features and phenomena that are found in human disease. There are two
main focal points of the model; the first is the effect of differing vascular density in
the native tissue and the second is the interaction with, and metabolic phenotype
of, recruited CAFs. The vascular density of the tissue in which the tumour grows
effected both the growth rate of the tumour and the preferred CAF phenotype; there
was an optimal vascular density for tumour growth at 9%, after which the vascula-
ture removed too much acid and the invasive potential of the tumour was reduced.
CAFs capable of metabolising lactate provided a growth advantage in very poorly
vascularised tissue, however in general provided the slowest growing tumours. Cou-
pling with CAFs which both produced and utilised lactate as in the ‘reverse Warburg
effect’, produced tumours which had much faster growth rates than any other pheno-
type and high treatment resistance due to their promotion of an acidic tumorigenic
niche. The no CAF condition produced in general the second slowest tumour growth,
however it offered high treatment resistance; particularly in highly vascular tissue.
The model presented here may be clinically valuable in understanding the tumour
interaction with its environment and may prove to be a useful tool in aiding the in-
terpretation of histopathology and metabolic imaging data in order to make informed,
patient-specific treatment decisions in the future.
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Chapter 5
Initial insights from early human
hyperpolarised 13C-pyruvate
imaging in the breast and brain
Hyperpolarised imaging with 13C-labelled molecules is an emerging tech-
nique with the ability to dynamically and non-invasively probe tissue
metabolism. Since the first human study was published in 2014, sites
around the world have been refining and optimising the technique for clin-
ical application. The first molecule to be approved for human use is [1-
13C]pyruvate, the conversion of which to [1-13C]lactate has been shown
to correlate with tumour grade and to detect treatment response in pre-
clinical animal models. Accurate quantification of this exchange reaction
is therefore of high importance if hyperpolarised data is to be utilised to
inform clinical decisions. Hyperpolarised 13C imaging data is presented
from four of the first subjects to be imaged at Addenbrooke’s Hospital in
Cambridge. Two cancer patients and two healthy volunteers, representing
the first healthy brain images to be acquired globally, received dynamic
hyperpolarised 13C MRI imaging following injection with 0.4 mL/kg of
hyperpolarised 13C-pyruvate solution at ∼250 mM. Previously developed
analysis and quantification methods, consisting of a Markov random field
segmentation for automatic lesion detection, kinetic modelling and model-
free quantification methods are applied to the data. The suitability these
methodologies to provide an accurate and objective means of quantifying
human 13C imaging data is demonstrated.
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5.1 Introduction
Since the initial conception of dynamic nuclear polarisation (DNP) as a method of
retaining liquid-state polarisation of 13C-labelled molecules in 2003 [152], the field
of hyperpolarised imaging has expanded rapidly. The two proof of concept studies
published by Golman et al in the same year [186, 154] demonstrated for the first
time the feasibility of retaining sufficient polarisation to perform angiography with
13C-labelled urea in vivo. This was swiftly followed by the discovery that metabolites
of interest, initially [1-13C]pyruvate, could be imaged in real time, along with their
metabolic breakdown products, to non-invasively probe cellular metabolism [187].
The potential and versatility of the technique has led to a number of of pre-clinical
studies at multiple sites world wide, largely focused on the breakdown of 13C-pyruvate
to 13C-lactate as a marker of aerobic glycolysis and a potential indicator of treatment
response in oncology [291, 191, 169], as well as other applications including diabetes
[198] and cardiac metabolism [178]. Other 13C-labelled probes also demonstrated
early success for probing tissue biology in animal models; notably, 13C-bicarbonate to
image pH in vivo [165], the [1-13C]fumarate to [1-13C]malate reaction as a marker of
cellular necrosis [168] and [1-13C]glutamate for imaging tumour metabolism [204, 206].
The clinical potential of DNP has attracted significant interest not only in academia
but in industry as well. The technique is particularly appealing since existing MRI
technology which is already in clinical use for patient scanning can be re-purposed,
requiring only a clinical hyperpolariser and 13C-specific MR coils as additional hard-
ware. GE Global Healthcare became the main corporate driver for hardware inno-
vation and in 2011, published the design and sucessful testing of a prototype sterile
hyperpolariser intended for clinical use [155]. This was the first version of what would
become the GE SPINlab, the first commercial clinical hyperpolariser of which there
are now around 30 worldwide.
The first human study was carried out using a non-sterile prototype system in
a clean room at the University of California, San Fransisco (UCSF) in 2013 [156].
In this landmark first-in-man study, the safety and feasibility of the technique was
demonstrated in 31 prostate cancer patients who each received a dose of up to 0.1
mmol/kg of hyperpolarised [1-13C]pyruvate. Although there were 10 adverse effects
in 8 patients, these were all considered to be minor and the agent was tolerated
well in general. The conversion rate of pyruvate to lactate was found to be four to
five times higher in the tumour than in the surrounding healthy prostate and in one
case, a previously undetectable region of low grade tumour was detected, and later
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confirmed by biopsy, via high lactate production in the region. The forward reaction
rate constant kP was found to be 0.045 ± 0.025 s−1 for conversion of [1-13C]pyruvate
to [1-13C]lactate in tumour voxels and 0.009 ± 0.003 s−1 for contralateral voxels
containing healthy tissue.
Only two other human study in hyperpolarised 13C imaging has been published
to date, both limited to very few subjects. In 2016, a pilot study at Sunnybrook
Hospital Toronto imaged the metabolism of [1-13C]pyruvate to [1-13C]lactate and
13C-bicarbonate in the healthy human heart in four volunteers [214]. Bicarbonate
production was clearly observed in the myocardium whilst lactate signal was more
diffusely seen in the blood, muscle and tissues. The same dose as the previous study of
0.1 mmol/kg was given with no adverse effects. A very recent third publication from
UCSF images a single prostate cancer patient before and six weeks after treatment
with androgen deprivation therapy [215]. The kP was derived from a single large
tumour-containing voxel, with the pretreatment kP of 0.025 s
−1 dropping to 0.007 s−1
following treatment. This short case study provides a first glimpse of the potential
to image treatment response in human tumours.
Although there are no further published studies, there have been several conference
abstracts presented on human imaging over the last two years, mostly from UCSF
and Memorial Sloane Kettering (MSK) in New York. In 2016, MSK presented their
study of [1-13C]pyruvate metabolism in a breast tumour to the International Society
for Magnetic Resonance in Medicine (ISMRM) [211]. At the same conference the
following year, they presented a study in prostate cancer investigating metabolic dy-
namics of pyruvate to lactate conversion and comparing to histological grade [213]. In
the same year at ISMRM, UCSF presented imaging data of 13C-pyruvate metabolism
in three glioblastoma patients [212], along with a methodology abstract for auto-
mated kinetic modelling in human brain tumours using their SIVIC software [351].
They demonstrated the feasibility of a specialised symmetric echo planar imaging se-
quence for metabolite-specific imaging of hyperpolarised pyruvate and lactate in the
human prostate [352] and finally, presented spectroscopic imaging data from patients
with liver metastases [353]. Although these were the only two sites to present pa-
tient data, there has been a steady increase in both conference papers and published
articles on pre-clinical 13C imaging with new applications and new probes, and on
technical developments in pulse programming, reconstruction, image processing and
quantification from multiple sites worldwide over recent years.
Much of the early translational work in hyperpolarised 13C MRI has been in imag-
ing the abnormally high metabolism of pyruvate to lactate within various oncological
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applications. Of the small number of sites with the necessary technical set up and
regulatory approval to perform human imaging, two focus purely on cancer. UCSF
are currently imaging patients with renal cancer, glioblastoma, prostate cancer and
advanced metastases in the liver as well as other organs, while MSK are studying
cancer in the prostate and breast. Also popular is the application of 13C-pyruvate to
image the heart; both Sunnybrook and Oxford are beginning patient trials in cardiac
imaging to asses metabolic changes to damaged myocardial tissue. [1-13C]pyruvate is
currently the only 13C-labelled probe to be approved for patient imaging, however a
number of other molecules are likely to be available within the next few years. UCSF
are currently in the process of approving 13C-urea, [2-13C]pyruvate, [1-13C]lactate and
eventually [1-13C]fumarate for use in patients.
Here at Addenbrooke’s Hospital Cambridge, work has been under way to achieve
clinical translation of hyperpolarised imaging for around five years. In 2013, the 5
T GE SPINlab hyperpolariser was installed in MRIS in a small room adjacent to
the clinical 3 T GE sigma MRI scanner, with a small RF-safe hatch between the
two to transfer the hyperpolarised agent from the polariser to the patient. This was
followed around a year later by the installation of the quality control (QC) unit, which
measures the pyruvate concentration, pH, volume, EPA (electron paramagnetic agent)
concentration and polarisation of the hyperpolarised pyruvate solution to ensure each
of these parameters is within clinically safe bounds prior to injection into a patient via
a medrad syringe. While this hardware was being tested, calibrated and optimised, a
pharmacy was also being developed for the manufacture of sterile fluid paths on site.
These paths consist of closed, helium-flushed tubing, with a vial at one end containing
the compound for hyperpolarisation, along with an EPA, which is inserted down into
the SPINlab. The remaining two compartments are filled with a dissolution fluid and
buffer, all of which must be assembled in perfectly sterile conditions. In order to
achieve this, a laminar flow cabinet was set up within which the paths could be filled
by trained pharmacists. The quantities of each element going into the fluid paths then
required validation and testing to ensure consistent and physiologically safe results
after polarisation and measurement by the QC. Sterility checks were additionally
performed on the end product.
Technical developments were, and still are, a major part of the preparations for
both the collection and processing of clinical data. On the MRI scanner, multinuclear
spectroscopy (MNS) research software was installed and calibrated to provide the
highly specialised rapid sequences required to scan multiple metabolites at shifted
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13C-frequencies. Specialised MR transmit and receive coils duel-tuned to 1H/13C-
frequency were acquired from Rapid Biomedical in order to collect carbon and pro-
ton images sequentially, without a coil change, for co-registration of the metabolic
to anatomical data. Finally, methods for processing, analysing and quantifying the
complex 5-dimensional data produced were required; the previous chapters have been
directed at solving these problems and developing robust methodologies suitable for
clinical use. In order to make clinical decisions such as an assessment of treatment
response or the grade of a tumour based on hyperpolarised imaging data, reliable and
repeatable methods are required for processing and quantifying the data. The region
of interest (ROI) detection algorithm detailed in a previous chapter utilises a Markov
random field model to automatically detect regions of specific metabolic activities and
is capable of distinguishing low from high lactate production across a tumour. Cou-
pled with the rigorously tested kinetic modelling and model-free parametric mapping
approaches defined in chapter 2, this work has the potential to provide clinicians with
simple, clear quantitative measures which have the potential to aid such decisions.
Several projects are simultaneously occurring under the umbrella ‘MISSION’ ti-
tle at Cambridge, with each sub-project directed to a separate clinical question. In
oncology, patient studies are being carried out in glioma, and in breast, ovarian, and
liver cancers with patients recruited as fluid paths become available. Approval has
also been obtained for neurological applications in multiple sclerosis (MS) and stroke
imaging, with Cambridge the only clinical site to be planning studies in this area.
It is hoped that hyperpolarised 13C-pyruvate imaging will be valuable in studying
the glycolytic metabolism that occurs due to pathological immune response in MS
plaques, and in detecting viable tissue regions through their protective lactate pro-
duction in the recovering post-stroke brain. Although [1-13C]pyruvate is currently
the only molecule approved for human use, applications for [1-13C]fumarate approval
are being developed. At this point in time, a number of volunteers and patients have
received hyperpolarised 13C scans in Cambridge; successful 13C images have been pro-
duced from the brains of two healthy volunteers, one glioma patient and one breast
cancer patient, as well as from the brain of one MS patient and a liver volunteer.
In the remainder of this chapter, the first four of these early imaging trials will be
presented as case studies and the methods for analysing, segmenting and quantifying
the data set out in earlier chapters will be applied to each in turn to demonstrate
their applicability to clinical data. The quantitative methods applied, along with the
deeper understanding of lactate metabolism gleaned through the tumour simulation
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model detailed in chapter 4, will be valuable in the clinical interpretation of this and
future hyperpolarised imaging data.
5.2 Methods
5.2.1 Subject recruitment and patient background
Two healthy volunteers (HV) and two oncology patients, one breast and one glioma
case, received hyperpolarised [1-13C]pyruvate spectroscopic imaging scans between
September 2016 and January 2017 at Addenbrooke’s hospital Cambridge. Subjects
were recruited and gave informed written consent under the physiological study pro-
tocol ‘MISSION’ (Molecular Imaging and Spectroscopy with Stable Isotopes in On-
cology and Neurology), which was approved by the Cambridge South Research Ethics
Committee and sponsored by the University of Cambridge and Cambridge University
Hospitals NHS Foundation Trust. Exclusion criteria for both patients and volunteers
were as follows: under 18 years of age; uncontrolled diabetes or glucose deranging con-
dition; pregnant or breastfeeding; known allergies to gadolinium or pyruvate; MRI
unsuitable (e.g. severely obese, pacemaker, metal implants); BMI below 18.5 or above
32; failure to have full capacity to give informed written consent. Inclusion for cancer
patients required them to present with a confirmed, treatment naive tumour of a
suitable size for radiological imaging.
5.2.1.1 Breast case
A 61 year old female who was a BRCA gene carrier presented with a symptomatic
mass in the left breast. Initial radiological images from dynamic contrast-enhanced
MRI showed an irregular, avidly enhancing mass measuring 41×31×36 mm as well as
some minor local lymph node involvement. The primary breast mass was confirmed
by biopsy to be a grade 3, triple-negative invasive ductal carcinoma, positive for
cytokeratin on immunohistochemistry. The patient was recruited and imaged for the
hyperpolarised 13C study prior to receiving chemotherapy.
5.2.1.2 Glioma case
A 66 year old male presented after experiencing confusion and vacant spells suddenly
whilst on holiday. Initial radiological imaging identified a heterogeneously enhancing
lesion spanning the posterior part of the right temporal, and anterior of the adjacent
occipital lobes, with an axial size of 58×34 mm. The lesion was later confirmed as
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an IDH-wildtype grade IV glioblastoma, exhibiting moderate nuclear pleomorphism,
microvascular proliferation and palisading necrosis. The patient was imaged for the
hyerpolarised 13C study prior to receiving surgery.
5.2.2 13C-pyruvate administration
All subjects were injected with with 13C-pyruvate at a dose of 0.4 mL/kg of an
approximately 250 mM solution, equivalent to the 0.1 mmol/kg dose administered
in human studies at the other sites which have previously published human studies.
Sterile fluid paths were filled in a laminar flow cabinet, in clean room conditions, in
a pharmacy set up specifically for the purpose. Vials were filled with 1.47 g of [1-
13C]pyruvate (Sigma Aldrich) containing the EPA AH111501 [Tris(8-carboxy-2,2,6,6
(tetra(methoxyethyl) benzo-[1,24,5’]bis-(1,3)dithiole-4- yl)methyl sodium salt] at 15
mM. A receiver syringe was filled with 17.5 mL of neutralisation medium (600 mM
NaOH / 333mM TRIS buffer) and 19 mL of sterile water and the dissolution syringe
was filled with 38 mL of sterile water. A Medrad syringe was fitted to the sterile
fluid path aseptically to collect the solution for injection following dissolution and
filtering. This procedure was expected to produce a solution of approximately 250
mM pyruvate and physiological pH upon dissolution.
Fluid paths were stored at -20 ◦C and allowed to thaw for at least 60 minutes
before lowering into a GE SPINlab hyperpolariser with a quality control module.
Samples were polarised for at least 3 hours at 5 T and <1 K prior to dissolution.
Upon dissolution, pyruvate and EPA concentration, pH, temperature, volume and
polarisation were measured by the QC module to ensure each of these parameters
was within the physiological acceptable range for injection; measurements took 35 s
from dissolution time. In each case, the temperature was 34-35 ◦C and the volume
was >40 mL. Full QC results for each of the four subjects are shown in table 5.1.
Upon acceptance, the Medrad syringe containing the pyruvate solution was passed
through a small hatch into the MR scan room, where it was loaded into a power
injector and injected intravenously at a rate of 5 mL/s into the subject inside the
scanner bore. Pyruvate solution was injected at the correct volume for the subjects
weight up to a maximum of 40 mL (details in table 5.1), followed by a 20 mL saline
flush. Imaging began at 12 s following the end of the injection with the exception of
the breast patient, for whom imaging began after 25 s due to a technical error.
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Table 5.1: QC results, individual dose details and total time from dissolution to
injection for each subject.
Subject Subject Subject Polarisation pH Pyruvate EPA Volume Actual Total
ID age weight conc. conc. injected dose time
HV 1 38 95.8 kg 4.7% 7.5 253 mM 0.8 mM 38 mL 0.100 mmol/kg 56 s
HV 2 43 77.8 kg 24.9% 7.5 250 mM 0.4 mM 31 mL 0.100 mmol/kg 55 s
Breast 61 106 kg 24.1% 7.6 237 mM 0.5 mM 40 mL 0.089 mmol/kg 62 s
Glioma 66 97.7 kg 22.6% 7.9 232 mM 0.6 mM 39 mL 0.093 mmol/kg 58 s
5.2.3 Imaging and data acquisition
Subjects were imaged in a clinical 3 T MRI system (Signa HDx, GE Healthcare)
using a 13C-1H multinuclear coil. A 1 minute IDEAL spiral CSI acquisition [182]
was performed, with the imaging sequence initiated immediately following the end
of the saline flush. Single-metabolite data was collected at the frequencies for pyru-
vate, lactate, pyruvate hydrate, alanine and bicarbonate. Prior to injection, each
subject received 1H anatomical imaging for the purpose of localisation and further 1H
imaging was additionally performed on each subject for anatomical reference and/or
clinical diagnostic purposes. The imaging parameters differed between subjects and
are detailed individually below.
5.2.3.1 Healthy volunteers
Both healthy volunteers were imaged using a single channel dual-tuned 1H/13C trans-
mit/receive birdcage head coil (Rapid Biomedical). Both volunteers underwent 3D
BRAVO T1 imaging for anatomical reference with the following imaging parameters;
flip angle 12◦, repeat time (TR) = 8 ms, echo time (TE) = 32 ms, inversion time 450
ms, field of view (FOV) 24 cm, acquired resolution 2×2×2 mm, matrix size 256×256.
Each volunteer then received the hyperpolarised 13C-pyruvate injection before an ax-
ial IDEAL spiral acquisition was performed over 1 minute. Protocols for the 13C
imaging are given below for each volunteer.
HV1 was imaged with the following parameters: flip angle 5◦, TR = 500 ms, TE
= 1.7 ms, time resolution 4 s, FOV 24 cm, slice thickness 2 cm, inter-slice gap 2.5
mm, 4 slices, acquired resolution 6×6×20 mm. In this case, images were collected
only for pyruvate and lactate. HV2 was imaged with the following parameters: flip
angle 15◦, TR = 260 ms, TE = 1.4 ms, time resolution 2.08 s, FOV 24 cm, slice
thickness 3 cm, inter-slice gap 3.5 mm, 3 slices, acquired resolution 6×6×30 mm. All
five metabolites were imaged. Each time point acquired a full FID spectrum, followed
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by seven single shot 40-pt spiral acquisitions which, following Cartesian re-gridding
during reconstruction, produced a real resolution of approximately 12×12×20/30
mm. Gaussian k-space filtering was applied during post-processing, interpolating to
an effective image resolution of 1.875×1.875×20/30 mm.
5.2.3.2 Breast cancer patient
The patient was imaged using a prototype 8-channel 13C breast coil (Rapid Biomedi-
cal) with 2 transmit/receive coils, and 6 receive-only coils. Corresponding 1H anatom-
ical imaging was performed using the standard body coil in an axial orientation.
IDEAL spiral imaging was performed with the following parameters: flip angle 10◦,
TR = 260 ms, TE = 1.4 ms, time resolution 2.08 s, FOV 24 cm, slice thickness 3
cm, inter-slice gap 3 mm. 3 coronal slices were acquired with slice 2 centred on the
tumour. Each time point acquired a full FID spectrum, followed by seven single shot
40-pt spiral acquisitions which, following Cartesian re-gridding during reconstruction,
produced a real resolution of approximately 12×12×30 mm. Gaussian k-space filter-
ing was applied during post-processing, interpolating to an effective image resolution
of 1.875×1.875×30 mm.
5.2.3.3 Glioma Patient
The glioma patient was imaged with the same single channel dual-tuned 1H/13C trans-
mit/receive birdcage head coil as the volunteers. The patient received 3D BRAVO
T1 imaging for anatomical reference both pre- and post-contrast, with gadolinium
contrast agent given at a dose of 0.1 mL/kg prior to the second scan. The following
imaging parameters were used; flip angle 12◦, repeat time (TR) = 8 ms, echo time
(TE) = 32 ms, inversion time 450 ms, field of view (FOV) 24 cm, acquired resolution
2×2×2 mm, matrix size 256×256. Sagittal T2 CUBE images were additionally ac-
quired with the following parameters; flip angle 90◦, TR = 2.5 s, TE = 83 ms, FOV
24 cm, acquired in-plane resolution 1×1 mm, slice thickness 1.2 mm, slice spacing 0.6
mm, matrix size 512×512.
The hyperpolarised 13C-pyruvate injection was then administered with imaging
begining 12 s post-injection. Axial 3-slice IDEAL spiral acquisition was performed
over 1 minute, with slice 1 centred on the tumour. The following parameters were
used; flip angle 10◦, TR = 260 ms, TE = 1.4 ms, time resolution 2.08 s, FOV 24
cm, slice thickness 3 cm, inter-slice gap 3.5 mm, acquired resolution 6×6×30 mm.
Each time point acquired a full FID spectrum, followed by seven single shot 40-pt
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spiral acquisitions which, following Cartesian re-gridding during reconstruction, pro-
duced a real resolution of approximately 12×12×30 mm. Gaussian k-space filtering
was applied during post-processing, interpolating to an effective image resolution of
1.875×1.875×30 mm.
5.2.4 Analysis
Reconstructed 13C data and anatomical image DICOMs were imported into MATLAB
(Mathworks) for analysis. For the two data sets from cancer patients, Markov random
field (MRF) segmentation was applied in order to automatically detect the tumour
volume or region of interest. The algorithm is described in detail in chapter 3 and is
specifically designed to handle the 5D data (3D spatial, 1D frequency and 1D time)
produced by multi-metabolite 13C dynamic imaging. The algorithm relies on multiple
features of this data, including Bayesian priors based on metabolite ratios, temporal
profile shape and spatial location of pixels in order to segment the data based on
features less vulnerable to noise and variability than image contrast. The breast data
was segmented in 3 spatial dimensions and the glioma data was segmented in 2D, with
the tumour-containing slice 1 used. The fuzzy parameter λ was set to 2.6 in both
cases, with all other details of the algorithm as described in the previous chapter.
5.2.4.1 Kinetic modelling
Dynamic data for the two cancer patients was prepared for kinetic model fitting by
spatially averaging over voxels contained within the tumour ROI as detected by MRF
segmentation. Data was also extracted for HV2, however in this case the average
over all voxels in slice 2 was used. The following two-way differential kinetic model
with a continuous Heaviside-step inflow function was fit to the pyruvate and lactate
timecourse data:
dP (t)
dt
= ki
(
1− 1
1 + e−2(t−te)
)
+ kLL(t)− kPP (t)− ρP (t) (5.1)
dL(t)
dt
= kPP (t)− kLL(t)− ρL(t) (5.2)
where kP and kL are the forward and backward conversion rate constants respectively,
ki is the pyruvate inflow rate, ρ is the inverse decay constant and te is the inflow end
time. The first four of these were fit for as free parameters and the te was fixed at
the pyruvate peak time. Due to the acquisition beginning after the pyruvate peak
for the breast cancer patient, it was not possible to use an inflow function for this fit
and the ki was therefore fixed at zero. Fits were carried out in MATLAB using the
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fmincon function and ode45 solver. The optimisation is sensitive to the initial values
of P and L at t = 0 which are provided as inputs to the fit. A Monte Carlo method
with 1000 runs was therefore used to randomly vary these inputs over a Gaussian
distribution centred, with a standard deviation of 5%, on the measured value of P or
L. Parameter values were taken from the run with the best fit as determined by the
Bayesian objective function described in chapter 2.
The kinetic model chosen for this analysis was determined in chapter 2 to be the
most accurate method for quantifying in vivo data, however model-free metrics were
also assessed and as such, the two leading analyses were also applied to this work.
The area under the curve (AUC) ratio is defined as the ratio of two metabolites
after summing over all time points. This was calculated for lactate/pyruvate for each
subject and additionally for bicarbonate/pyruvate and lactate/bicarbonate for the
glioma case. The lactate time-to-peak (TTP) was also calculated. This is found by
fitting a bi-exponential function to the lactate data, then using this curve to measure
the time interval from where the lactate is equal to zero to the peak maximum.
5.2.4.2 Parameter mapping
Parameter maps were produced for both cancer patients. For the AUC and TTP
maps, the methods described above for ROI analysis were applied to the data from
the tumour containing slice on a voxel-by-voxel basis. Voxels detected to be part
of the background by the MRF segmentation were excluded. kP maps were also
produced in this way, however the kinetic model applied differed to that used for the
ROI fit. In order to significantly improve the computational runtime, the number
of Monte Carlo runs was reduced to 10 per voxel and a piecewise kinetic model was
used:
P (0 : tmax) =
ki
kP + ρ
(1− e−(kP+ρ)(t−t0)) (5.3)
L(0 : tmax) =
ki
ρ
(1− e−ρ(t−t0))− ki
kP + ρ
(1− e−(kP+ρ)(t−t0)) (5.4)
P (tmax : t) = Pmaxe
−(kP+ρ)(t−tmax) (5.5)
L(tmax : t) = Pmax(e
−ρ(t−tmax) − e−(kP+ρ)(t−tmax)) + Lmaxe−ρ(t−tmax) (5.6)
Here tmax is the pyruvate peak time and t0 is the start time, found by extrapolating
the pyruvate curve back to zero. The Monte Carlo sampling was applied to Pmax and
Lmax, which are the measured metabolite signal at tmax. kP , ki and ρ are fit for as
free parameters.
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5.3 Results
Four subjects were successfully imaged with IDEAL spiral CSI following an injection
containing 0.4 mL/kg hyperpolarised [1-13C]pyruvate. There were no adverse events
and none of the subjects reported any side effects; this finding is in agreement with
reports from other sites that the agent is tolerated well at this dose. One of the
four subjects HV1 received pyruvate at a low polarisation of 4.7%; the images for
this subject are therefore of very low signal-to-noise ratio (SNR) however it was still
possible to obtain 13C spectra in which several metabolite peaks can be visualised.
Images of pyruvate, lactate and in some cases bicarbonate over time were produced
for the remaining 3 subjects, all of whom received injections of pyruvate polarised to
>20%. The individual results for each subject are detailed below.
5.3.1 Healthy volunteer 1
Figure 5.1: Slice by slice 13C-pyruvate and anatomical reference images for healthy
volunteer HV1. T1 BRAVO anatomical imaging (top row),
13C-pyruvate averaged
over time points 3-9 (8-32 s) (middle row) and 13C spectra summed over all time
points (bottom row) are shown for each images slice 1-4.
Figure 5.1 shows the first healthy volunteer for whom four, 2 cm thick axial slices
in the brain were imaged at a time resolution of 4 s and a flip angle of 5◦. No
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lactate or bicarbonate images were obtained due to poor polarisation, however time-
averaging the pyruvate images over images 3-9 in the series (8-32 s) allows some
features of the brain to be seen, most notably the sagittal sinus which appears as a
bright spot anteriorly. The bottom row of 5.1 shows the 13C spectra, summed over
the whole acquisition time, for each whole image slice. The pyruvate peak at ∼0 Hz
is prominent for each slice and despite low SNR, the lactate peak at ∼392 Hz can also
be clearly seen. Furthermore, slices 2-4 show a small bicarbonate peak at -324 Hz.
The appearance of these two metabolites in the healthy brain raises questions about
their role in the normal brain and suggests significant normal brain metabolism in
the timescale of the experiment. However, it is important to note that the anatomical
location of the observed lactate and bicarbonate is unknown. Although it is possible
that the metabolites were produced within the brain cells, the signal is more likely
to originate from the endothelium, vasculature or extra-cranial tissues, which would
not necessitate the 13C-pyruvate crossing the blood brain barrier.
5.3.2 Healthy volunteer 2
The second healthy volunteer (HV2) was imaged with a higher flip angle of 15◦ and
higher time resolution of 2 s as HV1, with the objective of producing higher SNR
images of the healthy brain but with the compromise of retaining signal over a shorter
time period. To further increase the signal, a larger slice thickness of 3 cm with three
slices was used. Figure 5.2 shows the pyruvate lactate and bicarbonate images of the
first 40 s for slice 2. Good pyruvate images have been obtained with some signal
visible for the other two metabolites, although structural features of the brain are
visible only in the pyruvate images. After approximately 16 s no signal can be seen
for the lactate or bicarbonate images and the pyruvate signal decays by approximately
36 s. Lower temporal resolution could be effective in extending the time over which
signal is visible. Slice by slice data for HV2 is shown in figure 5.3. Metabolite images
are time-averaged over time points 1-13 (0-24 s) and spectra are summed over all 30
time points. The pyruvate images clearly show multiple structural elements of the
brain, with the venous sagittal sinus visible in each slice, passing through the centre
of the image as it traverses over the brain in slice 3. Pyruvate is also visible in the
skin and muscle of the head. Unlike the previous healthy volunteer data, the summed
spectra show little lactate and almost no bicarbonate, despite the acquisition having
higher SNR. It is likely that by not acquiring images at the bicarbonate frequency for
HV1, it allowed the metabolite to be visible in the spectra. Little of either metabolite
can be seen on the time-averaged images. This may in part be due to noise and
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Figure 5.2: Time series of pyruvate, lactate and bicarbonate 13C images for slice 2 in
healthy volunteer 2 are shown from t=0 to t=38. Images are individually scaled such
that for each image, the colour map takes the highest and lowest pixel values as the
dynamic range limits.
artefacts; the spiral artefact is clearly visible in slice 1, being particularly prominent
in the lactate image.
Slice 2 was chosen to examine the conversion to lactate in more detail as it was
largely free from artefacts and contained the highest overall signal. A two-way kinetic
model was fit to the pyruvate and lactate signals averaged over the whole image
slice. The fit gives a value of 0.017 s−1 for the forward pyruvate-to-lactate conversion
rate constant kP and a T1 of 18 s. The kP is in the expected range but the T1 is
lower than expected compared to other human results. This is most likely due the
model not accounting for the conversion of pyruvate to other metabolites, particularly
bicarbonate which is clearly seen to be produced. Also of note is the time at which
the lactate curve peaks, which in this case is simultaneous with the pyruvate peak.
Figure 5.4 shows the fit to the lactate curve peaking slightly later than the data does
which implies that the lactate seen here is not being produced in the brain, a process
which would incur a time delay not seen here. This lactate is therefore most likely
to have been washed in following its production in other body tissues, potentially in
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Figure 5.3: Slice by slice 13C images and summed 13C spectra with anatomical refer-
ence images for healthy volunteer HV2. T1 BRAVO anatomical imaging (top row),
13C-pyruvate (second row), 13C-lactate (third row) and 13C-bicarbonate (fourth row)
averaged over time points 1-13 (0-24 s), and 13C spectra summed over all time points
(bottom row) are shown for each images slice 1-3.
the lungs or endothelium, explaining its simultaneous arrival time with the pyruvate.
It is also possible that some of the observed lactate signal is artefactual, caused by
spill-over from very high pyruvate signal at this time.
5.3.3 Breast patient
A treatment-naive patient presenting with a triple-negative ductal adenocarcinoma
received hyperpolarised 13C imaging in three coronal slices, with slice two centred
on the tumour. As a compromise between the two healthy volunteers, a flip angle
of 10◦ was used with a time resolution of 2 s. Figure 5.5A shows the pyruvate and
lactate images over time for the tumour-containing slice 2. Unlike the images of
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Figure 5.4: Two-way kinetic model fit for pyruvate and lactate summed over the
whole of slice 2 for HV2.
the brain, pyruvate can only be seen within the tumour area which is very highly
perfused compared to the surrounding tissue comprising mostly fat. A small amount
of pyruvate is also visible in the subsequent slice 3, likely from the internal mammary
vessels which pass through this area. Given the 3 cm slice thickness, it is not possible
to determine whether the lactate seen in slice 3 is from blood or tumour. Given
the co-localisation of the lactate signal with that in slice 2, it is most likely to be
the latter. In order to automatically determine the tumour region of interest for
kinetic modelling, 3D Markov random field segmentation was performed on all 3
slices simultaneously. The results of the segmentation are shown in figure 5.5C along
with the time-averaged metabolite images used by the algorithm. The MRF algorithm
appears to have correctly identified the region of lactate production in both slices 2
and 3, whilst correctly identifying that slice 1 contains only noise. There were no
false positive or false negative regions based on a purely visual inspection of the data
and known tumour location. Voxels within the tumour region of interest, as shown
in yellow on figure 5.5C, were averaged to produce pyruvate and lactate timecourses
to which a two-way kinetic model was fit.
The lactate time-to-peak was also derived, with both results shown in figure 5.6.
Since the upstroke of the pyruvate curve was missed due to a late initiation of the
13C imaging sequence, a reduced model was used for the fit which does not contain
a pyruvate input function. The fit also appears visually to be very good, with the
lactate fitted curve in particular extremely close to the data. A value of 30.4 s was
obtained for the T1 which is very close to that expected in human blood and the kP
was found to be 0.020 s−1 which is consistent with values obtained at other sites,
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Figure 5.5: 13C and anatomical imaging for breast patient. A. Slice 2 13C-pyruvate
and 13C-lactate images shown for every second time point; B. Coronal 1H anatomical
reference image showing the centres of the three 13C image slices; C. Time-averaged
pyruvate and lactate as used by the MRF segmentation algorithm, along with the
segmentation result for each image slice.
although only slightly higher than in the healthy volunteer HV2. There is no reason
to expect kP values derived from these disparate tissues to be of comparable size; with
blood brain barrier transport a rate limiting step, the kP derived from HV2 could
be expected to be considerably lower. The lactate time-to-peak was found to be 7.9
s, although accuracy may be limited by the fact that the much of the early lactate
curve data was not acquired. The lactate to pyruvate AUC ratio was also calculated
and found to be 0.357.
Parameter mapping was run over all voxels which were not identified as back-
ground by the MRF algorithm. The lower part of figure 5.6 shows the voxel-wise kP ,
TTP and lactate-to-pyruvate AUC ratios for this region. For all three maps, results
are fairly uniform within the tumour boundary, as identified by the automatic seg-
mentation, but more variable outside where there is little or no lactate and increased
noise. The tendency for all three maps to give high values towards the edge of the
region, when technically values should be much lower outside of the tumour core, is
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Figure 5.6: Model fits and parameter mapping for breast patient data. Top: two-
way kinetic model fit (left) and lactate time-to-peak fit (right) for pyruvate and
lactate time courses derived by averaging over the tumour ROI as defined by MRF
segmentation. Bottom: voxel-wise parameter mapping over tumour ROI plus non-
background vovels. kP (left), lactate time-to-peak (centre) and lactate to pyruvate
area-under-the-curve ratio maps (right) are shown.
caused by two main problems. Firstly; the very high perfusion of pyruvate into the
centre of the tumour region skews the results, as the increase in lactate above the
noise floor in this region is less than the increase in pyruvate at the tumour centre
compared to the edge. The AUC ratio map clearly demonstrates this effect and the
kP map mirrors it. Secondly; this effect is exaggerated by partial voluming and by the
manner in which the images are interpolated to artificially higher resolution. These
results suggest initially that parameter mapping may only be suitable inside the ROI
and that using lower resolution images, closer to the acquired resolution, may give
less misleading results.
5.3.4 Glioma patient
Finally, a treatment-naive male presenting with a high grade glioma underwent hy-
perpolarised 13C imaging in three 3 cm axial slices, with slice one centred on the
tumour. As with the breast patient. a flip angle of 10◦ and time resolution of 2 s
was used. Pre- and post-contrast T1 BRAVO images were also acquired, with the
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Figure 5.7: Glioma patient 1H and time-averaged 13C images for each slice 1-3. Pre-
and post-contrast T1 BRAVO images (left and centre-left), and time averaged
13C-
pyruvate (centre), 13C-lactate (centre-right) and 13C-bicarbonate (right) are shown
for each slice. Time-averaging is from MRF segmentation output.
pre-contrast images providing co-registered anatomical images for the 13C data fol-
lowing a translation of 22.5 mm anteriorly. Figure 5.7 shows both sets of T1 BRAVO
images in addition to 13C-pyruvate, 13C-lactate and 13C-bicarbonate images, time-
averaged by the MRF segmentation process. The pre- and post-contrast images have
been aligned at the tumour centre, although a movement artefact of the patients
head between scans prohibits better registration of these two sets. A similar level
of brain structure can be seen as in the pyruvate images for HV2, however lactate
and bicarbonate are now also clearly visible and unobscured by artefacts. The use
of the lower flip angle for this subject may be a contributing factor in the clarity
of the images, as other parameters remain similar. Structural elements can be seen
in the lactate image as well as the pyruvate image; the visible sagittal sinus in slice
3 confirms the presence of lactate in the vessels as was suggested by the HV2 data.
Lactate can also be seen in the tumour and is accompanied by an increase in pyruvate
perfusion to the same region. There also appears to be increased lactate production
in the neighbouring slice which, being of 3 cm thickness, is likely to cover some of the
tumour area.
2D MRF segmentation was performed on slice 1, with the results shown in fig-
ure 5.8D alongside time-averaged pyruvate and lactate overlayed onto the proton
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Figure 5.8: MRF results, parameter maps and kinetic model fit results for glioma
patient. A. pre-contrast T1 BRAVO anatomical reference image; B.
13C-pyruvate
and C. 13C-lactate overlays, time-averaged as by the MRF algorithm; D. MRF seg-
mentation results showing ‘no conversion’ class (blue), ‘low lactate’ class (yellow) and
‘high lactate’ class (green); E. kP map; F. lactate time-to-peak map; G. lactate-to-
pyruvate and H. lactate-to-bicarbonate AUC ratio maps; I. two-way kinetic model fit
and J. lactate time-to-peak fit to voxels averaged over the ‘high lactate’ class region
of interest.
anatomical reference. The segmentation has correctly identified the tumour, placing
the region into the ‘high lactate’ class. Both the MRF and lactate overlay images
indicate that the tumour is not uniformly metabolically active; the inner part of the
tumour shows no increased lactate production compared to the normal brain, possi-
bly indicating an area of necrotic tissue. The sagittal sinus has also been identified
as a region of interest by the MRF segmentation, with the vessel placed in the ‘low
lactate’ class. Although the lactate is objectively higher than much of the rest of
the brain, figure 5.8G shows a low lactate-to-pyruvate ratio within the vessel. This
information could be used to better inform the algorithm to avoid detecting vessels in
the future. Figures 5.8E-G show kP , time-to-peak and AUC maps, acquired over all
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voxels not detected as the ‘background’ class by the MRF segmentation. Although
lactate is clearly visible in the tumour, none of these maps show a clear difference in
the vicinity of the tumour, with any potential variation obscured by the general noise
level. The main reason for this lack of variation can be deduced from the lactate-
to-pyruvate AUC ratio map. The increased lactate seen in the tumour is due to the
increased perfusion of pyruvate to the region in the same proportion; the conversion
rate is not ostensibly different, nor is the time-to-peak. The higher pyruvate perfu-
sion provides increased SNR in the tumour area, with parameter maps less affected by
noise and therefore appearing more uniform within the tumour. Only the lactate-to-
bicarbonate AUC ratio map appears to show any real difference between the tumour
and contralateral tissue.
The bottom row of figure 5.8 shows the two-way kinetic model fit and time-to-
peak fit over the average of voxels within the ‘high lactate’ class ROI as identified
by the MRF segmentation. The kP is calculated to be 0.025 s
−1, which is higher
than that of the breast patient and of HV2. The T1 was found to be 25.0 s which is
between the values obtained for the other two subjects and within the range expected
in vivo. Comparing this kinetic model fit to that of the healthy brain volunteer, an
interesting feature is visible. The lactate curve fit has underestimated the peak time
of the data, the opposite result as for HV2. This unaccounted for delay, which was
not seen with the breast patient, is likely to represent the additional time required
for the hyperpolarised 13C-pyruvate to cross the blood brain barrier. Although the
blood brain barrier is compromised at the site of the glioma, as is evident from the
hugely increased pyruvate perfusion to the region, there is nevertheless a time lag. Any
modelling of pyruvate to lactate conversion in the brain may need to take this lag into
account in order to achieve accurate fitting. The lactate time-to-peak was found to
be 8.78 s; this is longer than in the breast, despite the fact that the kP is higher in the
breast. This again suggests the need to account for the blood brain barrier transit time
in the brain and highlights the need for organ-specific standards when reviewing such
metrics. The lactate-to-pyruvate, bicarbonate-to-pyruvate and lactate-to-bicarbonate
AUC ratios was also calculated for the ROI and found to be 0.390, 0.128 and 3.05
respectively. In order to compare these values with healthy tissue, the ‘high lactate’
ROI was compared to the contralateral side of the brain. The voxels contained in
this mirrored region were averaged to produce normal tissue comparison data. The
same model fits were run for the kP and lactate time-to-peak, with the values 0.024
s−1 and 7.33 s obtained respectively. The kP is lower although not significantly so
and the lower time-to-peak is consistent with what may be expected given lactate
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data of HV2. AUC ratios were also calculated as follows; lactate-to-pyruvate 0.379;
bicarbonate-to-pyruvate 0.247; lactate-to-bicarbonate 1.53. The lactate-to-pyruvate
ratio is slightly lower than the tumour result although not significantly so, however the
bicarbonate results are quite interesting. Both bicarbonate ratios are very different
from the tumour results, echoing the result seen for the lactate-to-bicarbonate ratio
map. Although the SNR of the bicarbonate images is low, there appears to be a slight
decrease of 12.3% in the bicarbonate produced in the metabolically active tumour
region compared to the healthy tissue suggesting that pyruvate metabolism may be
shunted away from the TCA cycle into lactate.
The results from all four subjects are summarised below in table 5.2.
Table 5.2: Summary of imaging performed, 13C imaging results and quantitative
analysis results for each subject.
Subject Anatomical 13C scan 13C results kP fit kP Other
ID imaging parameters value quantification
HV 1 3D BRAVO T1 Flip angle 5
◦
Time res. 4 s
Slices 4
Thickness 2 cm
Pyruvate images only,
pyruvate, lactate and
bicarbonate visible in
spectra.
None N/A None
HV 2 3D BRAVO T1 Flip angle 15
◦
Time res. 2.08 s
Slices 3
Thickness 3 cm
Good pyruvate im-
ages, some lactate
and bicarbonate po-
tentially visible but
unconfirmed.
Two-way
kinetic model
0.017 s−1 T1 = 18 s
Breast Axial T2 FRFSE
FatSat
Flip angle 10◦
Time res. 2.08 s
Slices 3
Thickness 3 cm
Pyruvate and lactate
clearly visible.
Two-way
kinetic model
no inflow
0.020 s−1 T1 = 30.4 s
TTP = 7.9 s
AUCL/P = 0.357 s
Glioma 3D BRAVO T1
pre- and post-
gadolinium
T2 CUBE
Flip angle 10◦
Time res. 2.08 s
Slices 3
Thickness 3 cm
Pyruvate, lactate and
bicarbonate all clearly
visible in images.
Two-way
kinetic model
0.025 s−1 T1 = 25.0 s
TTP = 8.8 s
AUCL/P = 0.390 s
AUCB/P = 0.128 s
AUCL/B = 3.05 s
5.4 Discussion
The results presented in this work represent the early successful hyperpolarised 13C
images acquired from two cancer patients, as well as the first ever healthy volun-
teers to be imaged, at Addenbrooke’s hospital Cambridge. Firstly, the safety of the
approach is demonstrated with no subjects reporting any adverse effects, even of a
minor nature. Although side effects have been reported at other sites at the same
dose of 0.4 mL/kg of 250 mM [1-13C]pyruvate, these were all considered minor. The
results presented here therefore support the general consensus that the agent is safe
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and well tolerated. Secondly, the feasibility of simultaneously imaging multiple 13C-
labelled metabolites in the human breast and brain, and in healthy and diseased
tissue, is demonstrated. [1-13C]Pyruvate images were successfully produced for each
subject, with lactate clearly seen in both cancer patients and bicarbonate addition-
ally detected in the spectra of all subject brains and imaged in the glioma case. The
ability to detect all three metabolites raises the possibility of using the technique to
further understand metabolism in the normal brain, as well as for the detection and
characterisation of disease such as cancer, multiple sclerosis and stroke.
Although there has been some debate over whether imaging the human brain
with [1-13C]pyruvate is feasible due to the necessity of the agent to cross the blood
brain barrier, the early results presented here for the volunteers and glioma patient are
encouraging. It is possible to identify many structural features within the brain in the
pyruvate images, with the sagittal sinus particularly prominent and other large vessels
transiently visible during the passage of the pyruvate bolus. Viewing the glioma
patient data which has the highest SNR of the three, pyruvate can also be seen in
the skin and muscle, with lactate more clearly confined to the anatomical boundaries
of the brain. It is likely that the majority of the hyperpolarised [1-13C]pyruvate
does not cross the blood brain barrier; the fit for HV2 shows the two metabolites
peaking at a similar time implying that lactate may also be forming in outside of the
brain parenchyma, but further work is required to confirm this especially given the
high noise levels and visible artefact. Considering the glioma patient data, the long
time delay before the lactate peak unaccounted for by the kinetic model is highly
suggestive of a delay due to blood brain barrier transit. Although it seems highly
likely that transit of 13C-pyruvate occurs where there is compromised integrity of the
blood brain barrier, higher SNR data is required in order to judge whether it also
crosses into healthy brain cells.
The feasibility of imaging with [1-13C]pyruvate in breast cancer was also demon-
strated, with clear images produced of both pyruvate and lactate over time. No other
13C metabolites were detected in the breast. The composition of breast tissue, being
mostly fat, lead to an interesting effect in the images where pyruvate was only visible
within the tumour and to a much lesser extent, in the internal mammary vessels on
the adjacent slice. Adipose tissue has very low metabolic activity compared to the
tumour tissue, explaining the absence of metabolite signal outside the tumour ROI.
This high, tumour-only pyruvate perfusion made identification of the tumour very
obvious; detection of even very small lesions in the breast may be possible with [1-
13C]pyruvate due to this perfusion benefit and a comparison with DCE-MRI could
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be undertaken in future studies to address this. A potential point of concern here is
the potentially misleading results found by parameter mapping with kP and lactate
time-to-peak in the breast. These appeared to show a ring of high activity surround-
ing the region identified by the MRF segmentation algorithm as lactate producing,
with a less metabolically active core. This result is likely not biologically driven, but
rather due to the extremely high pyruvate signal at the centre of the tumour and the
increase in lactate in this region from the noise floor being proportionally less than
the increase in pyruvate. It could potentially represent true signal if the centre of the
tumour was very necrotic, however histology would be required to confirm this.
The MRF segmentation produced good results in the breast, correctly identify-
ing the regions of lactate production across multiple slices, even when these areas
of lactate were very small. It is not possible to comment on how well the region
identified as metabolically active aligned with the anatomical tumour volume; future
imaging trials will ensure co-registered anatomical reference images are collected for
this purpose, as well as collecting tissue for histological analysis and comparison. The
kinetic model fit and lactate time-to-peak fit produced from the average of the MRF-
identified ROI were excellent, despite the absence of the pyruvate upstroke from the
data. The kP and T1 values of 0.020 s
−1 and 30.4 s respectively are at the centre of the
ranges reported by other sites undertaking human subjects, suggesting that kinetic
modelling is well suited the breast and that accurate estimates of kinetic parameters
can be obtained for clinical assessment of tumour metabolism. The time-to-peak fit
appeared visually accurate, but further work is required to more fully understand the
quantitative values acquired.
The highest SNR 13C images of pyruvate, lactate and bicarbonate were those
acquired from the glioma patient. These images were the least affected by artefacts of
the three brain subjects and had the highest SNR, making it possible to see structural
features of the brain not only in the pyruvate images, but also in the lactate images.
Applying the automatic MRF segmentation algorithm to slice 2 of the glioma data,
the tumour was correctly identified, appearing as a metabolically active crescent at
the outer edge of the tumour. Since the anatomical tumour boundary appears as
an oval on the co-registered T1 BRAVO image, this mismatch suggests that there is
metabolic heterogeneity within the tumour when compared to perfusion alone. This
may reflect cell death or metabolic alterations and comparison to histology is required
to further evaluate this.
Fitting the two-way kinetic model to the ROI-averaged glioma data produced a kP
value of 0.025 s−1. The researchers at UCSF reported finding the prostate tumour kP
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to be 0.045±0.025 s−1, so this value is with in the range reported for human tumours
so far. However, the kP for the contralateral brain region was 0.024 s
−1 and that
for the whole brain in HV2 was 0.017 s−1; both within the tumour range, but higher
than the healthy prostate tissue kP range of 0.009±0.003 s−1 that UCSF report. The
relative uniformity of the glioma whole-brain kP map also suggests lactate formation
outside of the tumour. There is growing evidence that lactate production in astrocytes
is part of normal brain metabolism; is is possible that imaging with 13C-pyruvate in
the brain may be a useful tool to better understand the underlying biology of this
process. Furthermore, the use of hyperpolarised 13C-lactate in the future may also
be a valuable tool to help probe this process.
Although increased lactate in the tumour could clearly be seen and detected by
the segmentation algorithm, there was a similar increase in pyruvate in the tumour
due to increased perfusion which rendered the parameter maps quite featureless. Al-
though this data represents a single subject, it raises potential problems in using
hyperpolarised pyruvate to image the human brain, suggesting that different quan-
tification methods may be required for analysing the whole brain. Of the metrics
tested, only the lactate-to-bicarbonate ratio was significantly different in the tumour
to contralateral region; the values being 3.05 and 1.53 respectively. It appears that
less bicarbonate is being produced in the malignant compared to healthy tissue due
to a shift away from the TCA cycle towards lactate production. It is possible that
bicarbonate ratios will provide a useful clinical metric in assessing both healthy and
pathological brain metabolism.
The SNR of the 13C images is very heavily affected by the choice of flip angle and
repeat time used in the IDEAL spiral CSI acquisition. Each applied radio frequency
pulse of flip angle α irreversibly depletes the overall polarisation by 1−cos(α), however
the signal acquired at the pulse is proportional to sin(α) resulting in a trade off
between SNR and polarisation retention. A flip angle of 5◦ was used for HV1 which
produced very poor SNR images, albeit due mostly to poor initial polarisation. For
HV2 the flip angle was increased to 15◦ and the TR was lowered from 500 ms to 260
ms. This produced images with much improved SNR, however most of the signal had
decayed after 20 s. Furthermore, the high flip angle applied to the early, very high
signal pyruvate may be partly responsible for the large spiral artefact on these images
due to truncation of the free induction decay. For both of the cancer cases, the flip
angle was set to 10◦ with the TR fixed at 260 ms. Although helped by the fact that
a tumour was being imaged rather than healthy tissue, the images produced are of
better quality than HV1 and HV2. Therefore, for future studies, it would seem that
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10◦ provides a good compromise. It is also possible to improve the image quality
further at the expense of temporal resolution: e.g. by increasing the TR from 260 to
500 ms and decreasing the time resolution to 4 s. Although this would reduce the
accuracy of the kinetic modelling to some extent, the increased signal should allow
for a more accurate characterisation of the biology and would be an appropriate
compromise at this point in time.
Since the technique of hyperpolarised imaging with 13C is still very much in its
infancy, there is much to be done in terms of the validation of results such as those
presented here. Test-retest studies, with subjects imaged two or more times on dif-
ferent days, or at different sites, are now crucial to evaluate the repeatability and
reliability of the imaging technique and any quantification metrics derived from the
data. The images produced are particularly vulnerable physical and physiological
variations, such as slight changes in injection and acquisition timing, initial polarisa-
tion, pyruvate concentration and patient physiology will all have a dramatic effect on
the quality and content of the imaging data.
The quantification methods presented and applied here are specifically aimed at
reducing the impact of this variation and at producing the most robust and reliable
possible means of quantification. The MRF segmentation algorithm uses each of the
five dimensions of the data to segment according to relative, rather than absolute,
metabolite intensities. It also utilises features of the data such as temporal shape
profiles which can be adjusted for the specific imaging parameters used in the ac-
quisition, and which are less affected by artefacts and changes in SNR. The two-way
kinetic model used in this work has been shown to be the most robust model choice
when tested on a large in vitro data set with known enzyme activity. Although these
methods are efficient in reducing the effects of variability in the images, information
on the repeatability of measures such as the kP in human subjects are now required.
Repeatability studies should be undertaken before any quantitative measures derived
from 13C imaging data can be relied on to evaluate questions such as treatment re-
sponse in tumours.
5.5 Conclusion
These results represent some of the first subjects to be successfully imaged with [1-
13C]pyruvate at Addenbrooke’s hospital Cambridge and the first volunteer studies
ever to be undertaken. Feasibility of hyperpolarised MRI is demonstrated in the
brains of two healthy volunteers and two cancer patients; one breast and one glioma.
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In each case, conversion to [1-13C]lactate was observed in the 13C spectra acquired,
with lactate images produced for three subjects and 13C-bicarbonate in one volunteer
and the glioma patient. An automatic Markov random field segmentation algorithm,
previously untested on human data, was applied to the two cancer cases and the
tumour region of interest was correctly identified in each case. A two-way kinetic
model was fit to dynamic pyruvate and lactate timecourse data taken from these
tumour ROIs. The forward reaction rate constants kP , as well as the decay constants
T1, obtained from this fit were all within the range observed in human tumours
by other sites. The exception to this was the high kP values obtained from fits to
healthy brain tissue, implying a low level of lactate production in the normal brain.
The results from this early data will be used to refine and improve the hyperpolarised
imaging protocol as the number of subjects imaged at Addenbrooke’s grows over the
following months. The successful application of quantitative methods to this early
data is encouraging and will allow for repeatable and robust characterisation and
comparison of future patient data.
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Chapter 6
Discussion
Dissolution dynamic nuclear polarisation is a new technique which enables the meta-
bolism of hyperpolarised 13C-labelled molecules to be dynamically and non-invasively
imaged in tissue using existing MRI technology. As the first human subjects at sites
around the world are imaged with 13C-labelled compounds, the early results look
promising for the future of the technique. The only molecule approved for human
use to date is [1-13C]pyruvate which has been well tolerated with no serious adverse
effects reported at the clinical dose that is currently being used. Furthermore, it has
been possible to obtain dynamic, multi-metabolite images of [1-13C]pyruvate and its
metabolic breakdown products, notably [1-13C]lactate and 13C-bicarbonate, in a range
of human organs including the heart, brain, liver, prostate and breast. Although the
technique is still in its infancy, the progress that has been made in the last fifteen
years is truly remarkable. Since Ardenkjær-Larsen et al published their method for
obtaining stable liquid-state polarisation in 2003, dynamic nuclear polarisation of 13C-
labelled molecules has captured the imagination of pre-clinical biologists, clinicians,
industry researchers and large corporations. The 13C research circle that formed from
these groups accelerated research output through diverse collaboration and just eleven
years later, the first-in-man study from UCSF was published in 2014.
The number of sites with the capability for human hyperpolarised 13C imaging is
rising rapidly and it is now important that the community validates the technique
and standardises the methodology. By harmonising protocols and analysis methods
between and within sites, the repeatability and reproducibility of the technique may
be assessed and the potential for multi-centre studies becomes available; these are
both important steps on the road to widespread translation. A large proportion of
the work presented here was undertaken with the view to aiding and advising the
process of clinical standardisation and developing reproducible analysis techniques.
The remainder presents a more theoretical approach to the analysis of 13C data, using
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mathematical modelling techniques to understand the processes that govern lactate
metabolism in both tumours and the cells with which they share their environment.
These two very different approaches are complementary, providing both the rigorous
technical methods to effectively handle both clinical and research data, as well as
providing a thoughtful analysis of the biological processes which generate the observed
metabolic dynamics.
This thesis began with a comprehensive analysis of the quantitative methods which
have previously been applied to hyperpolarised 13C data and compared these to some
novel approaches. The means of quantification studied can be divided into two sub-
sets comprised of model based and model-free methods. Kinetic modelling methods
assume that the biological reaction underlying the data can be described by a simple
mathematical model; this is then fit to the data in order to derive parameter val-
ues such as the forward reaction rate constant kP . On the other hand, model-free
methods derive simple quantitative metrics, such as ratios or curve widths, directly
from the data. The aim of this study was to identify the most appropriate methods
to apply, for both research and clinical settings, as determined by the correlation of
their outputs with the known lactate dehydrogenase (LDH) enzyme concentration in
a large in vitro dataset. The performance of each approach was then tested on a
small in vivo dataset from a rat xenograft model.
The most accurate and robust model choice for kinetic analysis of hyperpolarised
data was found to be the two-way differential model. Incorporating a Heaviside-
step inflow function into this model provided the best means of characterising in
vivo data, whilst minimising the number of free parameters according to the Akaike
information criterion. Of the simple model-free metrics tested, the lactate time-to-
peak demonstrated the highest correlation with the in vitro LDH correlation and
provided excellent correlation with in vivo model-derived kP values. The lactate to
pyruvate area-under-the-curve ratio also produced good results. Additionally, this
study compared two methods of extracting data from the hyperpolarised images:
taking the data from the pixel of highest intensity (POI), or averaging over a region
of interest (ROI). Although the ROI method was found to have greater sensitivity
to changes in metabolism, the POI approach was sufficiently robust to suggest that
pixel-by-pixel parameter mapping can be confidently applied to data of this kind.
In vivo ROIs for the model comparison study were defined by manual delineation
of the anatomical tumour boundary. A key reason for this choice, rather than us-
ing a thresholding approach, was the observation that parameters derived from ROI
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data had high sensitivity to the exact choice of thresholding level if this alterna-
tive method was used. This result highlighted the need for a robust, repeatable and
objective method of defining an ROI on multi-dimensional hyperpolarised 13C data.
Furthermore, it was clear that the chosen method of segmentation should not be based
solely on image contrast, should consider multiple metabolite images simultaneously,
and should ideally utilise the temporal component of the data.
A Markov random field (MRF) approach was chosen for having the capability to
incorporate multiple sources of information into the segmentation decision process.
Temporal, 3D spatial and metabolite ratio information for each voxel were stored
in Bayesian priors, whilst the intensities from multiple metabolites were treated as
components of a single vector, similar to the RGB components in a colour image. All
of this information is considered concurrently during the iterative segmentation pro-
cedure which sorts voxels into six metabolic classes. The conversion of 13C-pyruvate
into 13C-lactate, 13C-alanine and 13C-bicarbonate, in addition to no-conversion and
no-perfusion regions, were considered. Finally, continuous fuzzy logic was utilised in
order to compensate for low resolution, noisy images by retaining information about
the true contents of each voxel throughout the segmentation process.
The proposed MRF segmentation algorithm was tested on an in silico dataset with
variable SNR, metabolite conversion rates and region sizes, where its superiority over
a reference thresholding-based method was demonstrated. The algorithm was consis-
tently able to detect the region in which there was high conversion into lactate with
no false positives produced. However, regions with very low SNR were occasionally
missed. The fuzzy MRF segmentation was then applied in 2 and 3 spatial dimen-
sions to in vivo animal data where, in each case, the anatomical tumour location was
correctly identified. In several cases, large artefacts were visible in the lactate images
with comparable magnitude to the signal acquired from areas of genuine metabolic
activity; however, none of these were falsely detected by the algorithm. This high-
lights the importance of properly utilising multidimensional data to better inform the
algorithm in the presence of noisy, artefact-prone data such as that considered here.
If hyperpolarised imaging is to be used to make clinical decisions, it is of high
importance to better understand the biological processes which produce the observed
image contrast. Although increased glycolysis is a key hallmark of cancer, there has
been significant interest recently in the metabolic interplay between tumours and
their environment. Lactate production and metabolism is a feature of many healthy
cells, which have the potential to form metabolic couplings with the tumour cells and
each other. Cancer associated fibroblasts (CAFs) have been repeatedly implicated
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as a driver of aggressive, invasive behaviour and have been shown to exhibit altered
lactate metabolism in the presence of tumour cells. The ‘reverse Warburg’ effect
describes an experimentally observed phenomenon in which tumour cells metabolise
the lactate produced by CAFs as an alternative energy source. A mathematical model
was built to examine the relationship of the tumour with its environment and to
simulate different growth and treatment outcomes as both the tissue vascularity and
the metabolic coupling between tumour and CAFs was varied. The model presented
in the thesis focused on the use and production of lactate in the tumour environment.
It was found that there is an optimal tissue vascularity in which tumour growth
rate is maximised; above this, increased access to nutrients is outweighed by the
removal of lactate from the system which reduces invasive potential. Lactate produc-
tion was found to be lowest in the optimal tissue and increasing as vascularity was
either increased or decreased. Of the four scenarios simulated, the reverse Warburg
coupling, where both tumour and CAFs could use and produce lactate, produced the
fastest growing tumours which exhibited high treatment resistance through the pro-
motion of an acidic tumorigenic niche. Partial coupling, where CAFs could only use
but not produce lactate, resulted in the slowest growing tumours in all but the most
nutrient-starved tissue conditions. Tumours with no CAF interaction were slower
growing but more resistant to treatment, particularly in tissues with denser than
optimal vasculature. The model is developed with the objective of better under-
standing the tumour interaction with its environment and aiding the interpretation
of combined histopathology and metabolic imaging data in order to make informed,
patient-specific treatment decisions.
In the final section, the approaches developed in earlier chapters for the analysis of
hyperpolarised 13C data were applied to a small initial dataset comprising two healthy
volunteers and two patients; one presenting with a breast tumour and the other with a
glioblastoma. Each subject received IDEAL spiral multi-metabolite imaging following
the injection of 0.4 mL/kg of 250 mM hyperpolarised [1-13C]pyruvate solution. The
agent was well tolerated with no adverse effects reported and its conversion to [1-
13C]lactate was observed in the 13C spectra acquired from each subject. Lactate
images were acquired for three subjects, with 13C-bicarbonate images additionally
produced from one volunteer and the glioma patient.
MRF segmentation was applied to the two oncology cases, correctly identifying
the tumour as the highest conversion region in each data set. Voxels contained within
these ROIs were averaged to produce pyruvate and lactate timecourse data for quan-
titative analysis. A two-way differential kinetic model, previously determined to have
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the highest accuracy and robustness of the models tested, was applied to ROI data
from the two patients, as well as to data from the second healthy volunteer brain,
averaged over the whole central slice. The kP values obtained from this analysis were
within the range previously reported from the only other human tumour study that
has been published, however the results from the volunteer suggest higher levels of
normal brain lactate metabolism than in other healthy tissues. The pyruvate T1 was
also calculated, ranging between 18-25 in the brain and 30 s in the breast, where the
expected range was 25-30 s. The low brain T1 observed may be due to conversion of
pyruvate into bicarbonate, a process not accounted for by the model.
There is still a long way to go before hyperpolarised imaging with 13C-labelled
compounds will be considered a standard imaging modality, or even a clinical rather
than a research technique. Nevertheless, the early data produced at Addenbrooke’s,
as well as at other sites with clinical capability, is encouraging and clearly demon-
strates both the feasibility and safety of human imaging. In the immediate future,
emphasis must be placed on demonstrating the reliability and repeatability of both
data acquisition and quantification. Although the methods presented in this work for
the analysis of 13C data are designed specifically to be robust to the known sources of
variability, rigorous testing on patient data will be required to assess their suitability
for each specific clinical application. It is likely that a different analysis approach will
be required for quantifying brain metabolism compared to other tissues, where blood
brain barrier transit and background tissue metabolism significantly influence data
acquisition.
Test retest studies, whereby patients receive multiple scans within a short time
frame, are needed to assess the intrinsic variability of the imaging approach and
the reliability of any derived quantification metrics. Furthermore, it remains to be
seen whether the data produced from hyperpolarised imaging can be replicated at
other sites, a key requirement for multi-centre studies. One crucial element of this,
both within and between sites, is the need to understand how the choice of imaging
sequence affects the results. Theoretically, the same kP value should be derived
from the imaging data regardless of the exact scanner and pulse sequence that was
used to acquire it. In reality, the complicated experimental 13C sequences and their
reconstructions, which still need much refinement and optimisation, are likely to
have intrinsic biases which skew results. As variable flip angle schemes and clever
optimisations for maximising the signal from each metabolite become more widely
used, the resulting process of quantifying the data they produce is burdened with
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additional sources of error. Understanding and compensating for these errors will be
an important part of the process as 13C data analysis methods develop.
Many early studies, both clinical and preclinical, have been focused on the appli-
cations of 13C imaging in oncology. The suitability of pyruvate for polarisation, com-
bined with the almost ubiquitous glycolytic metabolism observed in cancers, mean this
is a natural first application of the technique in patients. Aside from simply detect-
ing tumours, imaging with 13C-pyruvate has the potential to detect early metabolic
changes in neoplastic tissue before a mass is visible with anatomical imaging. By
quantifying the conversion rate to lactate, it may be possible to grade cancers based
on imaging; early data from Memorial Sloane Kettering suggests this is possible in
human prostate cancer. The application of 13C imaging that is most highly antici-
pated however, is in the early detection of treatment response. Quantifying changes
in metabolism before and after treatment is likely to become one of the key uses of
the technique should it prove clinically viable. This is certainly looking likely, as a
wealth of preclinical studies, in addition to a recent case report on a single prostate
cancer patient at UCSF, demonstrate the feasibility of this application.
Abnormal metabolism is by no means limited to cancer. There is significant in-
terest in imaging ischaemia, with early studies concentrating on the heart and the
loss of 13C-bicarbonate production observed following an ischaemic event. The po-
tential for imaging the human heart has already been demonstrated and it is hoped
that the technique will be valuable for identifying damaged myocardium. The early
signs of hypoxic renal damage that occur with diabetes may be detected by imaging
the increased conversion of 13C-pyruvate to 13C-lactate in the kidney. It may also be
possible to image ischaemic damage to the brain, following stroke or traumatic injury.
Although limited preclinical data is available due to the difficulty in producing a pre-
clinical model of stroke, this remains an exciting potential application with studies in
patients already planned. The blood brain barrier is known to be compromised fol-
lowing a stroke, which may facilitate perfusion of pyruvate to the region peripheral to
the occlusion; areas of lactate production would indicate perfused and metabolically
active tissue as opposed to ischaemic tissue, offering the potential to determine the
ischaemic penumbra and the extent of tissue damage.
Other neurological applications include imaging the metabolic changes that occur
with degenerative diseases and the increased lactate production observed in multiple
sclerosis (MS) plaques due to high immune activity; a physiological trial to image MS
in patients is already under way in Cambridge. Similar metabolic changes are known
to occur at sites of inflammation. Although little has been investigated in this area so
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far, there is potential for hyperpolarised 13C-pyruvate imaging as a tool for studying
autoimmune diseases, infection and immunometabolism.
Although 13C-pyruvate is the first molecule to gain clinical approval and has been
the focus of a majority of studies so far, there are a number of other 13C-labelled
biomarkers which are likely to be approved in the near future, each with a wealth
of potential applications. Notable forerunners include 13C-fumarate, the conversion
of which to 13C-malate is a negative marker of cellular necrosis and may be valuable
alongside 13C-pyruvate for determining treatment response in tumours. 13C-urea is
being developed as a marker of perfusion and 13C-bicarbonate as a marker of pH.
Preclinical research into new 13C tracers continues to identify molecules of biological
significance suitable for polarization and as the technique improves, the possibilities
continue to expand. The vast number of potential 13C agents which may provide
unique insights into in vivo tissue metabolism and which could be imaged simultane-
ously or sequentially, are some of the strengths of hyperpolarised imaging.
One of the major challenges to widespread adoption of any new technique is
demonstrating that it fulfils some unmet clinical requirement. This may be by provid-
ing valuable information unattainable with current technologies, or by demonstrating
a significant improvement to competing modalities on either cost or patient safety.
The main competitor in the case of hyperpolarised imaging is clearly PET, with the
most commonly used tracer, 18F-FDG, providing comparable clinical information to
13C-pyruvate as a marker of tumour glycolysis. The two modalities are similar in
terms of in-plane image resolution, however PET has much higher 3D resolution and
has far higher molecular sensitivity; 18F-FDG may be detected in nanomolar quan-
tities compared to 13C-pyruvate in the millimolar or high micromolar range. Whole
body imaging is common with PET, however the field of view for hyperpolarised
imaging is currently limited to small regions and few slices.
One of the main advantages offered by 13C is the dynamic information it provides.
Where 18F-FDG PET shows only a map of glucose uptake, hyperpolarised imaging is
capable of dynamically imaging multiple metabolites at once, making it a much more
specific marker of glycolysis, but also expanding the use of the tracer to applications
such as cardiac metabolism. Although dynamic imaging is possible with PET, it is
rarely used in clinical practice. Similarly, the wide range of alternative PET tracers
have been confined almost exclusively to research uses due to their high cost and
difficult manufacture, often requiring an on-site cyclotron. Introducing new stable
13C tracers should be far more straightforward. 18F-FDG demonstrates high uptake
in the brain, heart gut and urinary system which can often obscure disease in these
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regions; with much more specific uptake, this problem is avoided with hyperpolarised
imaging. Finally, 13C-pyruvate MRI is a radiation-free technology which may be
applied repeatedly. Compared to the high radiation dose associated with PET-CT,
there are clear benefits for hyperpolarised imaging in terms of patient safety, opening
up the potential to repeatedly image patients especially children and pregnant women.
There are currently two major limitations facing clinical hyperpolarised imag-
ing. The first is its high operational cost: a single injection of hyperpolarised [1-
13C]pyruvate costs around £3000 and this is coupled with the cost of time on the
MRI scanner, plus the high costs of purchasing and maintaining a hyperpolariser sys-
tem and establishing a pharmacy. Clearly this is a very high barrier for many sites to
overcome, however there is no reason why costs will not reduce as demand for ster-
ile fluid paths (SFPs) or pharmacy kits and 13C-labelled pharmaceuticals increases,
due to economy of scale. Furthermore, the high cost of the procedure may be offset
by its utility; if [1-13C]pyruvate proves to be a valuable tool for assessing treatment
response, huge sums could be saved on expensive and ineffective cancer drugs and
unnecessary surgical procedures, making the technique financially viable in the long
run.
The second limitation is quite simply the technical difficulty involved in produc-
ing hyperpolarised data. From SFP assembly, the hyperpolarisation procedure, QC
testing, to the injection and acquisition, there are many points in the process that
are vulnerable to both human and technical error and variation. The rapid decay
of hyperpolarised signal leaves little buffering for errors and images acquired after a
delay of even a minute demonstrate unusably low SNR. Furthermore, the current ster-
ile fluid path design is prone to variability of pH and pyruvate concentration, with
around 10-50% of samples rejected during QC analysis. Initial polarisation is also
prone to high levels of variation, significantly affecting the images produced. Despite
these difficulties, early patient data of good quality has been acquired at Cambridge
and at other sites. As the number of patients imaged grows, it is hoped that protocols
will become optimised, with many sources of error being reduced or eliminated over
time. However, the current procedure is in need of simplification if hyperpolarisation
is to become more than a research technique.
With these limitations in mind, it is interesting to consider possible solutions for
technical developments which could dramatically improve access to hyperpolarised
imaging. One suggestion for both reducing cost and hardware requirements is to
have a central facility which is capable of polarising and shipping injectable solutions
to multiple sites. Retaining the polarisation during transit will be the challenge to
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overcome, however in high magnetic field and low temperature it should be possible
to reduce the T1 of molecules significantly to several hours or even days. One of the
huge advantages of hyperpolarised imaging is that it uses existing MRI technology
already present in most clinical facilities. If the need for an on-site hyperpolariser
and pharmacy is removed then the cost of the technique is significantly reduced, with
the added benefit of immensely simplifying the clinical procedure required of on-
site staff. Although a centralised hyperpolarisation system is currently theoretical, it
would provide an excellent way of overcoming many of the obstructions to widespread
clinical use.
Hyperpolarised imaging has the potential to dynamically image the in vivo metabolism
13C-labelled compounds, providing a unique insight into cellular metabolism and the
changes that may occur through disease. This is a remarkable time to be a part of
the field; few novel imaging techniques develop into multi-site clinical studies, and
the acid test will be the results from early clinical trials published over the coming
years. The possibilities of this technique should not be underestimated. The brief
summery given above does not cover the full potential of 13C-pyruvate as a metabolic
biomarker, let alone the multitude of other possible compounds. Even so, the appli-
cation of [1-13C]pyruvate and its conversion to [1-13C]lactate as a measure of tumour
response to treatment is sufficiently strong to propel the technique forward. It is with
this particular application in mind that the work in this thesis has been developed.
It is hoped that the mathematical approaches presented here will provide the means
to both analyse and interpret hyperpolarised 13C imaging data, aiding the clinical
translation of this novel imaging modality.
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